Single and Dual Growth Factor Delivery from Poly-E-caprolactone Scaffolds for Pre-Fabricated Bone Flap Engineering. by Patel, Janki Jayesh
Single and Dual Growth Factor Delivery from Poly-Ɛ-caprolactone Scaffolds for 
Pre-Fabricated Bone Flap Engineering 
 
by 
 
Janki Jayesh Patel 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Biomedical Engineering) 
in the University of Michigan 
2015 
 
 
 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
Professor Scott J. Hollister, Chair 
Associate Professor Sean P. Edwards 
Professor Paul H. Krebsbach 
Professor Jan P. Stegemann 
 
  
 
 
 
 
 
 
 
 
 
©Janki Jayesh Patel 
 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
2015 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
˗˗˗ α ˗˗˗ 
To my parents and sister whose love and guidance have made me  
the person I am today. I could not have done this without you. 
iii 
 
ACKNOWLEDGEMENTS 
 
I pursued a Ph.D. in Biomedical Engineering to feed my passion for science and 
to explore the boundaries of research to make an impact in the field of tissue engineering. 
I was told that all I need to do is complete my Masters coursework, pass my qualifying 
exam, and complete my dissertation. That was the approach I had in mind when starting 
graduate school at the University of Michigan. It seemed pretty straight-forward. I 
thought I would simply complete the steps one by one, and I would see the light at the 
end of the tunnel. False. Little did I know that graduate school was filled with limitations, 
alternative methods, and troubleshooting. What should happen in theory does not always 
correlate to what happens in reality. To get to the end there were set-backs, optimizing, 
encouragement and sometimes just plain luck. I was challenged to think creatively and to 
critically solve issues when faced with frustrations with protein assays and data analysis. 
My involvement with dance teams in the evenings helped to round out my experience and 
gave me the opportunity to make some long-lasting friendships. Through the ups and 
downs that I faced at the University of Michigan as a Ph.D. student, I have created some 
unforgettable memories. I could not have completed this dissertation without the support, 
well-wishes, and advice that my colleagues, friends, and family have provided me with. 
Firstly, I’d like to thank Dr. Scott Hollister, my research advisor, for always being there 
to lend a guiding hand and to help me outline my project. He gave me the creative 
freedom to independently outline goals and was always there to share advice. Thank you 
iv 
 
for believing in my potential and always encouraging me to stay positive. Other academic 
mentors were my committee members: Drs. Paul Krebsbach, Sean Edwards, and Jan 
Stegemann. Thank you for sharing your knowledge and providing your support 
throughout the years. Your enthusiasm for science, medicine, and technology is 
contagious.  
I’d like to thank the Biomedical Engineering Department and especially Maria 
Steele for being so prompt when handling all of the logistics. Maria was always there to 
give me a last minute copy of my transcript, tell me which form to fill out, and tell me 
exactly who to contact for a reimbursement. 
 Research is rarely completed individually, and I received a lot of support from the 
members of the Scaffold and Tissue Engineering Group. Thank you to: Annie Mitsak, 
Auresa Thomas, Marta Dias, Colleen Flanagan, Xiuyuan Yang, Eiji Saito, and Sophia 
Pilipchuk. You were there to motivate me during the late nights spent in lab or when I 
needed to discuss project details. I would like to mention a special thank you to Annie 
Mitsak who took the time to mentor me when I first joined the lab and helped me to avoid 
a lot of the pitfalls that first years fall into. Thanks to Colleen Flanagan who was always 
there to calm me down when I made a mistake, to help edit my papers, or just to talk 
about science fiction T.V. shows on long road-trips to Illinois. Also, thank you to all of 
the undergraduate and graduate students that assisted me in my research projects- Crystal 
Chen, Kari Green, Manasa Amancherla, Sean Miller, Kevin Merchak, Manny Hill, Rui 
Fan, Joshua Duel, and Jane Modes. The long hours you spent doing cell culture, 
mechanical testing, protein assays, and histology have helped me tremendously, and I 
greatly appreciate it. Also, I’d like to thank the Dr. Rhima Coleman’s Laboratory, and the 
v 
 
MicroCT and Histology Cores at the Dental School because without your assistance, my 
research would incomplete. 
 Although I spent most of my time on research, I also invested some time in 
extracurricular activities. I met some wonderful people through my involvement with the 
Michigan TAAL dance team and the Biomedical Engineering Graduate Student Council. 
Thank you, Ishani, for your positive encouragement and helping me to use dance as a 
positive outlet for the frustrations I faced in lab. I will remember the hours spent listening 
to music, choreographing, and creating formations. To Paras and Melanie, thank you for 
your mentorship and helping me to navigate the complex Ph.D. maze from your own 
experiences. 
I would like to thank all of my friends for their unconditional support, words of 
encouragement, and unwavering patience. I am so lucky to have all of you in my life, and 
I consider you a family away from home. Thank you to my Georgia Tech and high school 
friends: Kalpi, Ricky, Neil, Bijal, Janu, Sonali, Tasha, and Nikki. Those hour-long skype 
dates, phone calls, and long emails have provided words of encouragement, strengthened 
my confidence, and lifted my spirits. You have been an amazing support system for me. 
To my Michigan friends- especially Matt, John, Sriram, Nidhi, Sydney, and Niharika- 
thank you for all of the unforgettable memories which include exploring Ann Arbor, 
impromptu pool parties, movie nights, grapes, and orange leaf outings.   
Finally, I would like to express my gratitude to my family for their unwavering 
support and love and for always pushing me to do my best. Thank you to my parents for 
encouraging me to relax and take a step back when I felt overwhelmed or stressed. Mom, 
I loved the lunches we had together at the University of Michigan Hospital, and Dad, 
vi 
 
thanks for always being there to count on when I needed to move apartments or when my 
car was in trouble. I loved coming home to recharge with some delicious home-cooked 
food. To Radhika, through the years you’ve always been a role model for me, and I strive 
to follow in your footsteps. Thanks for always being there to lend a guiding hand and for 
teaching me the do’s and don’ts of graduate school. You always knew the right words to 
tell me to make me feel better after I was rejected by science. Lastly, thank you to Harish 
for being my number one fan and chanting every time I had positive experimental results. 
Thank you for believing in me even when I thought everything was going wrong and 
falling apart. Your love and support have meant everything to me.  
 
vii 
 
TABLE OF CONTENTS 
Dedication…………………………………………………………………………………ii 
Acknowledgements………………………………………………………………………iii 
List of Figures…………………………………………………………………………….xi 
List of Tables……………………………………………………………………………xiii  
Abstract……………………………………………………………………………….....xiv 
Chapter 1: Introduction……………………………………………………………………1 
1.1 Problem Statement…………………………………………………………….1 
1.2 Repairing Bone Defects……………………………………………………….2 
1.3 Pre-Fabricating a Bone Flap………………………………………………..…8 
1.4 Thesis Aims………………………………………………………………….10 
1.5 Dissertation Contents………………………………………………………...14 
1.6 References………………………………………………………....................15 
Chapter 2: Bone Development, Regeneration, and Growth Factors ……………………20 
2.1 Endochondral vs. Intramembranous Ossification……………………………20 
2.2 Bone Morphogenetic Protein-2 and Bone Regeneration………………….…23 
2.3 Vascular Endothelial Growth Factor and Bone Regeneration…………….…27 
2.4 Erythropoietin and Bone Regeneration………………………………………29 
2.5 Conclusion…………………………………………………………………...31 
2.6 References……………………………………………………………………32
viii 
 
Chapter 3: Scaffold Tissue Engineering-Fabrication Methods and Protein Delivery 
Vehicles…………………………………………………………………………………..40 
3.1 Introduction ………………………………………………………………….40 
3.2 Fabricating Synthetic Scaffolds……………………………………………...40 
3.3 BMP2 Growth Factor Delivery Methods…………………………………….45 
3.4 BMP2 & VEGF Dual Delivery………………………………………………48 
3.5 BMP2 & EPO Dual Growth Factor Delivery………………………………..51 
3.6 Conclusion…………………………………………………………………...54 
3.7 References……………………………………………………………………54 
Chapter 4: Bone Morphogenetic Protein-2 Adsorption onto Poly-Ɛ-caprolactone Better 
Preserves Bioactivity In Vitro and Produces More Bone In Vivo than Conjugation Under 
Clinically Relevant Loading Scenarios…………………………………………………..63 
4.1 Abstract………………………………………………………………………63 
4.2 Introduction…………………………………………………………………..65 
4.3 Materials and Methods……………………………………………………….67 
4.4 Results………………………………………………………………………..75 
4.5 Discussion……………………………………………………………………83 
4.6 Conclusions…………………………………………………………………..87 
4.7 References……………………………………………………………………88 
Chapter 5: Dual Delivery of BMP2 and VEGF from a Polycaprolactone/Collagen Sponge 
Construct to Increase Bone Growth in Ectopic Sites for Flap Prefabrication………...…92 
5.1 Abstract………………………………………………………………………92 
5.2 Introduction…………………………………………………………………..94 
ix 
 
5.3 Materials and Methods……………………………………………………….96 
5.4 Results………………………………………………………………………104 
5.5 Discussion…………………………………………………………………..111 
5.6 Conclusions…………………………………………………………………113 
5.7 References…………………………………………………………………..115 
Chapter 6: Dual Delivery of BMP2 and VEGF from a Modular Polycaprolactone 
Scaffold for the Treatment of Large Bone Defects……………………………………..119 
6.1 Abstract……………………………………………………………………..119 
6.2 Introduction…………………………………………………………………121 
6.3 Materials and Methods……………………………………………………...123 
6.4 Results………………………………………………………………………129 
6.5 Discussion…………………………………………………………………..134 
6.6 Conclusions…………………………………………………………………137 
6.7 References…………………………………………………………………..138 
Chapter 7: Dual Delivery of BMP2 and EPO from a Novel Modular Polycaprolactone 
Scaffold to Increase Early Ectopic Bone Regeneration in Prefabricated Flaps………...142 
7.1 Abstract……………………………………………………………………..142 
7.2 Introduction…………………………………………………………………144 
7.3 Materials and Methods……………………………………………………...146 
7.4 Results………………………………………………………………………152 
7.5 Discussion…………………………………………………………………..158 
7.6 Conclusions…………………………………………………………………162 
7.7 References…………………………………………………………………..163 
x 
 
Chapter 8: Conclusions and Future Directions…………………………………………167 
8.1 Conclusions…………………………………………………………………167 
8.2 Future Work………………………………………………………………...173 
8.3 References…………………………………………………………………..176 
xi 
 
LIST OF FIGURES 
 
Figure 2.1: The Stages of Endochondral Ossification…………………………………...21 
Figure 2.2: The Stages of Bone Fracture Healing………………………………………..22 
Figure 2.3: Cell Signaling Pathway for BMP2 Activity…………………………………25 
Figure 2.4: Cell Signaling Pathway for VEGF Activity…………………………………28 
Figure 2.5: Cell Signaling Pathway for EPO Activity…………………………………...30 
Figure 4.1: PCL Scaffold Geometries……………………………………………………68 
Figure 4.2: BMP2 Binding to PCL Discs via Adsorption or Conjugation………………76 
Figure 4.3: BMP2/PCL Cytotoxicity & Bioactivity……………………………………..77 
Figure 4.4: BMP2 Binding to PCL Discs and Scaffolds………………………………...78 
Figure 4.5: Conjugated and Adsorbed BMP2 Released from PCL……………………...79 
Figure 4.6: Regenerated Bone Analysis………………………………………………….80 
Figure 4.7: Ring Analysis for Bone Growth into Scaffold………………………………81 
Figure 4.8: Compressive Mechanical Testing…………………………………………...82 
Figure 4.9: H&E Images of PCL/BMP2 Scaffold Pores………………………………...83 
Figure 5.1: PCL/Collagen Sponge Construct…………………………………………….97 
Figure 5.2: BMP2 and VEGF Bioactivity………………………………………………104 
Figure 5.3: Bone Volume Analysis ……..……………..................................................105 
Figure 5.4: Microview Images of Explanted Specimen MicroCT Scans...………….....106 
Figure 5.5: Regenerated Bone Volume in the Middle of Construct…………................106
xii 
 
Figure 5.6: Explanted Construct TMC and TMD Analysis…………………………….107 
Figure 5.7: Cylindrical Ring Analyses for Bone Ingrowth……………………………..108 
Figure 5.8: Explanted Specimen Compressive Mechanical Testing…………………...109 
Figure 5.9: H&E Stain of Construct Sections…………………………………………..110 
Figure 5.10: Blood Vessel Density……………………………………………………..110 
Figure 6.1: Modular Scaffold Assembly………………………………………………..123 
Figure 6.2: Protein Binding and Release Kinetics……………………………………...129 
Figure 6.3: Adsorbed VEGF Bioactivity……………………………………………….130 
Figure 6.4: Modular Scaffold MicroCT Analysis ……………………………………...131 
Figure 6.5: Bone Volume in Pores and Bone Ingrowth………………………………...132 
Figure 6.6: Tissue Mineral Density…………………………………………………….133 
Figure 6.7: Histology: H&E Staining…………………………………………………..134 
Figure 7.1: Modular Scaffold Assembly………………………………………………..147 
Figure 7.2: Protein Release Profiles…………………………………………………….153 
Figure 7.3: Adsorbed EPO Bioactivity…………………………………………………154 
Figure 7.4: MicroCT Analysis of Regenerated Bone…………………………………..155 
Figure 7.5: Pore Bone Growth and Scaffold Ingrowth…………………………………156 
Figure 7.6: Tissue Mineral Density Analysis of Regenerated Bone……………………157 
Figure 7.7: Histology: H&E Staining…………………………………………………..158 
xiii 
 
LIST OF TABLES 
 
Table 2.1: Osteogenic and Angiogenic Factors and Their Role in Bone Regeneration…23 
Table 4.1: Sample Numbers for In Vivo Analyses ………………………………………73 
Table 5.1: Sample Numbers for In Vivo Analyses……………………………...………102 
Table 6.1: Sample Numbers for In Vivo Analyses ……………………………………..127 
Table 7.1: Sample Numbers for In Vivo Analyses……………………………………...151 
xiv 
 
ABSTRACT  
 
 
 Approximately 2.2 million bone graft procedures are performed worldwide 
annually. Autografts are widely utilized to reconstruct large craniofacial bone defects; 
however, they result in donor site morbidity and defect geometry mismatch. Pre-
fabricating a bone flap overcomes these drawbacks and involves integrating a patient 
specific scaffold with biologics, implanting it in the latissimus dorsi for a period of time 
and then transplanting it to the defect site as a partially remodeled construct. Poly-Ɛ-
caprolactone (PCL) is a biocompatible polymer that has mechanical properties suitable 
for bone tissue engineering; however, it must be integrated with biologics to stimulate 
bone formation. The purpose of this work was to investigate single and dual growth 
factor binding to PCL scaffolds in a clinically applicable environment and analyze the 
bone regenerated in an ectopic site for pre-fabrication applications.  
Bone morphogenetic protein-2 (BMP2) was adsorbed or conjugated onto a PCL 
scaffold in a clinically applicable setting (1hour exposure at room temperature). 
Adsorbed BMP2 had in a small burst release and was bioactive as indicated by C2C12 
alkaline phosphatase expression. Interestingly, conjugated BMP2 had a sustained release 
but was not bioactive. When implanted subcutaneously, adsorbed BMP2 had increased 
bone volume (BV), elastic modulus, and ingrowth when compared to conjugation. Next, 
a collagen sponge was fabricated inside of a BMP2-adsorbed PCL scaffold to deliver 
vascular endothelial growth factor (VEGF). Also, a modular PCL scaffold was developed 
xv 
 
in which the inner and outer modular portions were adsorbed with BMP2 and VEGF, 
respectively.  In both systems, the VEGF was bioactive as indicated by increased 
endothelial cell proliferation.  Dual delivery of BMP2 and VEGF significantly increased 
BV from 4 to 8weeks in an ectopic location, whereas, BMP2 alone did not. Finally, 
erythropoietin (EPO) and BMP2 were delivered from the outer and inner portions of the 
modular scaffold, respectively. The adsorbed EPO was bioactive as indicated by 
increased endothelial cell proliferation. At 4 weeks, dual EPO and BMP2 delivery had 
increased BV and ingrowth when compared to BMP2 alone.  
In conclusion, adsorbing BMP2 onto PCL may be optimal for clinical use. 
Delivering VEGF with BMP2 increases the bone regeneration rate from 4 to 8 weeks and 
delivering EPO with BMP2 increases the BV at 4 weeks when compared to BMP2 alone. 
Multiple biologics delivery is a promising method to increase the regenerated bone for 
pre-fabricated flaps. Future studies should investigate adsorbing the whole scaffold with 
both proteins, optimizing protein dosages, and determining the mechanism of synergy 
between the growth factors. 
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CHAPTER 1 
 INTRODUCTION 
 
1.1 Problem Statement 
Annually, approximately 2.2 million bone graft procedures are performed 
worldwide of which 500,000 are performed in the U.S., a $1.39 billion market [1-3]. 
Bone graft usage will most likely increase due to an aging population. Methods to treat 
bone defects resulting from trauma, tumor resection, developmental anomalies or facture 
non-unions include autografts, allografts, synthetics, or natural material scaffolds. 
Autografts are considered the gold standard; however, they have the drawbacks of donor 
site morbidity, increased risk for infection, and geometry mismatch. Alternatives such as 
allografts and natural scaffolds have the limitations of mechanical failure and poor 
growth factor delivery. Due to inadequate delivery, a large dose is needed which 
increases the product cost and potential complications as seen with Medtronic’s product 
Infuse
TM
. Bone morphogenetic protein-2 devices can cost as much as $5,000 per product, 
whereas demineralized bone matrix and ceramics cost about $700-$1,000 per implant [4]. 
There is a need to tissue engineer a patient-specific bone graft that is autologous in nature 
to reduce the drawbacks associated with autografts and alternative bone grafts. 
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1.2 Repairing Bone Defects  
 Fracture non-unions, tumor resections, trauma, and developmental anomalies can 
result in large bone defects that will not heal naturally. In these situations a bone graft is 
needed to fill the void and assist in the regeneration process. The worldwide market value 
for bone grafts and substitutes is expected to rise from $2.1 billion in 2013 to 
approximately $2.7 billion by 2020. The United States holds the largest market share 
with 65.6%, and the revenue is expected to rise from $1.39 billion to $1.78 billion [3]. 
Bone and bone graft substitutes used to repair defects include autografts, allografts, and 
synthetic/natural material grafts [5].   
1.2.1 Autografts & Allografts 
The gold standard for reconstructing large bone defects is an autograft typically 
taken from the patient’s fibula, iliac crest, or scapula. These osteoconductive, 
osteoinductive, and osteogenic autografts can either be used as a graft or as a flap (a graft 
with an attached vascular pedicle). The vascular pedicle in the bone flap is connected to a 
local vessel at the defect site to provide blood flow. Autografts have proven to integrate 
well at the defect site and support further remodeling; however, each of the harvest sites 
varies in bone quality. The fibula offers the longest bone with a good pedicle, but it is 
frequently not available due to atherosclerosis or congenital vascular anomalies. The iliac 
crest offers limited soft tissue, a short pedicle, and significant morbidity. Autografts from 
the scapula are the most limited in terms of bone quality and pedicle length. With these 
limitations, it is difficult to provide the best quality of life, functional return and aesthetic 
recovery for the patient. In addition to these limitations, autografts are associated with 
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major drawbacks that include high donor site morbidity, increased risk for infection, and 
poorly matched defect geometry. 
One alternative to an autograft is an allograft, which is a bone graft that is taken 
from another person (usually a cadaver) and implanted into the defect site. These 
cancellous or cortical bone grafts maintain biologic (osteoconductive) properties and 
mechanical integrity. First, the donor is screened and then the graft is collected, 
processed, disinfected, and tested to ensure it is safe for use. Allografts are provided in 
fresh, fresh-frozen, or freeze-dried forms. There is limited time to test fresh grafts for 
diseases, and there have been four cases of human immunodeficiency virus (HIV) 
infection associated with using fresh-frozen allografts [6].  Fresh-frozen grafts are 
regulated by the Food and Drug Administration (FDA), and the processing method 
preserves biomechanical properties. Freeze-dried grafts can be stored for a longer period 
of time; however, processing negatively impacts the graft effectiveness in terms of 
mechanical integrity and osteoconductive abilities. In addition to the risk of disease 
transfer and eliciting an immune response, the process of screening a donor, harvesting, 
packaging, and processing can be expensive. For these reasons, allografts are a 
substandard alternative to autografts [6].  Both autografts and allografts result in poorly 
matched defect geometry, making them suboptimal solutions for reconstructing complex 
geometries in the craniofacial region. 
1.2.2 Bone Graft Substitutes 
Bone graft substitutes can address a few of the drawbacks associated with 
allografts and autografts. Some commercially available substitutes are made of calcium 
phosphate (CaP), calcium sulfate (CaS), hydroxyapatite (HA), or tricalcium phosphate 
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(TCP). These materials can be used individually or in combination to increase the 
osteoinductive or osteoconductive properties.  
The scaffold resorption rates and mechanical properties vary greatly depending on 
the material, geometry, and porosity. CaP products have a very high compressive strength 
once hardened and can be injected. CaS has a low compressive strength so it is not used 
for load bearing applications and is used as a bone void filler. HA is derived from marine 
coral exoskeletons that are converted to hydroxyapatite. The porous structure resembles 
cancellous bone porosity. TCP has a modulus that is in the lower range of cancellous 
bone. It is available in block, wedge, or granule forms [7]. Sometimes β-TCP (a more 
porous version of TCP) is used to create more porous scaffolds [8].  Commercial bone 
void fillers include Biomet’s BonePlast® (CaS/HA), Exactech’s OpteMxTM (HA/TCP), 
Medtronic’s MasterGraft® Granules (HA/ β-TCP), Wright Medical Technology’s PRO-
DENSE
®
 (CaS/CaP), Synthes Norian SRS
®
 (CaP), and Orthovita’s Vitoss® (β-TCP) [9]. 
Other commercially available bone graft substitutes are derived from naturally 
occurring materials such as demineralized bone matrix (DBM) and collagen type I. DBM 
is an osteoconductive material produced from processed allograft bone. It is composed of 
noncollagenous proteins, growth factors (GFs), and collagen [1]. DBM is available in the 
form of powder, granules, or it can be mixed into a gelatin or hydrogel (a glycoprotein) to 
make putty. Approved products include Biomet’s InterGro® (DBM/lecithin), Exactech’s 
Optecure
®
 (DBM/hydrogel) and Optefil
®
 (DBM/gelatin), Life Net Health’s Optium 
DBM
®
 (DBM/glycerol), Medtronic’s Osteofil® (DBM/gelatin),  Smith and Nephew’s 
VIAGRAF (DBM/glycerol), and Osteotech’s GRAFTON Plus® (DBM). Although 
successful in some applications, due to the sterilization methods utilized the bone 
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morphogenetic protein-2 (BMP2) availability may decrease. There also exists batch to 
batch variation in protein content. 
Other natural materials (e.g. collagen, alginate, hyaluronic acid) are utilized as 
scaffold materials for mineralized tissue.  Collagen based matrices are generally highly 
purified type 1 bovine dermal fibrillar collagen. Natural materials are structurally 
complex and more difficult to manipulate into specific geometries when compared to 
synthetic polymers. They lack the mechanical properties needed to withstand the forces 
that exist in the bone environment, and they would not be useful in a large bone defect in 
which a large bone volume is needed [10,11]. For these reasons, natural bone graft 
materials are generally used as bone void fillers. To strengthen load bearing properties, 
collagen can be combined with a ceramic such as Integra’s Mozaik™ (β-TCP/Collagen) 
or Medtronic’s MasterGraft Strip® (hyaluronic acid/ β-TCP/Collagen) [9]. 
Currently, two biologic/material combination devices are approved by the FDA 
for clinical use. One is BMP2 loaded into a collagen matrix (Infuse
TM
, Medtronic 
Sofamor Danek, Inc) used to for spinal fusion, open tibial fractures, sinus augmentation, 
and dental procedures. The other is bone morphogenetic protein-7 (BMP7) (OP-1TM, 
Stryker Biotech) [9] used for long bone defects and non-union treatment [12]. These 
products are costly due to high BMP doses (2-12mg) which greatly exceed the physical 
concentrations (18.8-22pg/mL) present in defect areas by several orders of magnitude 
[12]. 
Synthetic polymers can be fabricated to match a patient’s complex facial 
geometry and can be integrated with biologics to induce bone growth when implanted in 
vivo. Synthetic scaffolds have controllable properties such as degradation rate, pore 
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structure, and mechanical stability. Poly-L-lactic acid (PLLA), poly-glycolic acid (PGA), 
poly-D,L-lactic coglycolic acid (PLGA), and poly-Ɛ-caprolactone (PCL) are commonly 
used in bone plugs, and screws. The ester linkages on their backbone degrade via 
hydrolysis into non-toxic metabolites, and their degradation rates are controlled by 
altering their crystallinity and lactide/glycolide ratio [13]. A mineral coating such as TCP 
can be added to alter the surface chemistry or to promote GF binding/release [14]. HA or 
CaP can also be mixed into the synthetic polymer to increase osteoconductivity [15].  
Although successful in some tissue engineering applications, non-osteoinductive 
synthetic materials are not ideal for reconstructing large craniofacial bone defects when 
used in isolation. These polymer grafts could be readily available and easily produced; 
however, they do not integrate as well as autografts when placed directly into a large 
defect site [16]. Generally, surrounding blood vessels cannot penetrate the graft 
sufficiently to provide nutrients to the graft’s core. This may be because nutrient 
diffusion is optimally effective within 150-200µm from a blood supply source and 
irradiated wound sites are not conducive to developing a rich vasculature [17,18].  
To increase osteoinductive properties, stem cells can be added to the synthetic 
scaffold to promote graft integration and bone remodeling. The most common stem cell 
sources are adult stem cells which can come from the bone marrow as mesenchymal stem 
cells (MSCs) or more frequently from easy-to-harvest adipose tissue (adipose derived 
stem cells) [16]. Bone growth on a cell-seeded graft is better than its acellular 
counterpart, which indicates that stem cells have a positive impact on graft maturation; 
however, challenges associated with adding cells include obtaining enough stem cells 
from the patient and then rapidly and uniformly seeding a large scaffold [19-21]. 
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Although cell therapy has been widely studied, translation of this process into clinical 
practice has been hindered due to the lack of FDA-approved off-the-shelf devices that 
incorporate patient cells [22]. 
1.2.3 Tissue Engineering a Bone Graft 
An ideal large synthetic graft should have osteoinductive/conductive properties as 
well as native autograft mechanical properties. The matured flap should have a vascular 
pedicle that can be connected to a blood vessel at the defect site to provide nutrient 
supply throughout the flap. To tissue engineer a scaffold with these properties, first, a 
patient-specific biomaterial scaffold design is combined with a biologic at a site remote 
from the defect site. Next, after a maturation period the construct is transplanted as a 
bone flap to the defect site. The maturation phase can be completed in vitro or in vivo.  
 In vitro fabrication requires the scaffold to be seeded with the patient’s stem cells 
and then placed in an external bioreactor. Integration has been comparable to that of an 
autograft [16]; however, this method is a very complicated and variable one due to the 
need for uniform cell seeding and for maintaining an optimal nutrient perfusion 
throughout the construct. Furthermore, the internal interconnecting microarchitecture not 
only needs to be sufficiently porous to promote cell ingrowth and nutrient diffusion (150-
200µm from the blood supply) [17,18], but also strong enough to withstand the forces 
exerted in the region [15]. As mentioned previously, a cell-based construct will need to 
overcome many regulatory hurdles prior to entering the clinic. An alternative to creating 
the flap in vitro is to fabricate the bone flap in vivo by using the patient’s body as a 
bioreactor to partially remodel the construct prior to transplanting it to the defect site. 
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1.3 Pre-Fabricating a Bone Flap  
 Pre-fabricating a flap in vivo involves implanting a customized synthetic scaffold 
with associated biologics in the latissimus dorsi for a maturation period, and then 
transplanting it to the defect site as a complex bone tissue flap with an attached vascular 
pedicle. The latissimus dorsi was chosen due to its high vascularity and easy access 
during surgery. Studies in this field have been conducted in Europe and Asia, but not in 
the United States to the best of our knowledge. There are few reports of this procedure in 
animal models [23-28] and even less in humans [29-31]. 
In a study conducted by Warnke et al [28], an external titanium mesh cage in the 
shape of a human mandible was filled with BioOss blocks, soaked in 3.5mg BMP7, and 
implanted in a minipig for six weeks. The engineered bone had similar mechanical 
properties to that of natural bone. In 2004, the same research group conducted a clinical 
trial using a customized titanium mesh cage filled with bone mineral blocks soaked in 
7mg BMP7 and added the patient’s bone marrow [30]. Despite initial positive results, 9 
months post implantation the construct fractured due to overloading, became infected, 
and contained necrotic areas [31]. Terheyden et al. created collagen cylinders filled with 
BioOss soaked in 0-1000µg BMP7 and implanted the cylinders in a minipig. Results 
found 1mg BMP7 was needed to produce sufficient bone [27]. Finally, Heliotis et al. 
used a hydroxyapatite scaffold with 3.5mg osteopontin-1 (BMP7) in a clinical trial. No 
patient stem cells or bone marrow were added. Five months post transplantation to the 
defect, the graft was infected with methicillin-resistant staphylococcus aureus (MRSA) 
and failed [29].  
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The constructs used in previous pre-fabricated flap studies had relatively crude 
geometries. Furthermore, using titanium as the scaffolding material can cause titanium 
mesh exposure and fatigue issues. An ideal flap would contain a scaffold with mechanical 
properties similar to that of bone which degrades gradually as the bone tissue regenerates. 
The material should be biocompatible and easily integrated with GFs in the clinic. Tissue 
engineering a vascularized bone flap in vivo is a promising alternative to using an 
autograft to reconstruct a large craniofacial defect.   
1.3.1 Multiple Biologics Delivery 
BMP2 has been extensively investigated for bone tissue engineering applications 
due to its potent osteogenic properties. Depending on the binding and delivery method 
utilized, BMP2 can regenerate bone on both synthetic and natural scaffolds.  
Additionally, there is a positive relationship between osteogenic and angiogenic factors in 
native bone healing.  Angiogenic protein vascular endothelial growth factor (VEGF) has 
been delivered with BMP2 utilizing various complex dual delivery devices; however, the 
results are conflicting regarding the impact on the regenerated bone volume in an ectopic 
location [11,32-34]. The effect of dual delivering hematopoietic protein erythropoietin 
(EPO) and BMP2 has been superficially investigated due to the two proteins’ synergistic 
relationship [35,36], but further studies are needed to determine the effect of locally 
delivering both proteins on ectopic bone regeneration. With respect to pre-fabricated 
flaps, considering the clinical applicability when binding the GFs to a scaffold and 
delivering multiple biologics have not been investigated to the best of our knowledge.  
The ultimate goal of bone tissue engineering for large bony defects is to fabricate 
a vascularized bone flap in vivo that regenerates enough bone and a vascular pedicle for 
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successful reconstruction. PCL is an appropriate material for bone tissue engineering 
applications due to its slow degradation rate that will support load while bone is 
regenerating, its compatibility with selective laser sintering to fabricate complex 
geometries, and its ability to deliver osteogenic growth factor BMP2.  Electrostatic 
adsorption completed in a clinically applicable environment may be more advantageous 
over covalent conjugation via sulfo-SMCC for binding BMP2 to PCL because it 
regenerates more bone. Delivering angiogenic protein VEGF along with BMP2 could be 
a potential method to increase the bone regeneration rate due to increased vasculature and 
nutrient delivery. Finally, since EPO has a synergistic relationship with BMP2, dual 
delivery may increase the regenerated bone volume.   Increased bone volume is important 
for pre-fabricated flap applications because the flap would mature faster and could be 
transplanted at an earlier time point. This dissertation investigates osteogenic factor 
binding to PCL scaffolds in a clinically applicable environment and determines the effect 
of dual GF delivery on bone regenerated in an ectopic location to further optimize the 
pre-fabrication process. 
1.4 Thesis Aims 
This thesis addresses the limitations of the current pre-fabrication process and 
advances it by integrating patient-specific design, 3D printing, multiple biologics 
delivery, and considering a clinical setting.  AIM I refines and compares BMP2 
adsorption and conjugation binding methods to PCL scaffolds in a clinically applicable 
setting (<1 hour protein to material exposure at room temperature) and analyzes the 
resulting bone regenerated in vivo. BMP2 binding and release kinetics are also 
characterized. Scaffolds with adsorbed or conjugated BMP2 are implanted 
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subcutaneously in mice for 8 weeks to determine the resulting bone formation. AIM II 
determines the effect of delivering VEGF along with BMP2 on ectopic bone 
regeneration. BMP2 is delivered from a PCL scaffold as described in AIM I, and VEGF 
is delivered from a collagen sponge fabricated inside of the PCL scaffold.  Dual delivery 
scaffolds are implanted in mice for 4 & 8 weeks to determine the bone growth. In AIM 
III a novel modular scaffold is created to modify dual growth factor binding to be 
clinically applicable.  BMP2 and VEGF are adsorbed onto the inner and outer portions of 
a modular scaffold, respectively, for 1 hour. The two scaffolds are then manually 
assembled and implanted in vivo for 4 & 8 weeks. The results are compared to BMP2 
delivery alone. Finally, in AIM IV we determine the binding and release kinetics of 
BMP2 and EPO from the inner and outer portions of the modular scaffold, respectively, 
that is described in AIM III.  We then assess the effect of dual BMP2 and EPO delivery 
on ectopic bone regeneration in comparison to BMP2 delivery alone. The objectives of 
each aim are summarized as follows: 
AIM I: Compare conjugation and adsorption methods of binding BMP2 to PCL 
in a clinically applicable setting (<1 hour protein exposure to PCL) and analyze 
the resulting regenerated bone in an ectopic site.  
We hypothesize that adsorption will be more optimal than conjugation for clinical 
usage due to protocol simplicity, retained bioactivity, and increased bone 
regenerated in vivo. 
AIM II: Develop a novel dual BMP2 and VEGF delivery system comprised of 
PCL and a collagen sponge to increase the bone regeneration rate. 
12 
 
AIM III: Create a modular PCL dual growth factor delivery scaffold such that 
BMP2 and VEGF are bound in a clinically applicable setting (<1 hour protein to 
PCL exposure) to the inner and outer modules, and assess the bone regenerated in 
an ectopic site. 
We hypothesize that delivering VEGF along with BMP2 from a PCL construct 
will increase the regenerated bone rate from 4 to 8 weeks when compared to 
BMP2 delivery alone in an ectopic location. 
AIM IV: Characterize binding and release kinetics of BMP2 and EPO from the 
components of a modular PCL scaffold, and determine if locally delivering both 
factors increases the bone regenerated at an early time point.  
We hypothesize that delivering adsorbed EPO with BMP2 from a modular PCL 
scaffold will result in more regenerated bone volume at 4 weeks when compared 
to BMP2 delivery alone in an ectopic location. 
 
These aims are connected by their goal to further optimize the pre-fabricated flap 
process. The first aim refines a method of binding BMP2 to PCL while considering a 
clinical setting. Current methods vary greatly for binding BMP2 to scaffolds, and they 
fail to consider an operating room (OR) environment. Studies have used various methods 
for delivering BMP2 from biomaterial scaffolds including sulfosuccinimidyl-4-(N-
maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC), heparin, trauts, adsorption, 
or microparticle incorporation [37-45]. Temperatures and exposure times at which 
protein binding studies have been tested range from 4
o
C-37
o
C and 1-24 hours 
[14,39,46,47].  However, temperatures that are different than the OR environment and 
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long protein to scaffold exposure times make it very difficult to use such binding methods 
in a clinical setting. We hypothesize that adsorption will be more optimal than 
conjugation for clinical usage due to protocol simplicity, retained bioactivity, and 
increased bone regenerated in vivo. 
To create a bone flap for a large defect, there must be enough bone volume as 
well as sufficient vasculature to provide nutrients and remove waste for the regenerating 
bone. Delivering angiogenic growth factor VEGF along with BMP2 from complex 
carriers has resulted in conflicting information that either shows an increase or no change 
in the regenerated bone volume [11,32-34,48].  In AIMS II and III, we apply the BMP2 
and VEGF dual delivery concept to the pre-fabrication model. The two delivery systems 
investigated are a BMP2-adsorbed PCL scaffold with an internal collagen sponge to 
deliver VEGF and a modular PCL scaffold with BMP2 and VEGF adsorbed onto the 
inner and outer portions of a modular scaffold, respectively, and manually assembled. We 
hypothesize that delivering VEGF along with BMP2 from a PCL construct will increase 
the regenerated bone rate from 4 to 8 weeks when compared to BMP2 delivery alone in 
an ectopic location.  
Finally, the time required for the flap to mature once implanted is crucial for 
oncology patients awaiting adjuvant therapy. Hematopoietic protein EPO is FDA 
approved and has resulted in increased orthotopic bone growth when delivered in 
combination with BMP2 [36]. There are few studies that deliver both factors locally [36] 
and none of which we know that investigate dual delivery on PCL or designed scaffolds 
in general. In AIM IV, we apply dual EPO and BMP2 delivery to the prefabrication 
process. We hypothesize that delivering adsorbed EPO with BMP2 from a modular PCL 
14 
 
scaffold will result in more regenerated bone volume at 4 weeks when compared to 
BMP2 delivery alone in an ectopic location. The results of these studies will increase 
scientific knowledge for researchers looking to pre-fabricate a customized complex bone 
tissue flap to reconstruct craniofacial bone defects. 
1.5 Dissertation Contents 
Chapters 2 and 3 of this dissertation review the background of topics used in the 
experimental work included in Chapters 4-7. Chapter 2 provides more information on the 
natural bone regeneration stages and describes the roles that BMP2, VEGF, and EPO 
play in native bone healing.  After understanding how these proteins are naturally 
expressed, we can mimic their expression to produce a tissue engineered construct. 
Chapter 3 elaborates on fabrication methods for synthetic scaffolds used to deliver GFs. 
Single and dual growth factor delivery vehicles are described as well as their effect on 
bone regeneration. Chapter 4 is the first experimental chapter that discusses protein 
binding and release of adsorbed and conjugated BMP2 to PCL scaffolds. BMP2-modified 
scaffolds were implanted subcutaneously in mice and explanted samples were assessed 
for bone regeneration using micro computed tomography (microCT), mechanical testing, 
and histology analyses methods. Chapter 5 builds on Chapter 4’s results by fabricating a 
collagen sponge inside of the BMP2-adsorbed PCL scaffold to co-deliver VEGF. Similar 
methods of assessing bone formation used in Chapter 4 are employed in Chapter 5, 
except that two in vivo time points (4 & 8 weeks) are studied instead of one. In Chapter 6, 
a novel modular PCL construct is developed to deliver both GFs. The scaffold is 
composed of inner and outer modular components that are individually exposed to 
growth factors in a clinically applicable setting, manually assembled, and implanted 
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subcutaneously in a murine model. Two VEGF dosages were tested, and the regenerated 
bone was analyzed as previously described in Chapter 4. Chapter 7 investigates 
delivering EPO along with BMP2 from the modular scaffold. Binding and release 
kinetics were characterized and the regenerated bone in an ectopic location was analyzed 
as previously mentioned. Finally, Chapter 8 will discuss a summary of the results and 
will propose suggestions for future studies. 
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CHAPTER 2 
BONE DEVELOPMENT, REGENERATION, AND GROWTH FACTORS 
 
2.1 Endochondral vs. Intramembranous Ossification 
There are two methods by which bone forms during development: endochondral 
and intramembranous ossification. Long bones are formed through endochondral 
ossification, and flat bones, such as those seen in the skull, are created through 
intramembranous ossification. During the latter method, capillaries invade the 
mesenchymal zone and mesenchymal stem cells (MSCs) differentiate into osteoblasts 
(bone forming cells). These osteoblasts deposit osteoid to form bone spicules which 
develop into the trabeculae. As the trabeculae grow, woven bone forms in a weak 
disorganized structure. After continuous remodeling, lamellar, or mature, bone forms [1].  
During endochondral ossification, long bones initially begin as a cartilage model 
and then transition to bone tissue. Prior to birth, ossification begins at the primary 
ossification center which is where the diaphysis (or shaft) of the bone will eventually 
form. After birth, the secondary ossification sites appear which are where the epiphyses 
(the two rounded ends of the long bone) form.  First, MSCs cluster and form a cartilage 
model of the bone (Figure 2.1A-C). Then, osteoblasts deposit osteoid around the cartilage 
and create a bone collar (Figure 2.1D). Osteoblasts secrete osteoid, and minerals like 
calcium are deposited. Next, the chondrocytes (cartilage cells) inside of the diaphysis 
proliferate, hypertrophy, and apoptose to create a cavity which allows for blood vessel 
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infiltration (Figure 2.1E). The vasculature transports osteoblasts to the marrow area and 
ossification begins which elongates the bone. Finally, trabecular (or cancellous) bone 
forms in the marrow space, and compact bone forms around the outside (Figure 2.1F) [1]. 
 
Figure 2.1: The Stages of Endochondral Ossification. A) MSCs condense. (B) MSCs 
differentiate into chondrocytes which form the cartilage model. (C) The primary 
ossification center forms and chondrocytes stop proliferating. (D) Osteoblasts form a 
bone collar. (E) The chondrocytes apoptose, and a cavity forms to allow for vascular 
infiltration to transport osteoblasts to the site. (F) Growth plates form at the secondary 
ossification centers after multiple cycles of chondrocyte hypertrophy, vascular invasion 
and osteoblast activity. Finally, trabecular and cortical bone are formed. (Image taken 
from Kanczler et al., Eur Cell Mater, 2008 [1]) 
 
Once a bone has fully developed, it continuously goes through a remodeling 
process in which old bone is removed by osteoclasts, and new bone is replaced by 
osteoblasts. Remodeling is needed to increase bone strength when there is extra stress 
applied and to release calcium to other parts of the body. Development and remodeling 
are not the only times that bone goes through regeneration. When bone tissue sustains an 
injury, such as a fracture, it progresses through a healing cycle. After the initial fracture, a 
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hematoma forms from the broken blood vessels, and an inflammatory response activates 
cytokines and growth factors which recruit osteoprogenitors and MSCs to the injury site 
(Figure 2.2A)[1-3]. Next, blood vessels and connective tissue stem cells infiltrate the 
fracture site to phagocytize the injury debris and form a fibrocartilaginous callus. Fibrous 
connective tissue and cartilage matrix is laid down so that new bone can form (Figure 
2.2B). Osteoclasts then break down the fibrous and cartilaginous portions, and osteoblasts 
lay down a bone matrix to form a callus of spongy bone [1,4].  The new bone volume is 
generally greater than the fracture volume (Figure 2.2C). In the final stage, osteoclasts 
and osteoblasts remodel the bone until the original dimension is recreated (Figure 2.2D) 
[1]. 
 
Figure 2.2: The Stages of Bone Fracture Healing. A) A hematoma forms at the fracture 
site. B) Neovascularization occurs, and the internal callus composed of fibrous tissue and 
cartilage forms. C) A boney callus is formed as osteoclasts remove the cartilage and 
osteoblasts lay down new bone. D) Bone remodeling occurs until the original geometry is 
achieved. (Image taken from: Cummings B. Figure 5.5. Stages in the Healing of a Bone 
Fracture: Pearson Education, Inc., 2004, [5]) 
 
 During this complex fracture healing process, many growth factors and signals are 
expressed to recruit cells and guide cell gene expression to stimulate osteogenesis and 
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angiogenesis. These factors are typically utilized in methods to tissue engineer bone due 
to their natural involvement in bone healing.  
Osteogenic 
Protein 
Role in Bone Regeneration References 
BMPs 
(BMP-2,-4) 
Influences MSCs to differentiate into osteoblasts 
[1,6-9] 
PDGF 
Releases when the hematoma forms and stimulates 
osteoblast migration  
Increases MSC proliferation 
[1,10-12] 
βFGF (-2b) 
Increases MSC proliferation 
Promotes an osteogenic response in progenitor cells by 
providing cytotoxic resistance to inflammatory oxidants 
[1,12-15] 
IGF (IGF-1) 
Stimulates osteoblast chemotaxis and activity 
Expressed in proliferating chondrocytes 
[12] 
TGFβ 
Influences MSCs to differentiate into the chondrogenic 
lineage and proliferate 
Involved in matrix production 
[1,9,16-18] 
Angiogenic 
Protein 
Role in Bone Regeneration References 
VEGF 
Coordinates metaphyseal and epiphyseal vascularization, 
cartilage formation, and ossification 
[1] 
βFGF (-2) 
Accelerates fracture repair 
Stimulates angiogenesis and osteoblast differentiation 
[14,19-23] 
TGFβ 
Released by endothelial cells and promotes bone 
deposition 
[24] 
Ang-1 
Potentiates the BMP2 signaling pathways and stimulates 
angiogenesis  
Increases trabecular bone and vascularity  
[25] 
EPO 
Influences HSCs to produce BMPs  
Activates MSCs to differentiate into osteoblasts 
Similar to VEGF and has angiogenic properties 
[26-29] 
Table 2.1: Osteogenic and Angiogenic Factors and their Role in Bone Regeneration. 
BMP: bone morphogenetic protein; PDGF: platelet derived growth factor, FGF: 
fibroblast growth factor; IGF: insulin like growth factor; TGF: transforming growth 
factor; VEGF: vascular endothelial growth factor; Ang-1: angiopoietin; EPO: 
erythropoietin; MSC: mesenchymal stem cells; HSC: hematopoietic stem cells 
 
2.2 Bone Morphogenetic Protein-2 and Bone Regeneration 
Bone morphogenetic proteins (BMPs) [30], fibroblast growth factors (FGFs) [31], 
insulin like growth factor-1 (IGF-1) [32], transforming growth factor-beta (TGF-β) [33], 
and platelet derived growth factor (PDGF) [34] are a few of the key factors temporally 
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expressed during bone healing that assist with the osteoblast recruitment, proliferation, 
and differentiation [35]. The most potent osteogenic proteins are the BMPs which induce 
cartilage and bone formation [36]. 
BMPs belong to the TGF-β superfamily and are naturally produced by MSCs, 
osteoblasts, and chondroblasts. MSCs [37], chondroblasts [38], osteoblasts [36], and 
fibroblasts [39] are present during bone regeneration and development, and if they are 
exposed to BMP2, they differentiate down an osteogenic lineage. BMP2 is a disulfide-
linked homodimeric protein consisting of two 114 amino acid residue subunits (~26kDa 
dimer). Its glycosylated form is about 36kDa. Molecularly, BMP (-2,-4,-7) dimerizes and 
binds to a receptor complex containing type I and type II serine/threonine receptor 
kinases on the cell membrane as seen in Figure 2.3. This unit then phosphorylates 
SMAD1, 5 and 8 which forms a complex with SMAD 4 and translocates into the nucleus 
where it interacts with Runx2 transcription factor [40,41]. This interaction up-regulates 
gene expression such as osterix, collagen type 1, alkaline phosphatase, and matrix 
metalloproteinase (MMP-13).   
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Figure 2.3: Cell Signaling Pathway for BMP2 Activity. (Chen et al., Int J Biol Sci, 2012 
[42]) 
 
Recombinant forms of BMP2 and BMP7 are potent osteoinductive agents that 
stimulate healing in long bone critical sized defects [43,44]. The earliest skeletal need for 
BMP signaling is during chondroblast compaction. Signaling then mediates chondroblast 
proliferation and hypertrophy indicating a direct role in chondrogenesis which is the first 
stage in endochondral ossification [45]. In models lacking skeletal BMP2 production, 
there were significant delays in the formation of the secondary ossification centers and 
increased micro-fractures. Osteoprogenitor cells were also unable to proliferate and 
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differentiate into fully functional osteoblasts, indicating BMP’s crucial role in 
progressing an osteoprogenitor cell into a mature osteocyte.  
In relation to fracture healing, the BMP2 signaling cascade begins during the 
initial phases of bone healing which triggers an inflammatory response and periosteal 
activation. BMP2 is also important during later stages of osteogenesis [46]. In one study, 
mice lacking bone-specific expression of BMP2 were unable to initiate a healing 
response [47]. Those with BMP2 produced new bone at the trauma site, and a highly 
proliferative callus was present. Femurs without BMP2 produced some bone but there 
was no bridging callus. In a similar study that lacked BMP4 and BMP7, normal fracture 
healing occurred despite the missing proteins [45]. Finally, loss of endogenous BMP 
activity leads to osteopenia, bone fragility, and spontaneous fracture. Taken together, this 
information indicates that BMP2 plays a crucial role in osteogenesis and fracture healing 
[42,47-49]. 
Recombinant human BMP2 (glycosylated) can be manufactured in mammalian 
cells such as chinese hamster ovary cells (CHO); however, this purification method is 
associated with post-translational problems, low yields, and high cost [50]. BMP2 can 
also be purified from Escherichia Coli (e-coli) which results in a higher yield and lower 
cost. E.coli produced BMP2 is not glycosylated which alters the protein’s solubility. 
When compared to glycosylated BMP2, the non-glycosylated version proves to be a more 
potent osteogenic agent that produces more bone in vivo [51].  
Currently, two BMP devices are approved by the Food and Drug Administration 
(FDA) for clinical usage: BMP2 loaded into a collagen matrix (Infuse
TM
, Medtronic 
Sofamor Danek, Inc) used for spinal fusion, open tibial fractures, sinus augmentation, and 
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dental procedures [52] and BMP7 (OP-1TM, Stryker Biotech) used for long bone defects 
and non-union treatment [35,53]. These products are costly due to high BMP doses (2-
12mg) which greatly exceed the physical concentrations (18.8-22g/mL) present in defect 
areas by several orders of magnitude [35].  
2.3 Vascular Endothelial Growth Factor and Bone Regeneration 
When regenerating a large bone volume, it is crucial to develop a rich vascular 
network. Vasculature provides developing bone with necessary nutrients such as growth 
factors, hormones, cytokines, chemokines and metabolites. Of the angiogenic proteins 
that can stimulate neovascularization, vascular endothelial growth factor (VEGF) is the 
most potent, and VEGF is expressed during the early phases of bone healing.   
VEGF has four isoforms: VEGF-A, VEGF-B, VEGF-C, and VEGF-D. VEGF-A 
(also known as VEGF-165) is a 34-46kD homodimeric glycoprotein produced by MSCs, 
osteoblasts, and chondrocytes. It has a high affinity receptor VEGFR2 (Flk-1/KDR) 
located on the cell membranes of monocytes, neurons, chondrocytes, osteoblasts, and 
osteoclasts. As seen in Figure 2.4, VEGF is involved in many cell signaling pathways. 
VEGF is essential in coordinating metaphyseal and epiphyseal vascularization, cartilage 
formation, and ossification during endochondral ossification [1]. During this time, VEGF 
promotes vascularization and regulates the survival and activity of endothelial, 
chondrogenic, and osteogenic cells [54]. Hypertrophic chondrocytes secrete VEGF which 
induces angiogenesis from the perichondrium and leads to the recruitment of osteoblasts, 
osteoclasts, and hematopoietic cells. These cells then assist with developing the primary 
ossification centers [1]. VEGF is responsible for forming a vascular network to provide 
nutrients, for recruiting endothelial progenitor cells [55], and for inducing osteoblast 
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migration and differentiation to produce bone [56]. On a molecular level, Runx2 
expression (also important in pre-osteoblast differentiation) may regulate VEGF 
expression and angiogenesis at the growth plate/trabeculae junction [1]. 
 
Figure 2.4: Cell Signaling Pathway for VEGF Activity. (Cao et al, Blood, 2010 [57]) 
 When bone is healing, angiogenic factors are expressed at an earlier time point 
while osteogenic factors are continuously expressed [58,59]. VEGF is highly expressed 
during the first seven days but decreases in later phases [60]. The growth factor is 
expressed before blood vessels are detected, and its expression is linked to bone 
formation [4,61]. With respect to facture healing, VEGF is expressed in chondroblasts, 
chondrocytes [62], osteoprogenitor cells and osteoblasts in the fracture callus [63].   
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Recombinant human VEGF-165 can be purified using various methods. One 
efficient method is to produce the protein in the endosperm tissue of barley grain 
(hordeum valgare) [64]. Wheat-produced VEGF results in up to 50 times less protease 
activity when compared to VEGF produced in e.coli [65] or in CHO cells [66]. 
During bone development, there is a natural interaction between osteogenesis and 
angiogenesis [67]. Sojo et al. showed that angiogenesis occurs before osteogenesis in 
bone lengthening [68]. Furthermore, the rate that bone marrow stromal cells (BMSCs) 
differentiate into osteoblasts may be controlled by endothelial cells by initiating 
osteoprogenitor cell recruitment to the bone remodeling site [69]. Co-culture experiments 
find osteoblast-like cells stimulate endothelial cell proliferation by producing VEGF, and 
endothelial cells stimulate osteoprogenitor cell differentiation by producing BMP2 [70-
72]. Exposing endothelial cells to VEGF increased BMP2 mRNA expression [73], 
indicating an interactive relationship between angiogenesis and osteogenesis. Overall, 
VEGF has the potential to synergistically interact with BMP2.  
2.4 Erythropoietin and Bone Regeneration 
 Erythropoietin (EPO) is an acidic glycoprotein with a molecular weight of 
30.4kDa. The core contains two bisulfide bridges composed of 165 amino acids [74]. 
EPO’s main function is as a hematopoietic hormone that is secreted from the liver and 
kidneys in response to hypoxia. This release is initiated by activating HIF-1α [29,75]. 
EPO regulates red blood cell proliferation and has angiogenic properties in various 
tissues [26,27]. Interestingly, EPO shares some functional and structural similarities with 
VEGF [27]. Once secreted, EPO binds to EPO receptors (EPOR) on cellular membranes. 
EPOR are also expressed on cells not involved in hematopoietic functions such as on 
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endothelial cells [27,76], neurons, and trophoblast cells [28]. Brines et al. [75] found 
EPO-EPOR signaling was activated in response to neuronal injury, and several other 
studies find EPO induces cell proliferation in the kidney, intestine, and skeletal muscle 
[77-79].  Due to EPOR expression on many cell types, EPO may have specific functions 
for different tissues [29]. 
 
Figure 2.5: Cell Signaling Pathway for EPO Activity. (Gao et al., Am Heart J, 2012 [80]) 
 
 There are several suggestions as to how EPO positively influences bone healing; 
however, the mechanisms regulating the process remain vague [29,81]. One study 
suggests EPO activates Jak-Stat signaling pathways in hematopoietic stem cells (HSCs) 
which leads to the production of BMPs. EPO also directly activates mesenchymal cells to 
differentiate into osteoblasts (in vitro). In vivo, mice treated systemically with 
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supraphysiological EPO doses had increased bone mineral density, bone volume fraction, 
and the osteoblasts that adhered to the bone surfaces [28,29]. EPO could increase bone 
healing directly by binding to EPOR on BMSCs to induce osteoblastic differentiation 
and/or indirectly by stimulating HSCs to produce BMPs which affects bone healing as 
mentioned in Section 2.2 [28,29]. Another method by which EPO could increase bone 
regeneration is EPO’s ability to increase osteoclastogenesis [81]. Osteoclasts can recruit 
MSCs to the site of bone remodeling, and these MSCs have the potential to differentiate 
into osteoblasts [81]. 
 Glycosylated EPO is required for its biological activity in vivo. For this reason, 
recombinant human EPO is manufactured in CHO cells. During glycosylation, several 
sugars are trimmed from the protein, it is folded and moved to the golgi complex, and 
then mannose elimination occurs before N-acetylglucosamine, galactose and sialic acid 
(N-acetylneuraminic acid) are added [74]. EPO’s survival in circulation requires the 
presence of terminal sialic acid residues of its N-glycans [74]. Amgen’s product 
EPOGEN
®
 is produced in mammalian cells and is FDA approved. EPOGEN
® 
uses EPO 
to increase the red blood cell levels caused by chronic kidney disease in anemic patients. 
Taking EPOGEN
®
 avoids the need for red blood cell transfusions and is safe to use in 
oncology patients [82,83]. 
2.5 Conclusion 
When engineering bone tissue, it is important to take into consideration the 
natural factors expressed during native bone development and bone fracture healing. Of 
all of the factors that stimulate bone healing, BMP2 is the most potent osteogenic factor 
that plays a key role in long bone development through its influence on a variety of cells. 
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VEGF is a widely studied potent angiogenic factor that stimulates vasculature 
development to transport MSCs to the bone formation site. Co-culture experiments find 
synergistic effects between BMP2 and VEGF which could positively influence bone 
healing. For this reason, we will use VEGF as the angiogenic protein to co-deliver with 
BMP2. EPO has shown to have positive effects on bone formation by directly influencing 
BMSCs to turn into osteoblasts or indirectly by influencing HSCs to produce BMPs. 
Since EPO is FDA approved and has shown to work synergistically with BMP2, we 
delivered it with BMP2. BMP2, VEGF, and EPO play a role in native bone healing; 
therefore, we delivered BMP2 alone and in combination with either VEGF or EPO to 
increase the bone regenerated on poly-Ɛ-caprolactone scaffolds that were implanted in an 
ectopic location.  
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CHAPTER 3 
SCAFFOLD TISSUE ENGINEERING-FABRICATION METHODS AND 
PROTEIN DELIVERY VEHICLES  
 
3.1 Introduction 
When designing a biologic carrier, it is helpful to consider native bone structure 
and material properties such as load bearing capabilities and porosity for nutrient 
diffusion. The scaffold should maintain incorporated biologic bioactivity, and the 
delivered growth factors (GFs) should stimulate bone development. Scaffold fabrication 
methods include salt leaching, solvent casting, phase separation, and rapid prototyping. 
Each of these has advantages and disadvantages for bone tissue engineering applications 
and meeting regulatory standards. Both natural and synthetic scaffold materials are 
currently utilized and employ numerous protein incorporation methods which result in 
varied GF release profiles. Sometimes two scaffold materials will be combined to deliver 
one or more proteins. This chapter will address scaffold manufacturing methods, protein 
incorporation methods, release profiles, and regenerated bone quality for bone 
morphogenetic protein-2 (BMP2), vascular endothelial growth factor (VEGF), and 
erythropoietin (EPO). 
3.2 Fabricating Synthetic Scaffolds 
To create a patient specific scaffold for the cranio-maxillofacial region, first a 
computed tomography (CT) image is taken of the face. Next, the image is translated into 
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a computer-aided design (CAD) model using software such as MIMICS™ (Materialise, 
Leuven, Belgium) or MATLAB™ (The Mathworks, Natick, MA). Using this software, a 
porous architecture is created to facilitate tissue ingrowth and to alter the mechanical 
properties. Finally, the scaffold is manufactured using a variety of 3-dimensional (3D) 
rapid prototyping techniques such as stereolithography, fused deposition modeling 
(FDM), or selective laser sintering (SLS). Other scaffold fabrication methods involve salt 
leaching, solvent casting, and thermal phase separation. Polylactic acid (PLA), 
polyglycolic acid (PLGA), and poly-Ɛ-caprolactone (PCL) are Food and Drug 
Administration (FDA) approved materials that are commonly utilized [1].   
3.2.1 Salt Leaching, Solvent Casting, and Phase Separation  
Commonly used scaffold fabrication methods involve spray/emulsion freeze 
drying, particulate leaching/solvent casting, and thermally induced phase separation [2]. 
Microspheres loaded with proteins or drugs can be prepared by a spray drying method 
which sprays a solid-in-oil dispersion or water-in-oil emulsion in a stream of heated air 
[2,3]. Drawbacks include low process efficacy and a risk of denaturing proteins due to 
dehydration. Microparticles could also adhere to the inner walls of the spray dryer [4]. 
Emulsion requires the use of hazardous organic solvents which need to be completely 
evaporated prior to using the scaffold. Due to this health risk, regulatory hurdles would 
increase if a fabrication method involves organic solvents. Furthermore, the high 
temperatures used in this process can damage or denature the loaded protein [2,4].  
Particulate leaching is a popular method which uses porogens such as salt or sugar to 
create pores in a biomaterial. Briefly, the porogen is ground into particles of a certain size 
and poured into a mold. The polymer solution is then cast into the mold and the solvent is 
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evaporated such that the salt crystals are leached away to create pores. This method 
requires less polymer solution; however, the pore shape and inter-pore openings cannot 
be controlled [5]. Solvent casting dissolves a polymer and drug mixture into a solvent to 
the desired proportion. The solvent is then cast at about 60
o
C until the toxic solvent is 
completely evaporated. One of the main drawbacks of this technique is that the solvent 
could denature the protein [4]. Phase separation uses temperature change to separate a 
polymer solution into two phases of either high or low polymer concentrations [5]. Since 
the process is mediated by a solvent and coacervate agent, the solutions can react with the 
protein and disrupt the secondary structure [2]. Phase separation techniques tend to 
produce agglomerated particles and also require the removal of large quantities of the 
organic phase from the microspheres [4].  
Scaffolds fabricated by these aforementioned techniques may retain some solvent 
toxicity if it is not removed completely and would face increased regulatory hurdles to 
translate into the clinic [5]. Overall, these methods result in less reproducible external and 
internal geometries which translate to decreased control over scaffold geometry, 
mechanical properties, and surface area needed for protein integration [1].   
3.2.2 Rapid Prototyping: Stereolithography, FDM, and SLS  
Stereolithography, FDM, and SLS are rapid prototyping techniques that can 
produce more complex geometry scaffolds than the methods discussed in Section 3.2.1 
[6-10]. Stereolithography selectively polymerizes photosensitive resin using ultraviolet 
(UV) light. The UV laser beam focuses on a layer of resin on a platform and polymerizes 
it. The platform then moves in the X and Y directions to form a 2D geometry. Next, a 
fresh layer of resin is added on top of the cured layer, and the laser is applied again. 
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Ultimately, the scaffold is built in the Z direction. Although stereolithography produces 
high resolution scaffolds with a good surface finish, it also requires post-curing steps, and 
there can be some shrinkage and curling due to the phase change. Furthermore, only 
photo polymers can be used with the machine which limits the number of compatible 
materials [11]. 
More materials are compatible with FDM which melts and selectively deposits a 
thin filament of thermoplastic polymer on a stage to form the scaffold layer by layer. The 
material is provided on a spool, and the wire is threaded through the FDM head. The 
table moves in the X and Y directions and a cross-hatch design is created with the 
filament. The table then moves down in the Z direction, and the next layer is added on 
top of the previous one. The two filament layers then fuse together due to the heat. 
Although FDM machines are economical and the material can be easily changed, this 
method is not compatible for high resolution details as the Z resolution is limited [11].  
SLS requires a material that is in powder form and selectively fuses the particles 
with a high power laser into the desired shape from the digital information received from 
CAD data [10]. The table then moves down in the Z direction, and a fresh layer of 
powder is added to the top. The laser fuses the powder again, and the 3D scaffold is 
created layer by layer in the Z direction. SLS can repeatedly and reproducibly produce 
scaffolds with complex geometries, controlled pore size, and detailed stiffness. Scaffold 
resolution is limited by the laser spot size and the powder particle size. The SLS build 
time is faster than the other mentioned methods, and the machine is compatible with a 
variety of materials such as nylon,  polyether ether ketone (PEEK), β tri-calcium 
phosphate (β-TCP), poly-l-lactide acid (PLLA), and PCL [11,12]. 
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The bone tissue scaffolding material can be chosen based on the fabrication 
method and the mechanical properties needed. With respect to maintaining incorporated 
protein bioactivity, the degraded material’s byproducts should also be taken into account. 
For example, as PLGA degrades, the released glycolic and lactic acids cause the pH to 
decrease, which results in a loss of protein bioactivity due to protein aggregation and 
chemical degradation [2]. PCL degradation generates less acidic byproducts and leads to 
less inflammation than the more rapidly-degrading polylactic acid based co-polymers 
[13].  
3.2.3 Poly-Ɛ-caprolactone  
PCL is a biocompatible and bioresorbable polymer that can be utilized with 
image-based CAD and SLS manufacturing techniques. The ester linkages on PCL’s 
backbone degrade via hydrolysis into non-toxic metabolites consisting mainly of 6-
hydroxyl caproic acid [14]. PCL degrades over three years, and its mechanical properties 
support its use for bone tissue engineering applications in complex reconstruction sites 
where bone may take over a year to form. In these sites, a PCL scaffold’s slower 
degradation time is an advantage to provide form and load bearing over a longer time 
period.  When compared to other synthetic materials, it is significantly less expensive and 
available in large quantities. PCL has already been approved for cranioplasty bone filling 
applications by the FDA [15,16]. Thus, the polymer has been widely tested, utilized, and 
has achieved regulatory approval as a bone repair scaffold. We propose using PCL as an 
ideal biologic delivery vehicle for pre-fabricated flaps because of the polymer’s 
mechanical properties and safe manufacturing method. 
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3.3 BMP2 Growth Factor Delivery Methods 
BMP2 has the potential to increase bone growth, but it has a very short half-life 
when delivered systemically in a solution. To increase its effectiveness, BMP2 can be 
delivered locally using synthetic or natural carrier materials. Various release profiles are 
observed depending on the material and binding method utilized.   
3.3.1 BMP2 Delivery Vehicles & Binding Methods 
Natural materials (i.e. collagen, alginate, hyaluronic acid) mentioned in Section 
1.2.2 are used as scaffolding for mineralized tissue; however, drawbacks include batch-
to-batch variations, potential for immune reactions, and mechanical properties that are 
well below that of native bone tissue [17]. Collagen is FDA approved as a carrier for 
BMP2 with Medtronic’s spinal fusion product INFUSE™; however, there is a large burst 
release within the first 2-3 days which can result in heterotopic bone growth [18]. 
Because of BMP2’s short half-life, a 1.5 mg/ml BMP2 (2-12 mg) dose is needed which 
has caused adverse reactions in patients and resulted in a lawsuit. 
Synthetic materials can be fabricated with controllable properties such as 
degradation rate, pore structure, and mechanical stability. A mineral coating like TCP can 
be added to alter the surface chemistry and to promote BMP2 binding and release [19]. 
BMP2 adsorbed onto PLLA/TCP scaffolds resulted in a 70% burst release during the first 
two days [20]. Jeon et al. compared slow and rapid BMP2 delivery from PLGA 
microspheres and found that sustained delivery resulted in enhanced bone formation [21].  
There are a wide range of methods used to bind BMP2 to materials, and the 
release profiles depend on the method employed. For example, a more controlled release 
was achieved by chemically conjugating BMP2 to chitosan with a cross linker 
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sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) in 
comparison to adsorption. Sulfo-SMCC is a heterobifunctional crosslinker with an NHS-
ester group that binds to amines and a maleimide group that binds to the cysteine group 
on BMP2. Since the cysteine is located in the BMP2 protein’s inner core, the sulfo-
SMCC may not be able to bind to the cysteine. In this situation, an unfavorable reaction 
occurs in which the maleimide interacts with free amines on the BMP2 protein. 
Conjugation enhanced the material’s in vitro osteoinductive properties; however, chitosan 
is not an ideal carrier because it lacks mechanical integrity for bone tissue engineering 
applications [22]. In that study, the scaffold was exposed to BMP2 for 10 hours at 4
o
C.  
Other studies combined sulfo-SMCC in combination with trauts reagent to bind BMP2 to 
a demineralized bone matrix or collagen [23,24]. In those scenarios, the protein was 
exposed to the material in a more clinically applicable time frame of 1 hour at room 
temperature.  
Heparin [25,26], 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) [27], 
and poly(ethylene-glycol) (PEG) [28] chemistry has also been used to covalently 
crosslink BMP2. These methods use BMP2’s N-terminal heparin binding site which 
creates a stronger bond than adsorption [29-31]. Heparin’s negatively charged sulfate 
groups interact with the protein’s positively charged amino acid residues. For these 
studies, the materials were exposed to BMP2 anywhere from 1 to 6 hours in room 
temperature or 4
o
C environments. When using heparin, release rates have reported to 
vary from 80% released in 28 days [25] to 99% BMP2 bound to PLGA and 100% 
released in 14 days [26]. PEG bound about 82% BMP2 to a PLGA scaffold after which 
there was a sustained release for 8 days and a gradual release for 28 days [28].  
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Adsorption is a much simpler GF incorporation method. Adsorption utilizes 
electrostatic forces to bind the GF to the surface and can be adjusted by altering the pH or 
the material’s surface roughness. PCL has a slightly negative charge which attracts the 
positively charged amino acid residues on BMP2’s surface. Adsorption is associated with 
a burst release trend instead of the sustained release observed with conjugation methods. 
Generally, GF exposure time to the materials ranges from 1 to 24 hours in environments 
from 4
o
C-37
o
C [19,32,33]. There are a few studies which superficially compare 
adsorption versus conjugation methods [24,26-28]; however, there are no studies of 
which we are aware that use highly controlled geometry scaffolds and clinical settings 
(<1 hour protein to material exposure at room temperature) for protein binding.  
Previously in our laboratory we compared adsorption versus sulfo-SMCC conjugation on 
salt-leached PCL scaffolds in which the scaffolds were exposed to the BMP2 for 16 hours 
at 4
o
C [24]. Studies assessing conjugation methods utilized either porogen leaching 
[24,26] or other fabrication methods resulting in large variations in pore architecture that 
may significantly affect release kinetics, not allowing a rigorous comparison of 
adsorption and conjugation methods [22,25,28]. Overall, there are many methods for 
incorporating BMP2 onto a biomaterial surface. When designing a binding method to use 
in the clinic, however, it is important to consider the conditions in an operating room 
(OR).  
PCL can be modified to integrate BMP2 [24,34]; however, further studies are 
needed to refine a method to functionalize PCL scaffolds with BMP2 in a clinically 
realistic time frame to produce bone when placed in an ectopic site (i.e. pre-fabricated 
flap applications). It is likely that any clinically relevant BMP2 delivery method for the 
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near future must be performed in the OR environment at room temperature with loading 
times of 1 hour or less, or it will face regulatory hurdles such as unknown sterilization 
effects on GF bioactivity.  
3.4 BMP2 & VEGF Dual Delivery 
Transplanting bone stock alone is insufficient to maintain construct viability, and 
it is crucial to develop a rich vasculature.  VEGF is a potent angiogenic factor that has the 
potential to stimulate blood vessel growth into the scaffold. Co-culture studies found that 
osteoblast-like cells stimulated endothelial cell proliferation by producing VEGF, and 
endothelial cells stimulated osteoprogenitor cell differentiation by producing BMP2 
[35,36]. These results suggest that there is a coupling between osteogenesis and 
angiogenesis. The methods utilized to deliver these growth factors vary and could impact 
the regenerated bone quality.   
3.4.1 VEGF Delivery Vehicles & Binding Methods 
Some of the scaffold materials used to deliver VEGF include PCL, PEG 
diacrylate, collagen, and alginate. Solvent casting, particulate leaching, 
photopolymerizaion, and crosslinking are manufacturing methods associated with these 
materials [37-41]. VEGF can be crosslinked to a surface using heparin or Arg-Gly-Asp 
acid (RGD), mixed into a hydrogel, or incorporated into microparticles. The nano or 
microparticles can be made of hyaluronic acid/chitosan, PLGA, or collagen. Furthermore, 
these particles can be used alone or in combination with scaffolds that embed the 
particles [42-48]. To prepare the scaffold, a double emulsion or solvent evaporation 
method is employed, which can result in a highly variable VEGF release lasting from 1 
day to 4 weeks. These growth factor integration and delivery methods are complex and 
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cannot be easily translated to the OR environment as mentioned in Section 3.2.1. It is 
important to note that because of VEGF’s short half-life at 37oC (approximately 90 
minutes) [49], it is often difficult to create a reliable release profile that represents in vivo 
release. If the protein rapidly degrades, an in vitro assay would not accurately detect 
proteins released into the solution.  
Sojo et al. found that angiogenesis occurs before the onset of osteogenesis and 
there is an interaction between the two stages [50]. Dual delivery of osteogenic and 
angiogenic proteins can further enhance the regenerative capacity of bone [51-53]. For 
example, when BMP2, VEGF, and bone marrow stromal cells (BMSCs) were delivered 
from a scaffold implanted in a critically sized mouse defect model, there was a significant 
increase in bone regeneration [53]. On one hand, simultaneous release studies have 
resulted in enhanced bone formation [51,54,55].  On the other hand, to mimic natural 
bone healing, sequential VEGF and BMP2 release systems are under investigation 
[56,57]. Polyelectrolyte multilayer films have been used to deliver both factors and 
resulted in 27% initial BMP2 release and 15% per day VEGF release for 5 days [58]. In 
another study, BMP2 was delivered from PLGA microspheres that were embedded in a 
polypropylene scaffold surrounded by a gelatin hydrogel that contained VEGF. There 
was a VEGF burst release in the first three days as the material degraded and sustained 
BMP2 delivery for 56 days [57]. Other studies use various dual delivery systems 
including: alginate/poly(D,L-lactic)(PDLLA) [54], biphasic CaP/PLGA 
microparticles/gelatin hydrogel [56], collagen sponge [55], gelatin 
microparticles/propylene fumarate (PPF) pores [59], and gelfoam disc [51]. In the study 
included in this dissertation, a collagen sponge was used to deliver VEGF with a 
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relatively rapid burst release since previous studies found that sponges release most of the 
growth factors or antibiotics within the first few days [60-64]. 
There are various systems used to attach VEGF to biomaterial surfaces: 
incorporation, encapsulation, conjugation, and adsorption. Incorporation involves mixing 
the GF into a coating or into a hydrogel. For example, VEGF in solution can be mixed 
into an alginate/fibrinogen based hydrogel or into a collagen gel and polymerized at 37
o
C 
[47,65].  In these studies, the VEGF was bound to the delivery vehicle via physical 
entrapment or weak chemical interaction and was released as the material degraded.  
Encapsulation incorporates the VEGF inside of synthetic or collagen 
microparticles. Nanoparticles, which are smaller than microparticles, could penetrate 
through capillaries and into the cell; this can have dangerous side effects. PLGA is 
commonly used to make microparticles, but the hydrophobic interactions between VEGF 
and PLGA can result in protein aggregation and denaturing. To decrease aggregation, 
PEG can be added to protect the protein and prevent hydrophobic interactions [2,66]. 
Conjugation uses a linking molecule to bind VEGF to the surface. Heparin is a 
widely studied protein used to bind VEGF to polymer surfaces [37,67]. Amino groups (-
NH2) on the material interact with heparin, and VEGF binds to the heparin because of the 
protein’s high affinity for heparin. Heparin is localized to the carboxyl-terminal 55 
residues [68]. Other studies utilize EDC chemistry [69], photoimmobilization [70], and 
cysteine conjugation [71] to link VEGF to the material surface. VEGF adsorbed onto 
polymer surfaces uses electrostatic interactions. The polymer is usually submerged in a 
GF solution for a period of time during which the protein binds to the surface. For PCL, 
the positively charged amino acid residues on VEGF interact with PCL’s hydrophobic 
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surface. Another form of adsorption includes saturating a sponge with a VEGF solution 
[72,73]. 
3.4.2 Pre-Clinical Studies 
The synergistic effect of BMP2 and VEGF are both time and location dependent 
(ectopic vs. orthotopic) [56,57,59], ratio dependent [74], and a high VEGF dose could 
inhibit osteogenesis [58,74]. Optimizing angiogenic and osteogenic protein delivery may 
increase bone regeneration. One study delivered both factors via gelatin microparticles in 
PPF pores implanted in a rat calvarial defect model and found no increase in bone 
formation [59]. Another study showed increased ectopic bone growth in rats with dual 
delivery, however, there was no increase in the orthotopic location [57]. Contrary to those 
results, another study implanted a dual delivery scaffold in a critical sized femur defect 
and found dual delivery regenerated significantly more bone. The studies which used 
microparticles in PPF pores and PLGA microparticles in a gelatin hydrogel for delivery 
systems found no difference in dual delivery versus BMP2 delivery alone [56,59,74]. 
Furthermore, they found that the timing of BMP2 release determined the speed and 
amount of ectopic bone formation in an intramuscular beagle model. The bone growth 
was independent of the VEGF release [56]. Studies delivering both BMP2 and VEGF use 
various animal models, implant locations, growth factor delivery methods (i.e. 
microparticle, gelatin), time points, and regenerated bone analyses methods making it 
difficult to draw a strong conclusion for pre-fabricated flap applications.  
3.5 BMP2 & EPO Dual Growth Factor Delivery 
In vitro, EPO directly influences mesenchymal stem cells to differentiate into 
osteoblasts and also influences hematopoietic stem cells (HSCs) to produce BMPs, which 
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indicates that EPO has the potential to influence bone regeneration [75,76].  Dual 
delivery of EPO and BMP2 has not been widely investigated. EPO has been delivered 
from gels, microspheres, and nanoparticles, however, for application other than bone 
regeneration.  
3.5.1 Delivery Vehicles and Binding Methods 
EPO is typically delivered systemically; however, drawbacks include serious side 
effects such as increased blood viscosity, hypertension, and thromboembolic events [77-
79]. EPO has a relatively short half-life of 8.5 hours, which requires the patients to be 
dosed repeatedly to have an effect [80]. To overcome these drawbacks, local EPO 
delivery is a viable alternative to systemic injection. Kobayashi et al. delivered EPO 
using a gelatin hydrogel at the surface of a rabbit heart [81], and Chen et al. delivered 
EPO using a fibrin gel to increase neovascularization [82].  EPO has been delivered using 
injectable hydrogels [83,84] for angiogenesis purposes and via synthetic materials such as 
dextran microparticle-based PLGA/PLA microspheres. In the microsphere study, there 
was a 20% burst release on the first day followed by a sustained release, resulting in 
about 90% released in 60 days [85]. Similarly, Frayed et al. incorporated EPO into PLGA 
nanoparticles resulting in a 33% loading efficiency and 82% release over 24 hours [86]. 
When delivered from chitosan nanoparticles, 30% was released in the first 48 hours, and 
a total of 63% was released over 15 days in phosphate buffered saline at 37
o
C [80]. With 
respect to dual BMP2 and EPO delivery, Nair et al. delivered both proteins from 
porogen-leached protein microbubble PLGA scaffolds that were implanted in a rat 
calvarial defect model.  No binding efficiencies or release kinetics were characterized 
[87]. 
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There is very limited information available on adsorption or conjugation EPO 
delivery methods. EPO adsorbed onto dialysis bags resulted in less than 7% bound [88], 
and EPO conjugated with PEG successfully lasted longer in solution. In the conjugation 
study, the maleimide on the PEG bound to the cysteine on the protein [89].  Another 
study successfully created benzaldehyde-terminated MPC polymers conjugated with EPO 
to extend the protein’s half-life [90]. We were unable to find any studies which 
immobilized EPO onto a synthetic polymer surface for local in vivo delivery.  
3.5.2 Pre-Clinical Studies 
Interactions between EPO and BMP2 have been studied in vitro [75,76] and in 
vivo [87,91], and the results find synergistic effects on bone formation. The advantage of 
delivering both BMP2 and EPO is that both proteins are FDA approved and regulatory 
hurdles would potentially decrease. Delivering two proteins, however, could conversely 
make regulatory approval more difficult. In one study, BMP2 was delivered from a 
collagen scaffold implanted in a rat calvarial defect, and EPO was injected 
subcutaneously at the defect site every other day for 2 weeks. After 6 weeks the dual 
delivery group had a higher bone volume fraction than the BMP2 alone group [91].  In 
another study, microbubble PLGA scaffolds delivering BMP2 and EPO were implanted 
in a calvarial defect and resulted in complete bridging. Furthermore, the authors found 
that EPO loaded scaffolds implanted subcutaneously in mice recruited autologous 
mesenchymal stem cells to the implant site. The effect of local dual EPO and BMP2 
delivery on bone regenerated in an ectopic location is still unknown.  
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3.6 Conclusion 
Developing a bioengineered vascularized bone flap in vivo is a promising 
alternative to using autografts to reconstruct large bone defects. The fabrication method, 
mechanical properties, geometry resolution, and protein incorporation methods are a few 
factors that should be considered when designing a scaffold for bone tissue engineering 
applications. Scaffold fabrication methods utilizing organic salts or toxic solvents will 
face challenges when overcoming regulatory hurdles because of the potential health 
hazards. 3D-printed scaffolds have better control over geometry, porosity, and 
degradation rate. BMP2, VEGF, and EPO have been delivered alone and in combination 
using various scaffolding materials. It is important to keep in mind the clinical 
applicability when integrating the protein because complex machinery and a long 
preparation time will make the process difficult to execute in the OR environment. If the 
scaffold is prepared outside of the OR room, there are unknown sterilization effects on 
protein bioactivity and shelf life time which increase the number of regulatory hurdles. 
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CHAPTER 4 
BONE MORPHOGENETIC PROTEIN-2 ADSORPTION ONTO 
POLYCAPROLACTONE BETTER PRESERVES BIOACTIVITY IN VITRO AND 
PRODUCES MORE BONE IN VIVO THAN CONJUGATION UNDER 
CLINICALLY RELAVENT LOADING SCENARIOS 
Colleen Flanagan and Scott Hollister assisted with the preparation of this chapter.  
Accepted by Tissue Engineering Part C; Oct, 2014 
4.1  Abstract 
Background: One strategy to reconstruct large bone defects is to pre-fabricate a 
vascularized flap by implanting a biomaterial scaffold with associated biologics into the 
latissimus dorsi and then transplanting this construct to the defect site after a maturation 
period. This strategy, like all clinically and regulatory feasible biologic approaches to 
surgical reconstruction, requires the ability to quickly (<1 hour within an operating room) 
and efficiently bind biologics to scaffolds. It also requires the ability to localize biologic 
delivery. In this study we investigated the efficacy of binding bone morphogenetic 
protein-2 (BMP2) to poly-Ɛ-caprolactone (PCL) using adsorption and conjugation as a 
function of time.   
Methods: BMP2 was adsorbed (Ads) or conjugated (Conj) to PCL scaffolds with the 
same 3D printed architecture while altering exposure time (0.5, 1, 5, 16hr), temperature 
(4
o
C, 23
o
C), and BMP2 concentration (1.4, 5, 20, 65µg/ml). The in vitro release was 
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quantified and C2C12 cell alkaline phosphatase (ALP) expression was used to confirm 
bioactivity. Scaffolds with either 65 or 20 µg/ml Ads or Conj BMP2 for 1hr at 23
o
C were 
implanted subcutaneously in mice to evaluate in vivo bone regeneration. MicroCT, 
compression testing, and histology were performed to characterize bone regeneration. 
Results: After 1hr exposure to 65µg/ml BMP2 at 23
o
C, Conj and Ads resulted in 
12.83±1.78µg and 10.78±1.49µg BMP2 attached, respectively. Adsorption resulted in a 
positive ALP response and had a small burst release; whereas, conjugation provided a 
sustained release with negligible ALP production, indicating that the conjugated BMP2 
may not be bioavailable. Adsorbed 65µg/ml BMP2 solution resulted in the greatest 
regenerated bone volume (15.0±3.0mm
3
), elastic modulus (20.1±3.0MPa), and %bone 
ingrowth in the scaffold interior (17.2±5.4%) when compared to conjugation. 
Conclusion: Adsorption may be optimal for the clinical application of pre-fabricating 
bone flaps due to BMP2 binding in a short exposure time, retained BMP2 bioactivity, 
bone growth adhering to scaffold geometry and into pores with healthy marrow 
development.  
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4.2  Introduction 
The gold standard for reconstructing a bone defect is a vascularized autologous 
flap. However, this procedure results in donor site morbidity and poorly matched defect 
geometry, especially for craniofacial reconstruction. Alternatives to autografts include 
allografts and synthetic grafts. Allografts carry the risk of transferring diseases and 
eliciting an immune response. Synthetic grafts made from polymers or metal cages are 
alternatives being investigated to address the drawbacks of allografts and autografts. 
Particularly, polymers can be fabricated to match the patient’s complex facial geometry 
and be integrated with biologics to induce bone growth when implanted into the defect-
site. Although these grafts could be readily available and produced, they do not integrate 
as well as autografts into the host bone [1]. Chronically infected and irradiated wound 
sites are challenging to reconstruct and are not conducive to general wound healing, let 
alone being able to support a bone graft.  Furthermore, blood vessels generally cannot 
penetrate the graft sufficiently to provide nutrients to the bone growing at the graft’s core, 
especially in large volume defects. To increase viability and integration of grafts 
implanted directly into the defect site, researchers are investigating pre-fabrication of a 
synthetic flap that is assembled at a site remote from the defect [2-5]. As an alternative to 
creating the flap in vitro (in which patient cells are harvested, expanded, and seeded on 
the construct to mature in an external bioreactor), we are looking to tissue engineer a 
bone flap in vivo by using the patient’s body as a bioreactor to achieve bone penetration 
into a biomaterial scaffold with associated biologics. There are few reports of this 
procedure in animal models [4,6-10] and even less in humans [2,3,11]. Previous studies 
have used BioOss/Hydroxyapatite blocks or titanium trays filled with BioOss blocks 
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soaked in growth factors [7,8].  A human mandibular case using a titanium mesh filled 
with hydroxyapatite blocks soaked in bone morphogenetic protein-7 (BMP7) fractured 
and failed [2].  
Our goal is to advance this pre-fabricated flap procedure by integrating patient-
specific computational design, 3D biomaterial printing, and post-fabrication biologic 
functionalization [12]. Poly-Ɛ-caprolactone (PCL) is a biocompatible and bioresorbable 
polymer that can be utilized with image-based computation aided design (CAD) and 
selective laser sintering (SLS) manufacturing techniques [13]. SLS can repeatedly and 
reproducibly produce PCL scaffolds with complex geometries, controlled pore size, and 
stiffness which degrade over three years.  Its degradation profile and mechanical 
properties supports its use for bone tissue engineering in complex reconstruction sites 
where bone may take over a year to form. In these sites, a PCL scaffold’s slower 
degradation time is an advantage to provide form and load bearing over a longer time 
period. Furthermore, PCL degradation generates less acidic byproducts and leads to less 
inflammation than more rapidly degrading polylactic acid based co-polymers [14].  PCL 
has been approved for cranioplasty bone filling applications by the FDA [15,16]. Thus, 
the polymer has been widely tested, utilized, and achieved regulatory approval as a bone 
repair scaffold. Furthermore, it may readily be formed into complex geometries by 3D 
printing techniques like SLS and Fused Deposition Modeling [13]. 
PCL can be modified to integrate the osteoinductive agent recombinant human 
bone morphogenetic protein-2 (BMP2) [17,18]. However, further studies are needed to 
refine a method of growth factor (GF) functionalization onto PCL scaffolds to produce 
bone when placed in the muscle bed (i.e. pre-fabricated flap applications) in a clinically 
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realistic time frame within the operating room (OR). Although a plethora of methods 
have been developed for conjugating and delivering BMP2 from scaffold materials, any 
conjugation technique requiring more than 1 hour performed outside the OR faces 
unknown sterilization effects on GF bioactivity and creates a significant uphill battle to 
be of any clinical relevance. It is likely that any clinically relevant BMP2 delivery 
method for the near future must be performed in the OR environment at room 
temperature with loading times of 1 hour or less. Current conjugation methods that more 
efficiently load BMP2 onto scaffolds than adsorption methods [19,20] do not fulfill these 
requirements. Additionally, studies that have assessed conjugation methods utilized either 
porogen leaching [18,19] or other methods resulting in large variations in pore 
architecture that may significantly affect release kinetics, not allowing a rigorous 
comparison of adsorption and conjugation methods [21-23]. Simpler adsorption methods 
have not been directly compared to conjugation methods [23-25]. Still, there is a lack of 
information on how conjugation methods compare directly to adsorption methods under 
OR relevant conditions on scaffolds with the exact same, rigorously controlled 
architecture in terms of not only in vitro loading efficiency and bioactivity, but also the 
direct translation into in vivo bone formation in terms of volume, localization and 
mechanical properties. The goal of this study was to investigate these questions both in 
vitro and in an in vivo ectopic model as a pre-cursor to large animal ectopic models for 
pre-fabricated flap construction.   
4.3  Materials & Methods  
PCL Fabrication 
PCL discs (15mm Diameter, 2mm Height, 176mm
2
 Surface Area) and 70% porous  
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scaffolds (6.35mm Diameter x 4mm Height, 170mm
2 
Surface Area) with 2.15mm 
spherical pores (Figure 4.1) in a 2mm unit cell were fabricated using a Formiga P100 
SLS machine (EOS, Inc., Novi, MI). The powder consisted of PCL (43-50kDa 
Polysciences, Warrington, PA) and 4 wt % hydroxyapatite (Plasma Biotal Limited, UK). 
Manufacturing conditions including bed temperature, laser power, particle size, PCL 
milling etc. followed protocols we previously developed and published for implantable 
PCL scaffolds [13,26-28]. After manufacturing, the discs and scaffolds were air blasted 
and then sonicated in 70% ethanol (EtOH) for 30 minutes to remove non-sintered 
powder, washed in distilled water (diH20), and air-dried at room temperature.  
 
Figure 4.1: PCL Scaffold Geometries  
A) PCL Scaffold C) PCL Disc 
 
BMP2 Binding  
For conjugation groups (Conj), PCL samples were exposed to 10% w/v 1,6-
hexanediamine in isopropanol for 1 hour at 37
o
C to add amine groups via aminolysis and 
then they were washed in diH20. After air-drying overnight, 1M Ninhydrin reagent 
(Sigma), prepared with 100% EtOH, was used to confirm successful aminolysis in a 
representative specimen by the development of a purple stain.  Note that this preparation 
can be done pre-sterilization and does not affect the capability to perform conjugation 
under OR relevant conditions. The samples were prewashed with activation buffer (BuPH 
Phosphate Buffered Saline Pack in diH20, pH 7.2, Pierce Biotechnology). The 
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heterobifunctional cross-linker sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-
carboxylate (sulfo-SMCC) (Pierce Biotechnology) was used to immobilize recombinant 
human BMP2 (e.coli derived, Creative Biomart, Shirley, NY) on the aminated surface. 
Samples were immersed in sulfo-SMCC (4mg/ml in activation buffer) for 1 hour at 23
o
C, 
followed by activation and conjugation buffer washes. Conjugation buffer (pH 7.0) 
contained activation buffer and 0.1M EDTA. Adsorption groups (Ads) followed the same 
procedure as Conj but without the aminolysis and sulfo-SMCC reactions. E.coli derived 
BMP2 is non-glycosylated and has shown to produce more bone in vivo at a lower dose 
when compared to a glycosylated BMP2 [29]. BMP2 was dissolved in 20mM acetic acid 
(1mg/ml) and then further diluted in conjugation buffer to the desired concentration. 
Ads/Conj PCL discs (n=3/group) were immersed in 1ml of 1.43μg/ml BMP2 solution for 
0.5, 1, 5, or 16 hours on a shaker at 4
o
C or 23
o
C. A simple disc geometry was used to 
understand initial binding trends prior to conducting concentration binding studies with a 
refined protocol on a more complex geometry.  Ads/Conj PCL scaffolds (n=3/group) 
were immersed in 1ml of 1.4, 5, 20, or 65μg/ml BMP2 for the refined conditions of 1 
hour exposure at 23
o
C. Note, an ELISA was used to determine the detected BMP2 
concentration (averaging 1.14, 3, 6.5, and 30μg/ml) with which to normalize binding 
values. Once BMP2 exposure was complete, samples were washed with diH20 and dried 
in a vacuum at 23
o
C overnight. BMP2 solution supernatants and diH20 washes were 
collected in LoBind microcentrifuge tubes (Eppendorf) to analyze for BMP2 content. 
Bovine Serum Albumin 1% (BSA) was added to the collected solution to result in 0.1% 
BSA, and the samples were stored at -80
o
C. BMP2 content was quantified using an 
indirect enzyme-linked immunoabsorbant assay (ELISA) kit (PeproTech) read at 405 and 
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650nm on a microplate reader (Multiskan Spectrum, Thermo Scientific, Pittsburg, PA). 
Results are reported as BMP2 bound (µg), BMP2 bound per mm
2
 PCL surface area 
(µg/mm
2
), or binding efficiency (%) and were calculated as shown below: 
𝐵𝑀𝑃2 𝐵𝑜𝑢𝑛𝑑 (µ𝑔)
= 𝐵𝑀𝑃2 𝑖𝑛 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 𝑏𝑦 𝐸𝐿𝐼𝑆𝐴
− (𝐵𝑀𝑃2 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 +  𝑤𝑎𝑠ℎ𝑒𝑠) 
𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) = (
𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝐴𝑚𝑡 − 𝐴𝑚𝑡 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑖𝑛 𝑠𝑜𝑙′𝑛
𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝐴𝑚𝑡
) ∗ 100 
Release Kinetics 
Ads and Conj BMP2 release profiles were determined for PCL scaffolds exposed to 
20µg/ml BMP2 for 1 hour at 23
o
C (n=3). After BMP2 exposure PCL samples were 
immersed in Dulbecco’s Phosphate Buffered Saline (DPBS) and incubated in a sterile 
environment at 37
o
C, 5% CO2, and 95% humidity. The supernatant was collected and 
replaced with fresh DPBS 1,3,5,7,14, and 21 days after initial exposure. Supernatant with 
added 0.1% BSA was stored at -80
o
C until BMP2 quantification by ELISA.  
BMP2 Quantification 
An e.coli derived BMP2 ELISA quantification kit (Peprotech) was used to indirectly 
quantify the amount of BMP2 bound to PCL and was conducted according to the 
manufacturer’s instructions.  High-binding 96-well plates (Costar) were coated with 
capture antibody overnight. Wells were blocked with 1% BSA in DPBS for 1 hour, 
thawed samples were added in triplicate wells for 2 hours, detection antibody for 2 hours, 
Avidin conjugated horseradish peroxidase for 0.5 hours, followed by the addition of 
ABTS liquid substrate solution (2,2'-azino-bis(3-ethylbenzthiazoline)-sulfonic acid) 
(Sigma) for colorimetric reading after 20 minutes. In between each step, wells were 
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washed four times with wash buffer (DPBS containing 0.05% Tween 20 (Sigma)). 
Absorbance was read at 405 and 650nm. 
Cell Culture  
C2C12 myoblastic cells are known to differentiate down an osteogenic lineage when 
exposed to active BMP2 and are extensively used in other studies as an initial screening 
for BMP2 bioactivity [30-33]. C2C12 cells (ATCC, Manassas, VA) were grown in high 
glucose Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine 
serum and 1% pennicillin/streptomycin and incubated in 37
o
C, 5% CO2 and 95% 
humidity (all reagents from Gibco, Carlsbad, CA). The Ads and Conj BMP2 discs were 
sterilized in 0.22µm filtered 70% EtOH for 30 min, washed with Hanks Balanced Salt 
Solution (HBSS), and maintained in DMEM under sterile conditions until cell seeding in 
a 24 well plate. Discs fit tightly into the well space. The DMEM was then replaced with 
culture medium and cells were added.  
Alkaline Phosphatase Assay 
C2C12 cells were seeded (1x10
4
cells/disc or 57cells/mm
2
) on discs with conjugated or 
adsorbed 0.7ml of 1.4µg/ml BMP2 for 1 hour at 23
o
C. The simple disc geometry was 
used for cell studies because the aim of the study was to determine if the bound BMP2 
maintained bioactivity and the extent of bioactivity was not compared.  Positive controls 
were 1µg BMP2 in culture medium (sol BMP2) and 0.7ml of 1.4µg/ml BMP2 adsorbed 
for 16hr at 4
o
C due to prior successful results in this laboratory for in vivo formation at 
that binding condition (n=4). The negative control was cells on PCL discs with no BMP2. 
After 4 days of static culture, cells were lysed with 700µl of CelLytic (Sigma) solution 
and (alkaline phosphatase) ALP production was quantified. The assay was conducted 
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using alkaline buffer solution, p-nitrophenol standard solution, and alkaline phosphatase 
substrate tablets (Sigma). Each sample (n=3/group) was read in triplicate wells at 405nm 
and results were normalized to total intracellular protein content (BCA, 
ThermoScientific) read at 562nm.  
MTS Assay 
An MTS assay was utilized to ensure cells attached and grew on the PCL to interact with 
the bound BMP2. Proliferation between groups was not compared. C2C12 cells were 
seeded (2.5x10
4
 cells/disc) on discs with Conj or Ads 1.43µg/ml BMP2 for 1 hour at 
23
o
C and Ads at 4
o
C (n=4). The positive control was cells seeded on PCL discs exposed 
to 1µg BMP2 in culture medium (sol BMP2). The negative control was cells on PCL 
discs with no BMP2. 260µl MTS solution (CellTiter96 Aqueous One Solution, Promega) 
was added to each disc after 72 hours of static culture. After incubating for two hours at 
37
o
C triplicates were read at 490nm. 
In Vivo Bioactivity: Subcutaneous Implantation 
Based on our in vitro studies, we chose the most clinically relevant conditions of 1 hour 
protein exposure at 23
o
C and exposed scaffolds to 20 or 65µg/ml adsorbed or conjugated 
BMP2. After treatment, scaffolds were implanted subcutaneously in 5-7 week old NIHS 
bg-nu-xid mice (Harlan Laboratories, Indianapolis, IN). Negative controls for the 
adsorption group were PCL scaffolds soaked in conjugation buffer for 1 hour. Negative 
controls for the conjugation group were PCL scaffolds treated through the sulfo-SMCC 
reaction step without BMP2 exposure. Groups were sterilized with 70% EtOH and 
washed with HBSS prior to implanting. Four scaffolds were implanted in each mouse. An 
incision was made in the back and four pockets were created angling toward each limb. 
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Scaffolds were assigned a quadrant to be implanted in such that at least one sample from 
each group was implanted in all quadrants. Mice were then euthanized 8 weeks post-
surgery to explant the specimen. Explanted specimen were placed in Z-Fix (Anatech, 
Battle Creek, MI) overnight, washed with diH20 for 5 hours and stored in 70% EtOH 
until testing. Table 4.1 gives total sample numbers as well as the number of samples used 
for each specific assay (µCT scan, mechanical test, and histology).  This study was 
conducted in compliance with the regulations set forth by the University Committee on 
Use and Care of Animals at the University of Michigan.  
Group µCT Scan Mechanical Test Histology Total Samples 
20µg/ml Conj N=8 N=5 N=3 N=8 
65µg/ml Conj N=9 N=6 N=3 N=9 
20µg/ml Ads N=8 N=5 N=3 N=8 
65µg/ml Ads N=9 N=6 N=3 N=9 
PCL-no BMP2 N=5 N=3 N=2 N=5 
Sulfo-SMCC N=9 N=6 N=3 N=9 
Table 4.1: Sample Numbers for In Vivo Analyses 
Number of explanted specimen used in each in vivo bone regeneration analysis method 
 
Micro-Computed Tomography (MicroCT) 
Fixed scaffolds were scanned in water with a high-resolution microCT scanner (Scanco 
Medical, Wayne, PA) at 16µm resolution and scans were calibrated to Hounsfield units 
(HU). Bone volume (BV), tissue mineral density (TMD), and tissue mineral content 
(TMC) data were determined. Bone was defined at a threshold of HU=1050 using 
Microview software (Parallax Innovations). TMD is an assessment of bone quality within 
the scaffold; the measure indicates the average density of the bone tissue (as defined by 
the threshold value of 1050HU) within a given 3D region of interest (or ROI) and is 
reported as the mass of hydroxyapatite per volume (mg HA/mm
3
). TMC quantifies the 
amount of mineral present in the bone (as defined by the threshold value of 1050HU) in a 
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given ROI and reported as the mass of hydroxyapatite (mg HA). To obtain TMD and 
TMC values, Dicoms from Scanco were imported into Microview and greyscale values 
for each voxel were exported to excel and converted to HU values. The scaffold region 
was represented as a cylindrical ROI (6mmD x 3.615mmH). Bone formed outside the 
scaffold ROI boundary was quantified and defined as “external” bone growth and bone 
inside the scaffold ROI was defined as “internal” bone volume.” External, internal and 
total BV, TMD, and TMC were calculated for each specimen.  
To determine bone penetration into the scaffold radially, four concentric, cylindrical rings 
were defined as ROI’s and were individually analyzed. The diameters of the 4 concentric 
rings are as follows: Ring 1: 6.00-4.84mm, Ring 2: 4.84-3.67mm, Ring 3: 3.67-2.5mm, 
Ring 4: 2.50-0.00mm. BV, TMC, and bone ingrowth of each ring was calculated using 
Microview Software. Bone ingrowth (%) was calculated as bone volume divided by the 
available pore volume for each ring. Available pore volume was calculated from the 
porosity of each ring based on the .STL design file for the scaffold. 
Compression Mechanical Testing 
Specimens were mechanically tested using an MTS Alliance RT30 electromechanical test 
frame (MTS Systems Corp, Minneapolis, MN) with a 500N load cell. Samples were 
compressed between two steel platens at a rate of 1.0 mm/min with a 0.5lbf preload. Data 
were collected and analyzed using TestWorks4 software (MTS Systems, Corp.). Data 
were collected to 25% strain, and the compressive elastic modulus was defined as the 
slope of linear region of the stress-strain curve prior to 15% strain. Data were normalized 
to scaffold area.  
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Histology 
Fixed samples from each group were decalcified with RDO (Apex Engineering Products 
Corporation) and sent to the Histology Core at the University of Michigan Dental School 
to be embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). 
H&E was used to visualize cells, tissue matrix, blood vessels, and general tissue 
morphology. A light microscope was used to image sections with a 10x objective. 
Statistical Analysis 
Data are expressed as mean ± standard deviation of the mean. An analysis of variance 
(ANOVA) was used to determine statistical significance between groups. A *p-value 
<0.05 (α<0.05) was considered statistically significant on a 95% confidence interval. 
4.4  Results  
Binding Environment Studies 
At 4
o
C, conjugation had significantly more BMP2 attached than adsorption at all 
exposure times. At 23
o
C, conjugation still had significantly more binding at 0.5 and 1 
hour exposures. Adsorption at 23
o
C resulted in significantly more BMP2 bound than at 
4
o
C except at the 16 hour exposure. After 1 hour exposure at 23
o
C, conjugated and 
adsorbed discs resulted in 0.0049±0.001µg/mm
2
 (99.5±0.1%) and 0.0036±0.0001µg/mm
2
 
(73.3±1.3%) BMP2 attached, respectively (Figure 4.2). Based on these results, we 
examined Conj and Ads groups that were exposed to BMP2 for 1 hour at 23
o
C in further 
studies.  
 76 
 
 
Figure 4.2: BMP2 Binding to PCL Discs via Adsorption or Conjugation  
PCL discs were exposed to 1.4µg/ml BMP2 solution for 0.5, 1, 5, or 16 hours at 23
o
C or 
4
o
C. BMP2 was quantified with an ELISA (n=3). 
 
BMP2 In Vitro Bioactivity 
To determine if the bound BMP2 was non-toxic and bioactive we seeded C2C12 
myoblastic cells on BMP2 Ads or Conj PCL discs. We found cells on all PCL discs 
proliferated significantly more than the negative control (Figure 4.3A). Cells on adsorbed 
groups produced significantly higher ALP than the conjugated group. ALP production of 
cells on PCL without BMP2 was the same as conjugation and significantly less than 
adsorption. There was no difference between discs that had BMP2 adsorbed at 4
o
C or 
23
o
C (p=0.10). Finally, the positive control of soluble BMP2 in cell culture medium 
showed significantly higher ALP (1.16nM ALP/mg protein/min) when compared to all 
other groups (Figure 4.3B). 
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Figure 4.3: BMP2/PCL Cytotoxicity & Bioactivity 
A) MTS assay results for relative C2C12 proliferation on BMP2/PCL discs. Cells were 
able to grow on PCL surface modified with BMP2. (n=4). 
B) ALP production of C2C12 cells seeded on BMP2/PCL discs. Data is normalized to 
total intracellular protein content and based on linear curve fit. *p<0.05 was significant. 
 
Concentration Binding Studies 
To transition to in vivo bioactivity studies, 70% porous scaffolds (176mm
2
) were exposed 
to increasing BMP2 concentrations for 1 hour at 23
o
C (adsorbed and conjugated). The 
BMP2 bound to the scaffolds was compared to the amount adsorbed onto a disc 
(170mm
2
). There was no significant difference in binding between adsorbed/conjugated 
scaffolds and discs at 5, 20, and 65µg/ml. Significantly more BMP2 bound to the surface 
as BMP2 concentration increased (Figure 4.4A). When exposed to 20µg/ml BMP2, 
3.03±0.18µg (0.018±0.001µg /mm
2
) BMP2 attached with conjugation and 2.49±0.35µg 
(0.015±0.002µg/mm
2
) attached with adsorption. When exposed to 65µg/ml, conjugation 
and adsorption bound 12.83±1.78µg (0.076±0.01µg/mm
2
) and 10.78±1.49µg BMP2 
(0.063±0.01µg/mm
2
), respectively.   Figure 4.4B shows the percentage of BMP2 in the 
original solution that bound to the scaffold surface (% binding efficiency). Conjugation 
bound significantly more BMP2 than adsorption when exposed to 1.4µg/ml. There was 
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no difference in the amount bound between the two methods as BMP2 concentrations 
increased to 5, 20, and 65µg/ml. 
 
Figure 4.4: BMP2 Binding to PCL Discs and Scaffolds 
A) PCL scaffolds were exposed to 1.43, 5, 20, or 65μg/ml BMP2 solution for 1 hour at 
23
o
C. The data were normalized to the ELISA detected concentration which averaged at 
1.14, 3, 6.5, 30μg/ml.  *p<0.05 
B) Bound BMP2 is expressed as a percentage of BMP2 in original solution (n=3). 
 
In Vitro Release Kinetics 
A carrier device’s release kinetics plays a crucial role in the quality of engineered bone. 
PCL scaffolds exposed to 20µg/ml BMP2 solution for 1 hour at 23
o
C showed after 22 
days, 0.0026± 0.0006µg and 0.0167±0.005µg of conjugated and adsorbed BMP2 was 
released, respectively (Figure 4.5A). A burst release commonly observed with adsorption 
occurred in the first 1-3 days during which about 0.0068µg BMP2 was released (Figure 
4.5B).  
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Figure 4.5: Conjugated and Adsorbed BMP2 Released from PCL 
A) Cumulative release of BMP2 from PCL scaffolds into DPBS when exposed to 
20µg/ml BMP2 for 1hr at 23
o
C. Release environment conditions were sterile, 37
o
C, 5% 
C02, and 95% humidity. *p<0.05 
B) BMP2 (µg) released per day. The supernatant was analyzed for BMP2 content with an 
ELISA (n=3). 
 
In Vivo Bone Formation  
After 8 weeks subcutaneous implantation, we found adsorbed PCL scaffolds exposed to 
20µg/ml and 65µg/ml BMP2 produced the greatest total bone volumes of 9.2±2.28mm
3
 
and 15.02±2.98mm
3
,
 
respectively. Conjugation produced 0.43±0.41mm
3
 and 5.9±2.0mm
3
 
total bone when exposed to 20µg/ml or 65µg/ml respectively. Negative control blank 
PCL produced significantly less bone (0.14±0.03mm
3
) than all other groups (Figure 
4.6A). Using Microview to visualize µCT scans of explanted specimen, we found 
conjugation produced a shell of bone that followed scaffold geometry. Adsorption 
resulted in bone following scaffold geometry as well as filling into the pores (Figure 
4.6B). The bone formed outside of the scaffold ROI for 65µg/ml adsorption (1.42±0.52 
mm
3
) and 65µg/ml conjugation (0.14±0.08 mm
3
) was not excessive (Figure 4.6A&B).  
65µg/ml adsorbed also had significantly higher tissue mineral content (8.44±1.7mg HA) 
than other groups. Finally, 65µg/ml conjugated, 20µg/ml adsorbed, and 65µg/ml 
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adsorbed produced bone that is within the normal density range of mandibular bone 
(551±25, 587±25, and 560±37mg HA/cm
3
, respectively) [13,34].  
 
Figure 4.6: Regenerated Bone Analysis 
A) Bone volume formed in explanted specimen using microCT scans 
(threshold=1050HU). “Inside scaffold” was defined as bone volume inside a cylindrical 
ROI (6mmD, 3.615mmH) and “outside scaffold” was the bone volume formed outside 
the ROI. 
B)  The microCT scans of two representative samples from each group are shown. Bright 
white areas indicate bone formation (blue arrow) and gray areas are scaffold (red*). Dark 
areas (orange dashed lines) indicate pores. Conjugation produced bone that closely 
followed PCL surface geometry. Adsorption produced bone growth into the pores in 
addition to following surface geometry. 
 
Ring analysis showed a similar relationship in that adsorption resulted in higher %bone 
ingrowth in all rings when compared to conjugation. Percent bone ingrowth was the same 
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throughout the scaffold for 65µg/ml adsorption. In the center of the scaffold, 65µg/ml 
adsorption and conjugation had 17.2±5.4% and 7.5±3.07% ingrowth, respectively (Figure 
4.7).  
 
Figure 4.7: Ring Analysis for Bone Growth into Scaffold 
A) Outer ROI diameters were 6.0, 4.84, 3.67, 2.50mm for Rings 1, 2, 3, and 4, 
respectively. 
B) Percentage bone ingrowth (bone volume divided by available pore space) showed 
65μg/ml adsorbed group had significantly more ingrowth than either conjugated groups. 
C) 65μg/ml adsorbed group resulted in the same bone penetration throughout the 
scaffold. 
 
Mechanical Testing  
As seen in Figure 4.8, nearly all of the groups had significantly higher moduli when 
compared to the blank PCL (12.7±1.1MPa) or sulfo-SMCC negative controls, with the 
exception of 20µg/ml conjugated (p=0.12). The 65µg/ml adsorbed group had the highest 
elastic modulus of 20.1 ± 3.0 MPa, which was significantly higher than the 65µg/ml 
2 
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conjugated group (15.1±1.3MPa).  However, at the lower concentration level, there was 
no difference between 20µg/ml conjugated and 20µg/ml adsorbed moduli.  
 
Figure 4.8: Compressive Mechanical Testing 
Specimen elastic modulus measured in compression was defined as the slope of linear 
region prior to 15% strain level and normalized to specimen surface area. 
 
Histology 
Scaffold pores of sulfo-SMCC, blank PCL, and 20µg/ml conjugated BMP2 were 
infiltrated primarily with fibrous and fatty tissue (Figure 4.9). Negligible bone formation 
was observed in these groups. However, both of the adsorbed groups (20 and 65µg/ml) 
showed blood, bone and fatty marrow growth into the scaffold pore space. There were 
multiple osteocytes embedded in the osteoid as well as osteoblasts lining the matrix.  The 
65µg/ml conjugated group showed bone growth, fibrous tissue, and a little fatty marrow 
as well; however, the resulting bone was primarily localized to the pore surface and did 
not grow into the pores as well as the adsorbed group.  
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Figure 4.9: H&E Images of PCL/BMP2 Scaffold Pores 
Bright field images of scaffold pores taken at 10x magnification. s=scaffold, b=bone, 
m=marrow, f=fibrous tissue.  Negative controls consisted mainly of fibrous tissue. 
 
4.5  Discussion  
Prefabricating a bone flap in vivo has been completed in Europe and Asia but not 
yet in the United States to the best of our knowledge. For the foreseeable future this will 
likely be the method that can best generate large vascularized bone constructs for 
reconstruction.  Medtronic’s product InfuseTM has been FDA approved for delivery of 
BMP2 from a collagen type 1 sponge in treatment of spinal fusion, open tibial fractures, 
sinus augmentation, and dental procedures [35]. Due to BMP2’s short half-life, a 
1.5mg/ml BMP2 dose was needed (greatly exceeding native concentrations of 18.8-
22pg/mL) which resulted in a large burst release during the first 2-3 days causing adverse 
reactions in some patients [36]. To control the release and prevent excessive bone 
growth, Park YJ et al chemically conjugated BMP2 to amine-containing chitosan with a 
sulfo-SMCC cross linker. Conjugation enhanced in vitro osteoinductive properties as 
determined by pre-osteoblast differentiation; however, chitosan would not be an ideal 
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carrier for creating a bone flap because it lacks mechanical integrity [21]. BMP2 
adsorption and conjugation via heparin and sulfo-SMCC onto uncoated polymer surfaces 
(PLGA and PCL) has been superficially compared but a study was needed to refine a 
simple BMP2 binding method onto 3D SLS manufactured PCL scaffolds in a clinically 
applicable environment [18,19]. 
In this study we aimed to refine a protocol for binding BMP2 to PCL considering 
the constraints of intra OR use and to test bone regeneration using the sulfo-SMCC and 
simple adsorption binding protocols in vivo. Studies have used various methods to deliver 
BMP2 from biomaterials including sulfo-SMCC, heparin, trauts, adsorption, and 
incorporation into a coating or microparticles [20,22,25,33,37-41]. Temperatures and 
exposure times at which protein binding studies have been tested range from 4
o
C-37
o
C 
and 1-24 hours [21,33,42,43]. However, temperatures outside room temperature and long 
exposure times make it very difficult to use such BMP2 conjugation methods clinically. 
In this current study, we found chemical conjugation with sulfo-SMCC bound more 
BMP2 during a shorter exposure time and at ambient temperature in comparison to 
adsorption; however, the conjugated BMP2 did not maintain bioactivity once bound to 
the surface as determined by an absence of ALP production in vitro. This inactivity could 
be due to the sulfo-SMCC binding reaction binding BMP2 in a conformation that does 
not ideally present its cell binding moiety. Even though adsorbed BMP2 may not have 
bound as efficiently as conjugated BMP2 at 23
o
C, it was shown to be bioactive in vitro 
and produced more bone that infiltrated the scaffold and pores in vivo. We also showed 
that adsorbed BMP2 bound more efficiently at 23
o
C than at 4
o
C, which is a clear 
advantage for the intra OR setting. This increased binding may have been due to 
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increased protein kinetics providing the protein with more opportunities to bind to the 
material surface. 
 GF delivery vehicle release kinetics are crucial to the resulting bone formed. 
Conjugation resulted in sustained GF release, whereas, adsorption had a slightly higher 
burst release after 1-3 days, followed by a sustained release over time. This burst release 
with adsorption is commonly seen in other studies [22,23,33]; however, in this case when 
BMP2 is delivered from laser sintered PCL the amount released, in a burst and during 
subsequent slower release, at the secondary site is extremely small (<1%)- much smaller 
than the other studies[22,33,43]. The released amount is still therapeutically relevant 
because the regenerated bone increased the scaffold’s load bearing abilities.  Since the in 
vitro release was at 37
o
C, the remaining BMP2 could have degraded and the ELISA may 
not have detected the BMP2 fragments. Although an ELISA is a widely used method to 
detect low BMP2 concentrations, an alternate detection method that could be utilized to 
confirm the release kinetics would be to use 
125
I-labeled BMP2 [21]. Overall, adsorption 
provided greater BMP2 release over time. A limitation to this study was that the in vitro 
release profile may not entirely accurately predict the in vivo release profile due to 
physiological factors such as enzymes cleaving BMP2 off of the surface. 
 To transition to in vivo studies and confirm BMP2 bioactivity, we increased the 
amount of BMP2 exposed to PCL and used the more complex geometry. We determined 
the same amount of BMP2 adsorbed onto discs as onto scaffolds and that samples bound 
increasingly more µg BMP2/mm
2
 when they were exposed to increasing BMP2 
concentrations. The higher concentrations may have caused a stronger concentration 
gradient that drove adsorption at a rate similar to that of conjugation. The in vivo study 
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showed that adsorption on PCL may be more clinically applicable because not only did 
bone formation follow scaffold surface geometry like conjugation but it also grew into 
the interior available pore space. This increased bone ingrowth is likely the reason 
adsorption had a higher elastic modulus than conjugation groups. This superior 
mechanical integrity will be crucial once the bone flap is transferred to the defect site. 
Adsorption also provided the most overall bone growth as well as bone formed at the 
center of the scaffold. When applied to a bone flap model it is important to produce as 
much bone as possible before transferring it to assist the flap to integrate into the defect 
site as well as facilitate further bone remodeling and growth. The ectopic model for bone 
regeneration was, due to our interest in pre-fabricated flaps, the process by which we 
wanted to test BMP2 delivery. 
This scaffold was acellular when implanted, therefore, we speculate that 
circulating cells such as mesenchymal stem cells and fibroblasts that migrated through 
the vasculature in the wound bed could have interacted with the released BMP2 and were 
involved in endochondral bone formation. Due to a lack of bioactivity exhibited in vitro, 
but the presence of bone formed in vivo, we believe that conjugated BMP2 may be 
released via proteolytic activity and adsorption released the protein through weak 
molecular interactions.  Overall, adsorption onto PCL makes BMP2 available faster to 
cells than conjugation via sulfo-SMCC. In the future, we would like to determine a dual 
GF delivery system to increase the bone growth rate into the scaffold so that the flap can 
be transplanted at an earlier time point for oncology patients waiting for adjunct therapy. 
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4.6  Conclusions 
To address the drawbacks associated with autographs, allografts, and synthetic 
grafts we propose the idea of pre-fabricating a flap that is autologous in nature.  The 
ability to create complex PCL geometries for craniofacial reconstruction is an advance in 
pre-fabricating flaps, as only crude geometries were utilized in other cases. Based on 
these studies, adsorbing BMP2 onto PCL may be more optimal for clinical use in 
comparison to conjugation via sulfo-SMCC due to BMP2 binding in a short exposure 
time at ambient temperature, retained BMP2 bioactivity, bone growth following 
geometry and into pores, and healthy marrow development. Further studies are currently 
being conducted to determine if these in vivo results can be replicated in a large porcine 
model and, furthermore, transplant the PCL implant to a mandibular angle defect. We 
will compare the pre-fabricated flap results to a PCL implant placed directly into the 
defect site.  
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CHAPTER 5  
DUAL DELIVERY OF BMP2 AND VEGF FROM A 
POLYCAPROLACTONE/COLLAGEN SPONGE CONSTRUCT TO INCREASE 
BONE GROWTH IN ECTOPIC SITES FOR FLAP PREFABRICATION 
Rui Fan, Sean Miller, Colleen Flanagan, Sean Edwards, and Scott Hollister assisted with 
the preparation of this chapter. 
Submitted to Journal of Biomedical Materials Research Part B. Dec 2014 
5.1  Abstract 
Background: Pre-fabricated bone flaps produced in vivo require the ability to grow 
relatively large bone volumes with associated vasculature to reconstruct large craniofacial 
defects.  Polycaprolactone (PCL) with adsorbed bone morphogenetic protein-2 (BMP2) 
regenerates bone in soft tissue pockets. With the goal of further optimizing bone ingrowth 
for prefabricated flap applications, this study investigates dual delivery of BMP2 and 
vascular endothelial growth factor (VEGF) from a composite PCL/collagen sponge 
construct. 
Methods: BMP2 (65µg/ml) was first adsorbed onto PCL scaffolds. Next, a lyophilized 
collagen sponge was created within the scaffold, and VEGF (5µg) was pipetted onto the 
sponge. BMP2 and VEGF bioactivity were confirmed using alkaline phosphatase and 
endothelial cell proliferation assays. The constructs were then implanted subcutaneously 
in mice. 
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Results: At 8 weeks, bone volume was greater for BMP2+VEGF (10.1±3.7mm3) 
compared to BMP2 (7.9±3.8mm3). Bone volume significantly increased from 4 to 8 
weeks with BMP2+VEGF and corresponded to a significant increase in construct 
modulus from 4 weeks (10.5±2.3MPa) to 8 weeks (14.7±2.7MPa).  
Conclusion: BMP2+VEGF delivery from PCL/collagen sponge constructs resulted in a 
greater increase in regenerated bone volume from 4 to 8 weeks when compared to BMP2 
alone. Dual delivery is a potential method to regenerate bone faster and in greater volume 
for a tissue engineered bone flap.  
Keywords: Bone morphogenetic protein-2, vascular endothelial growth factor, 
polycaprolactone, tissue engineering, protein delivery 
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5.2  Introduction 
The gold standard for reconstructing a large bone defect is to use an autograft 
(typically from the iliac crest or fibula). In cases with large bone defects with 
compromised vascularity in the recipient site, a vascularized flap is used. When 
vascularity is required, a vascular pedicle is taken from the donor site to attach to a vein 
and artery at the recipient site to ensure immediate perfusion. Major drawbacks to 
autografts include donor site morbidity and geometry mismatch for craniofacial 
reconstruction. Furthermore, chronically infected and irradiated wound sites are 
challenging to reconstruct and are not conducive to general wound healing, let alone 
being able to support a bone graft. An alternative to using an autograft or vascularized 
flap is to tissue engineer a bone flap in vivo. Pre-fabricating a patient-specific bone flap 
for large craniofacial defects involves implanting a biomaterial scaffold with associated 
biologics into the patient’s latissimus dorsi and then transplanting it to the defect site after 
a maturation period. There are few reports of this type of surgery in animals and humans 
[1-9]. It is important to note that for large defects, a large bone volume would be needed 
in the flap.  
Our goal is to advance the current pre-fabricated flap process by integrating 
patient-specific computational design, 3D biomaterial printing, and dual biologic 
functionalization [10]. Poly-Ɛ-caprolactone (PCL) is a biocompatible and bioresorbable 
polymer that has been approved for cranioplasty bone filling applications by the Food 
and Drug Administration (FDA) [11,12]. PCL is compatible with image-based 
computational aided design (CAD) and selective laser sintering (SLS) manufacturing 
techniques  to repeatedly produce scaffolds with complex geometries, controlled pore 
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size, and stiffness [13] and degrades over three years.  Its degradation profile and 
mechanical properties support its use for bone tissue engineering in complex 
reconstruction sites where bone may take over a year to form; however, PCL is not 
osteoconductive. 
Bone morphogenetic protein-2 (BMP2) is a potent osteoinductive growth factor 
which has been used to induce osteogenesis with various biomaterials [14-18]. Previously 
in our laboratory we adsorbed BMP2 onto PCL scaffolds and found that the resultant 
PCL/BMP2 scaffold regenerates bone when implanted in soft pockets in mice [19].   
Since the PCL/BMP2 constructs will be implanted without cells, the host’s cells 
need to migrate into the construct and differentiate into osteoblasts. Angiogenesis plays a 
key role in the bone regeneration process by providing transportation for nutrients, 
oxygen, and cells migrating to the construct. Many studies find vascular endothelial 
growth factor (VEGF) is a key mediator in angiogenesis by playing a role in early 
fracture repair and endochondral and intramembranous ossification [20-22]. 
Transplanting bone stock alone is insufficient to maintain construct viability, especially 
in large defects, and it is crucial to develop a supporting vascular network. To mimic 
natural bone healing many investigators have developed VEGF and BMP2 sequential 
release systems in which VEGF is incorporated into rapidly degrading gels and BMP2 is 
delivered slowly from poly(lactic-co-glycolic acid) (PLGA) microspheres embedded in 
scaffolds [23,24]. Studies which successfully increase bone growth with dual growth 
factor delivery used collagen sponge, PLGA microspheres/gelatin hydrogel, or poly-DL-
lactide (PDLLA)/alginate scaffolds and implanted the scaffolds in murine intramuscular, 
rat subcutaneous or rat critical size femur defects [24-27]. 
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On the contrary, some studies find that dual VEGF and BMP2 delivery has no 
effect on bone regeneration when implanted in beagle intramuscular or rat calvarial 
defect sites [23,28]. Furthermore, the studies suggest that it is the BMP2 release rate and 
implant location (ectopic vs. orthotopic), not the VEGF delivery, that effects the resulting 
bone growth [23,24]. Specifically, ectopic delivery locations resulted in increased bone 
formation with VEGF inclusion when compared to orthotopic sites. Due to these 
conflicting results of these studies, the suggestion that VEGF delivery may be more 
effective in an ectopic location, and the need to implement designed structured scaffolds 
for prefabricated flap generation, we applied the dual BMP2 and VEGF delivery method 
to our PCL/BMP2 system.  
Specifically, this study investigated the effect of dual BMP2 and VEGF delivery 
from a two phase composite scaffold system on subcutaneous regenerated bone volume 
in mice in comparison to BMP2 delivery alone.  The construct consisted of a designed 
structural PCL scaffold and an integrated collagen sponge scaffold. Adsorbed BMP2 was 
delivered from the PCL scaffold surface and VEGF was delivered from the internal 
collagen sponge. The integration and testing of multiple biologics from a designed 
scaffold construct with controlled anatomic shape and porous architecture is a novel 
approach in pre-fabricating bone flaps. 
5.3  Methods & Materials 
PCL Scaffold Fabrication 
Selective laser sintered 3D 70% porous PCL scaffolds (6.35mm D x 4mm H, 170mm
2 
surface area) with 2.15mm spherical pores were fabricated as previously described 
(Figure 5.1A)[19].   
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Figure 5.1: PCL/Collagen Sponge Construct 
A) PCL scaffold 
B) PCL scaffold filled with a collagen type 1 sponge 
C) SEM image of PCL/collagen sponge construct taken at 36x magnification and 
D) 204x magnification of the pore space in construct. 
 
BMP2 Binding 
BMP2 adsorption was completed as previously described [19]. Briefly, scaffolds were 
pre-washed in activation buffer (BuPH Phosphate Buffered Saline Pack in diH20, pH 7.2 
Pierce Biotechnology) and then washed in conjugation buffer (activation buffer plus 
0.1M EDTA) to wet the surface. They were then exposed to 1ml of 65µg/ml BMP2 
(Creative Biomart, Shirley, NY) for 1 hour at 23
o
C, washed in distilled water (diH20), 
and dried overnight. BMP2 was provided in lyophilized form and suspended to 1mg/ml 
in 20mM Acetic Acid. The BMP2 solution was diluted to 65µg/ml in conjugation buffer. 
PCL/Collagen Sponge Construct Fabrication 
Rat tail collagen type 1 gel was made according to the manufacturer’s instructions (BD 
Bioscience). The collagen gel consisted of 5mg/ml collagen, 10% 10x Dulbeccos 
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Phosphate Buffered Saline (DPBS), 1N sodium hydroxide (NaOH), and diH20. The 
volume of 1N NaOH added was equal to 0.023*(volume of collagen) and diH20 was used 
to adjust the final solution volume.  
BMP2 adsorbed PCL scaffolds were washed in DPBS under vacuum and placed into 
form-fitting Sylgard184 (Dow Corning) molds. Sylgard molds were created using solid 
PCL cylinders (6.35mmD, 5mmH) in the uncured Sylgard. The cylinders were removed 
with acetone after the Sylgard cured. Next, 80µl collagen gel was pipetted into the 
macroporous space within the scaffold, and the molds were placed in a vacuum for 2 
minutes. The PCL/collagen gel combination will now be referred to as a construct. The 
constructs were then incubated at 37
o
C for 30 minutes and frozen at -80
o
C for 12 hours. 
Finally, constructs were lyophilized for 24 hours to form a collagen sponge within the 
scaffold pores (Figure 5.1B). 
SEM Imaging 
Constructs were imaged at the Electron Beam Analysis Laboratory at the University of 
Michigan using a Philips/FEI XL30 FEG environmental scanning electron microscope 
(Figure 5.1C&D). Images were taken this 36x and 204x objectives to visualize the 
construct and the pore space, respectively. 
BMP2 Bioactivity-Alkaline Phosphatase Stain 
Cell studies used PCL discs (15mm diameter, 2mm height, 176 mm
2
 surface area) for 
simplicity. C2C12 myoblastic cells are known to differentiate down an osteogenic lineage 
when exposed to active BMP2 [29,30]. Since the adsorbed BMP2 will be subjected to the 
conditions to fabricate the collagen sponge, we next determined if BMP2 was bioactive at 
the end of the process.  C2C12 cells (ATCC, Manassas, VA) were grown in high glucose 
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Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum and 
1% penicillin/streptomycin and incubated in 37
o
C, 5% CO2 and 95% humidity (all 
reagents from Gibco, Carlsbad, CA).  
An Alkaline phosphatase (ALP) assay is commonly used to measure the activity of 
osteoblast-specific protein ALP which corresponds to cells differentiating down an 
osteogenic lineage. PCL discs adsorbed with 1µg BMP2 (n=3, 1.4x10
4
cells/cm
2
) were 
subjected to the conditions required to create a collagen sponge (30 min at 37
o
C, 12 hours 
at -80
o
C, and 24 hours lyophilization), and then C2C12 cells were seeded on them. The 
positive control was 1µg BMP2 adsorbed discs that did not go through the collagen 
sponge production process (n=3). The negative control was cells seeded on PCL discs 
without the addition of BMP2 (n=3). All of the sterile discs were washed with Hanks 
Balanced Salt Solution (HBSS), and maintained in DMEM under sterile conditions until 
cell seeding in a 24 well plate. Discs fit tightly into the well space. The DMEM was then 
replaced with culture medium, and cells were seeded. After 4 days of static culture, discs 
were stained using an Alkaline Phosphatase kit (Sigma) and carried out according to 
manufacturer’s directions. Briefly, discs were fixed, dyed with alkaline dye mixture, and 
counterstained with hematoxylin solution to stain the cell nuclei. A red/pink stain was 
produced if cells expressed ALP. 
VEGF Incorporation and Bioactivity 
Human umbilical vein endothelial cells (HUVECs) were a generous gift from Dr. 
Andrew Putnam’s laboratory and were harvested fresh from patients at the University of 
Michigan Hospital. HUVECs (second passage) were cultured using the EGM-2 Bullet kit 
(Lonza CC-3162) for 4 days in a T-75cm
2
 flask (BD Falcon) incubated at 37
o
C, 5% CO2 
 100 
 
and 95% humidity. Cells were detached using 0.05% EDTA Trypsin (Gibco) and 
quantified with a hemocytometer.  
100µg Vascular Endothelial Growth Factor-165 (VEGF-165) produced in the endosperm 
tissue of barley grain (Novus Biologicals) was dissolved in 1ml sterile diH20 to 
0.1mg/ml. Constructs were placed in an ultra-low bind 24 well plate and 0 or 5µg VEGF 
in 50µl diH20 (n=4) was added drop-wise onto each construct such that the collagen 
sponge was saturated without excess liquid. Constructs were placed in 37
o
C for 25 
minutes and then 50µl of cell medium was added to the constructs to ensure a wetted 
surface. After 20 min, 4.0x10
4
 cells were added drop-wise on one side, and the construct 
was incubated at 37
o
C for 2 hours. Next, constructs were flipped over, 4.0x10
4
 cells were 
added to the other side, and after incubating for another 2 hours 500µl HUVEC medium 
was added to each well. The negative control was constructs with no cells added. After 
72 hours of static culture, 100µl MTS solution (CellTiter96 Aqueous One Solution 
Promega) was added to each construct. Constructs were then incubated at 37
o
C for 4 
hours and triplicate aliquots from each specimen were read at 490nm. 
A standard curve (cell number vs. absorbance) was created by seeding 0, 2x10
4
, 4x10
4
, 
8x10
4
, 16x10
4
 HUVECs per well in standard tissue culture treated polystyrene wells (24 
well plate) in triplicate. After 1 hour, 100µl MTS solution was added to each well and 
triplicate aliquots from each specimen was read at 490nm after 4 hour incubation at 37
o
C 
using a microplate reader.  
In Vivo Bioactivity: Subcutaneous Implantation 
This study was conducted in compliance with the regulations set forth by the University 
Committee on Use and Care of Animals at the University of Michigan. Constructs 
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containing both 65µg/ml BMP2 and 5µg VEGF (BMP2+VEGF group) were implanted 
subcutaneously in 5-6 week old NIHS bg-nu-xid mice (Harlan Laboratories, Indianapolis, 
IN).  An immunocompromised model was used previously in our laboratory for bone 
regeneration studies involving cells delivered on the scaffolds. Therefore, we used the 
same model so that the results from this study could be compared to previous results. To 
provide a more challenging environment for the scaffold to regenerate bone, scaffolds 
were implanted in a subcutaneous region rather than intramuscular. The negative control 
was constructs with 5µg VEGF delivered via collagen sponge and no BMP2 delivered 
from the PCL (VEGF group). The positive control was a construct with BMP2 adsorbed 
onto the PCL scaffold and no VEGF in the collagen sponge (BMP2 group) (Table 5.1). 
Less sample numbers were used for the negative control group because that group was 
not expected to regenerate bone in an ectopic site and would not be included in the bone 
regeneration analyses. 50µl HBSS was added to each group prior to implanting to keep 
the surface wet. A dorsal incision was made and four subcutaneous pockets were created 
angling toward each limb. Four constructs were implanted in each mouse. Constructs 
were randomly assigned a quadrant to be implanted in such that at least one sample from 
each group was implanted in all quadrants. Mice were then euthanized at 4 or 8 weeks 
post-surgery to assess the regenerated bone. Explanted specimens were placed in Z-Fix 
(Anatech, Battle Creek, MI) overnight, washed with diH20 for 24 hours and stored in 
70% EtOH until testing. Table 5.1 describes total sample numbers as well as the number 
of samples used for each specific analysis method (µCT scan, mechanical testing, and 
histology).  Two constructs broke during fabrication in the 4 week BMP2+VEGF and 
BMP2 groups and they were not included in the study.  
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 µCT Scan Mechanical 
Test 
Histology Total 
Samples 
 4wk 8wk 4wk 8wk 4wk 8wk 4wk 8wk 
BMP2+VEGF 7 8 5 6 2 2 7 8 
BMP2 7 8 5 6 2 2 7 8 
VEGF 4 4 2 3 2 1 4 4 
Table 5.1: Sample Numbers for In Vivo Analyses 
Number of explanted specimen used in each in vivo bone regeneration analysis method. 
 
Micro-Computed Tomography (µCT) 
Constructs were scanned in water at 16µm voxel resolution with a µCT scanner (Scanco 
Medical, Wayne, PA). Scan data was generated in calibrated Hounsfield units (HU). Data 
from Microview software (Parallax Innovations, Ilderton, Canda) were used to analyze 
bone volume (BV), tissue mineral density (TMD), and tissue mineral content (TMC) 
using a 1050HU threshold value. The construct region was represented as a cylindrical 
region of interest (ROI) defined as 6mmD x 3.615mmH. Bone regenerated outside of the 
construct ROI boundary was defined as external bone growth and bone regenerated inside 
the construct ROI was defined as internal bone growth.  
To determine bone formation in the middle of the construct, the construct was divided 
into three planar zones as described in Figure 5.5A. Microview was used to calculate the 
bone volume formed in Zone 2 (6mmD, 1.205mmH ROI). This location was chosen 
because it is more challenging to regenerate bone inside of the construct. To determine 
bone penetration into the construct radially, four concentric, cylindrical ring ROIs were 
defined and were individually analyzed with respect to bone ingrowth (Figure 5.7A). The 
diameters of the 4 rings were as follows: Ring 1: 6.00-4.84mm, Ring 2: 4.84-3.67mm, 
Ring 3: 3.67-2.5mm, Ring 4: 2.50-0.00mm. Bone ingrowth for each ring was defined as: 
𝐵𝑜𝑛𝑒 𝐼𝑛𝑔𝑟𝑜𝑤𝑡ℎ (%) =
𝐵𝑜𝑛𝑒 𝑉𝑜𝑙𝑢𝑚𝑒
𝐴𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑃𝑜𝑟𝑒 𝑉𝑜𝑙𝑢𝑚𝑒
∗ 100 
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Available pore volume was calculated from the porosity of each ring based on the 
construct’s .STL design file. 
Compression Mechanical Testing 
Specimens were compressed between a fixed bottom and self-aligning upper steel platen 
at a rate of 1.0 mm/min after application of a 0.5lbf preload. Tests were conducted using 
an MTS Alliance RT30 electromechanical test frame (MTS Systems Corp, Minneapolis, 
MN) and a 500N load cell. Data were collected to 20% strain and analyzed using 
TestWorks4 software (MTS Systems, Corp.).  The compressive elastic modulus was 
defined as the slope of linear region of the stress-strain curve prior to 15% strain. 
Stiffness was defined as the slope of the load vs. displacement curve. Explanted construct 
dimensions were measured with calipers prior to testing, and the stress was calculated 
from the measured construct cross-sectional area.  
Histology 
Fixed samples from each group were decalcified with RDO (Apex Engineering Products 
Corporation), processed through a graded ethanol series, embedded in paraffin, and 
stored at -20
o
C. Samples were then sectioned using a microtome (MICRON HM 325, 
Thermo Scientific) and slides were dried overnight at 37
o
C. Sections were stained with 
hematoxylin and eosin (H&E) to visualize cells, tissue matrix, blood vessels, and general 
tissue morphology. Blood vessels were clearly observed in histology sections and 
manually counted using ImageJ software. Vessels were quantified from sections taken 
from the same location within constructs. 
Statistical Analysis 
Data are expressed as mean ± standard deviation of the mean. An analysis of variance  
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(ANOVA) was used to determine statistical significance between groups. A p-value less 
than 0.05 (α<0.05) was considered statistically significant. 
5.4  Results 
Protein Bioactivity 
 BMP2 bioactivity was confirmed with a noticeable red stain on BMP2 adsorbed 
PCL discs (Figure 5.2A). The negative control of cells seeded on PCL discs (without 
BMP2) produced little to no stain. Bioactivity of VEGF released from the internal 
collagen sponge was determined by HUVEC proliferation. Constructs with 5µg VEGF 
delivered via collagen sponge resulted in significantly increased HUVECs (6.83±0.91 x 
10
4 
cells) in comparison to the negative control (2.89±0.64 x 10
4 
cells) as seen in Figure 
5.2B. Based on these results we determined that BMP2 could be exposed to the sponge 
fabrication process and still be bioactive, and VEGF was bioactive when released from 
the collagen sponge. 
 
Figure 5.2: BMP2 and VEGF Bioactivity 
A) ALP stain of C2C12 cells seeded on PCL/BMP2 discs subjected to the conditions for 
creating a collagen sponge 
B) HUVEC proliferation on constructs with no VEGF and constructs with 5µg VEGF in 
the collagen sponge. *p<0.05 
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Regenerated Bone Volume  
At both 4 and 8 weeks, the BMP2+VEGF and BMP2 groups regenerated 
significantly more BV than the VEGF group (p<0.005, volume < 0.3mm
3
). For the 
BMP2+VEGF group, there was a significant increase in both total and internal BV from 
4 to 8 weeks, which was not the case for the BMP2 group. As a trend, at 4 weeks the 
BMP2+VEGF group produced less bone (4.9±1.9mm
3
) than BMP2 (5.7±2.4mm
3
), while 
at 8 weeks the BMP2+VEGF group produced more bone (10.1±3.7mm
3
) than BMP2 
(7.9±3.9mm
3
) (Figure 5.3). MicroCT scans illustrated the quantitative results that the 
BMP2+VEGF and BMP2 groups produced visibly more bone than the negative VEGF 
control. Both of the BMP+VEGF and BMP2 groups resulted in bone growth into 
construct pores and followed the surface geometry as seen in Figure 5.4. 
 
Figure 5.3: Bone Volume Analysis 
Regenerated bone volume (at a 1050HU threshold) was calculated for the whole 
explanted specimen (total), inside the 6mmD, 3.615mmH construct ROI (internal), and 
outside of the construct ROI (external).  There was a significant increase in bone volume 
from 4 to 8 weeks for BMP2+VEGF but not for BMP2. B=BMP2, B+V=BMP2+VEGF, 
*p<0.05 
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Figure 5.4: Microview Images of Explanted Specimen MicroCT Scans 
Bright white areas indicate bone formation (blue arrow) and gray areas indicate the PCL 
scaffold (red star). Dark areas (red dashed lines) indicate pores. BMP2+VEGF and BMP2 
resulted in bone growth into construct pores and followed surface geometry. VEGF 
produced little to no visible bone. 
 
To further investigate the bone distribution throughout the construct, the BV 
regenerated in the middle third of the construct was calculated (Figure 5.5A). There was a 
significant increase in bone volume from 4 to 8 weeks (4.9±1.9mm
3
 to 10.1±3.7mm
3
) for 
BMP2+VEGF as seen in Figure 5.5B, whereas, there was no significant increase for the 
BMP2 group (p=0.67). 
 
Figure 5.5: Regenerated Bone Volume in the Middle of Construct 
A) Side view of the construct which was divided into three Zones. 
B) Bone volume (1050HU threshold) regenerated in cylindrical Zone 2 ROI (6mmD, 
1.205mmH). BMP2+VEGF had a significant increase in bone formed from 4 to 8 weeks. 
*p<0.05 
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TMC, TMD, & Ingrowth 
TMC significantly increased over time for BMP2+VEGF from 2.4±1.0mg HA to 
5.8±2.1mg HA but not for BMP2 (Figure 5.6A). The TMD was not significantly different 
between groups at either time point, and both groups showed a significant increase in 
TMD from 4 to 8 weeks (Figure 5.6B). BMP2+VEGF TMD increased from 
493.5±33.7mg HA/cm
3
 to 575.4±31.3mg HA/cm
3
 and these values are within the range 
of native mandibular bone [13,31].  
 
Figure 5.6: Explanted Construct TMC and TMD Analysis 
A) Tissue mineral content of the whole construct. There was a significant increase in 
TMC from 4 to 8 weeks for BMP2+VEGF but not for BMP2. 
B) Tissue mineral density of whole construct. BMP2+VEGF and BMP2 showed a 
significant increase from 4 to 8 weeks. There was no difference between groups at either 
time point.  *p<0.05 
 
A ring analysis was conducted to determine the extent of bone ingrowth into the 
construct radially (Figure 5.7A). Only the BMP2+VEGF group showed a significant 
increase in ingrowth from 4 to 8 weeks in the outer ring, Ring 1, from 5.2±2.9% to 
13.5±7.8% (Figure 5.7B). For both single and dual delivery groups, there was no 
significant increase in %ingrowth from 4 to 8 weeks in Rings 2-4 (Figure 5.7B). 
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Figure 5.7: Cylindrical Ring Analyses for Bone Ingrowth 
A) .STL file image of the Ring ROIs. 
B) Percentage bone ingrowth (bone volume divided by available pore space). 
BMP2+VEGF %ingrowth in Ring 1 significantly increased from 4 to 8 weeks. There was 
no difference in ingrowth throughout all of the Rings at 4 weeks and at 8 weeks for 
BMP2 and BMP2+VEGF. B=BMP2, B+V=BMP2+VEGF, *p<0.05 
 
Mechanical Testing 
The elastic modulus and geometric stiffness of BMP2+VEGF increased 
significantly from 10.5±2.3MPa to 14.7±2.7MPa and from 81.5±16.35N/mm to 
115.2±20.1N/mm, respectively at 4 & 8 weeks (Figure 5.8). There was no significant 
increase for the BMP2 group. The elastic modulus for the BMP2 group increased from 
11.4±1.7MPa to 13.1±3.4MPa and stiffness increased from 91.3±13.3N/mm to 
101.5±26.6N/mm. 
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Figure 5.8: Explanted Specimen Compressive Mechanical Testing 
A) Elastic modulus defined as the slope of the linear region prior to 15% strain level and 
normalized to specimen surface area. There was a significant increase in modulus and for 
BMP2+VEGF from 4 to 8 weeks. 
B) Stiffness increased for BMP2+VEGF from 4 to 8 weeks but not for BMP2. *p<0.05 
 
Histology  
 General tissue morphology was observed with H&E staining (Figure 5.9). 
BMP2+VEGF and BMP2 constructs produced bone with embedded osteocytes and 
healthy cellular marrow. VEGF constructs consisted mostly of blood vessels and fibrous 
tissue. The average blood vessel density increased over time for both BMP2+VEGF (29 
to 49 vessels) and BMP2 (27 to 41 vessels) groups (Figure 5.10); however, with n=2 
there could be more variability.    
 110 
 
 
Figure 5.9: H&E Stain of Construct Sections 
Bright field images of tissue formed in available construct pore space. Images were taken 
with a 4x objective. s=scaffold, b=bone, m=marrow. BMP2+VEGF and BMP2 had 
healthy fatty bone marrow and osteoid formation. VEGF constructs consisted mostly of 
fibrous tissues 
 
Figure 5.10: Blood Vessel Density 
A) Blood vessels seen on H&E stained sections. B) The average number of blood vessels 
normalized over the construct area (n=2/group; n=1 for 8week VEGF). There was an 
increase in blood vessel density over time for BMP2+VEGF and BMP2. 
 
 
 
 111 
 
5.5  Discussion 
Co-culture experiments find that osteoblast-like cells stimulate endothelial cell 
proliferation by producing VEGF, and endothelial cells stimulate osteoprogenitor cell 
differentiation by producing BMP2 [32,33]. These results suggest that there is a 
BMP2/VEGF coupling between osteo/angiogenesis [34]. Simultaneous release studies 
have resulted in enhanced bone formation [20,28,35]. The release profiles of these studies 
show a burst release of VEGF in the first 3-5 days and a sustained delivery of BMP2 
[24,36]. Some researchers suggest that the synergistic effect of BMP2/VEGF is both time 
and location dependent (ectopic vs. orthotopic) [23,24,28], the dose ratio utilized is 
important [37], and a high VEGF dose inhibits osteogenesis [36]. Other studies that 
delivered both factors via gelatin microparticles in propylene fumerate (PPF) pores and 
implanted the scaffold in a rat calvarial defect showed no increase in bone formation for 
the dual delivery group [28].  
Studies investigating dual BMP2 and VEGF delivery use various animal models, 
implant locations, growth factor delivery methods (i.e. microparticle, gelatin), time 
points, and methods to analyze the regenerated bone. Our study is novel in that utilizing a 
PCL/collagen sponge construct to deliver VEGF and BMP2 in a subcutaneous 
implantation site has not been investigated to the best of our knowledge. Furthermore, 
dual delivery of growth factors for pre-fabricating bone flap applications is advancement 
to the current process. 
In this study, we used a collagen sponge to deliver VEGF with a relatively rapid 
burst release due to previous studies showing sponges release most of the growth factors 
or antibiotics within the first few days [38-42]. Adsorbed BMP2 onto PCL was 
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previously characterized in our laboratory, and the release profile resulted in a relatively 
small burst release in the first few days followed by a sustained release [19]. Based on 
this information, we expect VEGF to diffuse out of the sponge relatively faster than the 
release of adsorbed BMP2. The 65µg/ml BMP2 dose was chosen because in previous 
studies it regenerated bone in vivo [19].  The 5µg VEGF dose was used because lower 
doses did not cause a significant increase in HUVEC proliferation, in vitro. 
 Using the composite delivery system in this study, we showed that BMP2 
released from a PCL scaffold and VEGF released from a collagen sponge are bioactive. 
After 8 weeks implanted subcutaneously, the BMP2+VEGF group regenerated 
significantly more BV when compared to its 4 week time point. This increase may be 
attributed to increased vasculature to the construct site to facilitate cell, nutrition, and 
waste transportation. Although not significantly different, at 4 weeks BMP2+VEGF 
resulted in less bone than BMP2, and at 8 weeks, BMP2+VEGF resulted in more bone 
than BMP2. Overall, dual delivery of BMP2 and VEGF increased the regenerated BV 
from 4 to 8 weeks, whereas, there was no significant increase with the BMP2 group. The 
average increase in the regenerated BV for dual delivery was 2.3 times higher than with 
single BMP2 delivery. As illustrated by µCT images, the spatial distribution of the 
regenerated bone varied (i.e. more bone in the outer ring and in the middle of the 
construct). This variability could be attributed to the internal collagen sponge affecting 
the BMP2 diffusion route upon release from the scaffold. 
In addition to a significant increase in BV over time for the dual delivery group, 
there was also a significant increase in elastic modulus, stiffness, and TMC from 4 to 8 
weeks. Mechanical integrity is crucial for a craniofacial bone flap to support load while 
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integrating into the defect site and regenerating more bone. When the construct was 
divided into concentric rings, we found that when VEGF was delivered with BMP2, the 
bone ingrowth in the outer part of the construct increased from 4 to 8 weeks. BMP2 and 
BMP2+VEGF both had a significant increase in TMD over time and both groups 
regenerated bone in the range of native mandibular bone [13,31]. Investigating longer in 
vivo time points in a future study may result in significant difference between 
BMP2+VEGF and BMP2 regenerated BV. 
 Finally, we showed that BMP2+VEGF increased blood vessels density when 
compared to BMP2 alone. However, due to the small sample sizes, the results were not 
statistically significant.  Since the constructs were implanted without added cells in an 
ectopic location, it is crucial for the host cells to migrate to the construct and interact with 
the released BMP2 to form bone tissue. The increased vasculature with the dual factor 
group could explain the increased bone regeneration rate and bone volume at 8 weeks 
because vessels would provide more nutrients and transportation for cells migrating to the 
construct. Future studies should look at an earlier time point to quantify 
neovascularization. Overall, dual factor delivery shows promise for increasing the 
amount of regenerated bone volume for pre-fabricated flap applications.  
5.6  Conclusion 
 Tissue engineering a bone flap by using the patient’s body as a bioreactor is a 
potential alternative to using autografts, allografts, and synthetic bone grafts. Delivering 
two growth factors is advancement in the pre-fabrication process, and this study 
concluded that dual delivery of BMP2 and VEGF from a PCL/collagen sponge composite 
construct increased the regenerated bone volume from 4 to 8 weeks, whereas, BMP2 
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delivery alone did not. Dual factor delivery also resulted in an increased elastic modulus, 
TMD, and healthy bone marrow. Future studies should investigate the VEGF to BMP2 
dose ratio and develop another dual growth factor delivery system in hopes to further 
increase the regenerated bone volume while maintaining clinical applicability. 
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CHAPTER 6 
DUAL DELIVERY OF BMP2 AND VEGF FROM A MODULAR 
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6.1  Abstract 
Background: An alternative to using autografts to fix large craniofacial bone defects is to 
tissue engineer a replacement that is patient specific and composed of bone and blood. 
Previously in this laboratory we delivered absorbed bone morphogenetic protein-2 
(BMP2) from a poly-Ɛ-caprolactone (PCL) scaffold and found that bone regenerated in 
an ectopic location. A large defect requires a large volume of bone and vasculature to 
provide nutrients and transportation for cells migrating to the scaffold.  Vascular 
endothelial growth factor (VEGF) is a potent angiogenic protein.  In this study we 
investigate dual delivery of adsorbed VEGF and BMP2 from the outer and inner portions 
of a modular scaffold with the goal of increasing bone regeneration and further 
optimizing the pre-fabrication process. 
Methods: The inner porous PCL module was exposed to 65µg/ml BMP2 and the outer 
porous PCL module was exposed to either 5µg/ml VEGF (B+5V) or 
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10µg/ml VEGF (B+10V). The modules were exposed to the protein solution for 1 hour 
and then assembled. Protein binding was quantified with ELISA, Nanoorange, and 
Fluoroprofile assays.  Adsorbed VEGF bioactivity was determine by endothelial cell 
proliferation. B+5V, B+10V, BMP2, and VEGF groups were implanted subcutaneously 
in mice for 4 & 8 weeks. Bone distribution and histology were then assessed. 
Results: 8.6±1.4µg BMP2 attached to the inner module and 0.0316±0.0053µg BMP2 was 
released after 21 days. 3.1±0.9µg and 8.8±0.9µg VEGF bound to outer modules exposed 
to 5µg/ml or 10µg/ml VEGF, respectively. There was increased endothelial cell 
proliferation on VEGF adsorbed PCL indicating protein bioactivity. B+10V had a 
significant increase in bone volume and ingrowth from 4 to 8 weeks (2.7±1.2 mm
3
 to 
4.6±1.8mm
3
 and 1.8±0.8% to 3.16±1.2%, respectively). No increase was seen with B+5V 
or BMP2. The TMD for all experimental groups were in the range of native bone.  
Histology shows healthy marrow, osteoid, and blood vessel formation. 
Conclusion: VEGF delivered locally with BMP2 increased the bone regenerated from 4 
to 8 weeks. B+10V also produced the most bone volume after 8 weeks indicating that 
dual delivery could be a potential method to grow more bone for pre-fabrication 
applications. 
Keywords: BMP2, VEGF, Polycaprolactone 
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6.2  Introduction 
Large craniofacial bone defects are currently treated with an autograft which 
involves transferring a bone from one area in the patient’s body to the defect site as a 
bony and vascularized flap. Autografts have the drawbacks of donor site morbidity and 
poorly matched defect geometry.  Synthetic scaffolds modified with cells and growth 
factors can overcome these drawbacks; however, these scaffolds do not integrate as well 
into the host bone if implanted directly [1]. If the scaffold is placed directly into a large 
defect site, the surrounding vasculature is limited in its ability to grow into the scaffold, 
and the bone regenerating at the graft’s core can turn necrotic without a sufficient blood 
supply. To overcome this challenge, methods to tissue engineer a bone flap are under 
investigation so that the scaffold is partially remodeled when implanted into the defect 
site [1]. Tissue regeneration can occur in vitro in an external bioreactor (which requires 
an optimal environment and nutritional flow throughout the scaffold), or the flap can be 
regenerated in vivo.  
Pre-fabricating a bone flap in vivo involves implanting a patient-specific 
biomaterial scaffold with associated biologics in a patient's latissimus dorsi and then 
transplanting it to the defect site after a maturation period as a vascularized bone flap [2-
5].  A few animal [4,6-10] and human [2,3,11] studies have been completed but not in the 
United States to the best of our knowledge. Some of these studies used titanium mesh 
trays filled with BioOs/hydroxyapetite blocks to deliver bone morphogenetic protein-7. 
These implants had a crude geometry with the potential to fracture [2,7,8]. Poly-Ɛ-
caprolactone (PCL) is a biocompatible and biodegradable material that can be 3D printed 
into patient specific complex geometries using selective laser sintering (SLS) 
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manufacturing technique [12,13]. PCL is Food and Drug Administration (FDA) approved 
for cranioplasty applications [14,15] and has mechanical properties that are ideal for bone 
tissue engineering. Its slow degradation rate allows for bone regeneration while 
supporting load. Previously in our laboratory, PCL was integrated with osteogenic agent 
bone morphogenetic protein-2 (BMP2) under clinically relevant conditions (1 hour 
protein exposure at room temperature) to increase PCL’s osteoinductive properties, and 
the scaffold produced bone when subcutaneously implanted in mice [16].  
 An ideal flap requires a large bone volume as well as a rich vascular network to 
provide the regenerating bone with the necessary nutrients and to remove wastes. Since 
the scaffold is implanted without cells, the scaffold relies on recruited host cells to 
interact with the released BMP2. Vascular endothelial growth factor (VEGF) is a potent 
angiogenic protein that is a key mediator in angiogenesis by playing a role in early 
fracture repair [17-19].  By delivering VEGF with the BMP2, we hope to increase 
vascularization and cellular access to the released BMP2. Studies that have delivered 
VEGF with BMP2 have conflicting results regarding if bone volume increases [20-22] or 
does not change with the added VEGF delivery [23-25]. These studies vary in animal 
model, implant location, time points, protein dose, and delivery vehicle. Additionally, the 
scaffold fabrication and protein incorporation methods utilized are complex and not 
easily conducted in an operating room (OR) environment. Attaching growth factors 
outside of the OR room will increase regulatory challenges significantly due to unknown 
effects of sterilization on growth factor bioactivity. There is a lack of knowledge as to the 
quality of ectopic bone regenerated when BMP2 and VEGF are co-delivered via 
adsorption from PCL. To make the prefabrication process more clinically applicable (1 
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hour protein exposure to the scaffold at room temperature), in this study we investigated 
the effect of delivering adsorbed BMP2 and VEGF from the inner and outer portions of a 
modular PCL construct, respectively, and assessed the regenerated bone distribution and 
histology. 
6.3  Methods & Materials 
PCL Scaffold Fabrication 
Solid PCL discs (6mmD, 2mmH), 44% porous inner modules (3.5mm sides, 4.3mmH, 
106mm
2
SA), and 79% porous outer PCL modules (7mm sides, 4.3mmH, 357mm
2
SA) 
were fabricated using a Formiga P100 SLS machine (EOS, Inc., Novi, MI) (Figure 6.1). 
Combined inner and outer modular portions resulted in a 70% porous scaffold. PCL 
powder (43-50kDa Polysciences, Warrington, PA) and 4% hydroxyapatite (Plasma Biotal 
Limited, UK) were mixed. After manufacturing, the scaffolds were air blasted, sonicated 
in 70% ethanol (EtOH) for 30 minutes to remove non-sintered powder, sterilized in 
0.22µm filtered 70% EtOH for 30 minutes, and air-dried under sterile conditions at room 
temperature.  
 
Figure 6.1: Modular Scaffold Assembly 
65µg/ml BMP2 was adsorbed onto the inner scaffold module and either 5µg/ml or 
10µg/ml VEGF was adsorbed onto the outer scaffold module. The scaffolds were then 
manually assembled. 
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BMP2 Binding and Quantification 
BMP2 was adsorbed onto the inner module as previously described [16]. Briefly, 1mg 
lyophilized BMP2 (Creative Biomart, Shirley, NY) was dissolved in 1ml 20mM acetic 
acid and diluted in a BuPH (#28372, Pierce) buffer containing 0.1M EDTA (pH 7.0) to 
65µg/ml. An e-coli derived BMP2 ELISA (Peprotech) kit was used to quantify the 
protein content in the 65µg/ml BMP2 solution (average detected concentration was 
28.12±4.6µg/ml), and the binding studies were normalized to this value. Briefly, the 
scaffolds were washed in BuPH buffer (pH 7.2) followed by BuPH+0.1M EDTA buffer 
to wet the surface and then exposed to 1ml 65µg/ml BMP2 for 1 hour at 23
o
C. Finally, 
they were washed in distilled water (diH20) to remove loosely bound protein.  After the 
protein exposure, the remaining solution and washes were collected, 1% Bovine Serum 
Albumin (BSA) was added to result in 0.1% BSA content and samples were stored at -
80
o
C until ELISA analysis for BMP2 content.  
𝐵𝑀𝑃2 𝐵𝑜𝑢𝑛𝑑 (µ𝑔)
= (𝐵𝑀𝑃2 𝑖𝑛 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 𝑏𝑦 𝐸𝐿𝐼𝑆𝐴)
− (𝐵𝑀𝑃2 𝑖𝑛 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 + 𝐵𝑀𝑃2 𝑖𝑛 𝑤𝑎𝑠ℎ𝑒𝑠) 
The ELISA was carried out according to the manufacturer’s directions. Samples were 
read at 405nm and 650nm using a microplate reader. 
VEGF Binding and Quantification 
100µg VEGF-165 (Novus Biologicals, Littleton, CO) produced from the endosperm 
tissue of barley grain was dissolved in 1ml sterile diH20 and then further diluted to either 
5µg/ml or 10µg/ml in diH20. The outer modules were placed in ultra low bind 24 well 
plates (Costar), washed in diH20 and exposed to 1ml VEGF solution for 1 hour at 23
o
C, 
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and washed again in diH20. The remaining solution and washes were collected and stored 
for protein analysis using NanoOrange and Fluoroprofile.  These highly sensitive protein 
assays can detect low protein concentrations and were conducted according to the 
manufacturers’ directions. Briefly, a VEGF standard curve was created from 5µg/ml to 
0µg/ml and unknown samples were mixed with either 2x NanoOrange reagent (diluted in 
3x diluent) or with Fluoroprofile reagent and buffer.  A volume of working solution 
(NanoOrange or Fluoroprofile reagent) was added to the same volume of the unknown 
concentration sample. Samples were read in triplicates in a 96 well plate with a 
fluorometric reader (NanoOrange: 485 excitation, 590nm emission; Fluoroprofle: 520nm 
excitation, 620 emission). 
𝑉𝐸𝐺𝐹 𝐵𝑜𝑢𝑛𝑑 (µ𝑔)
= (𝑉𝐸𝐺𝐹 𝑖𝑛 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛)
− (𝑉𝐸𝐺𝐹 𝑖𝑛 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 + 𝑉𝐸𝐺𝐹 𝑖𝑛 𝑤𝑎𝑠ℎ𝑒𝑠) 
BMP2 Release 
BMP2 adsorbed inner scaffolds were assembled with a PCL outer scaffold (without 
VEGF), submerged in Dulbeccos Phosphate Buffered Saline (DPBS), and incubated at 
37
o
C, 5% CO2, and 95% humidity. The supernatant was collected and replenished 1, 2, 3, 
5, 7, 14, 21 days after the initial exposure. Supernatants with a final 0.1% BSA content 
were stored at -80
o
C until BMP2 quantification with an ELISA.  
Growth Factor Bioactivity 
Previous studies in the laboratory show that BMP2 adsorbed onto PCL is bioactive as 
seen by C2C12 cell alkaline phosphatase (ALP) production [16]. Pre-myoblastic C2C12 
cells differentiate down an osteoblastic lineage when exposed to active BMP2, and this is 
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a well-established model for determining BMP2 bioactivity. Endothelial cell proliferation 
is widely used as a measure of VEGF bioactivity. Human umbilical vein endothelial cells 
(HUVECs) were a generous gift from Dr. Andrew Putnam’s laboratory and were 
harvested fresh from patients at the University of Michigan Hospital. HUVECs at second 
passage were grown in an EGM-2 Bullet kit (Lonza CC-3162) for 4 days at 37
o
C, 5% 
CO2 and 95% humidity. Cells were trypsinized using 0.05% Trypsin with EDTA (Gibco) 
and quantified with an automatic cell counter MoxieZ (Orflo,Ketchum, ID). Proliferation 
studies were completed on a disc geometry with a flat surface to understand adsorbed 
VEGF bioactivity prior to using a complex geometry used for in vivo studies.  
1ml EGM media was added to PCL discs that had 5µg/ml VEGF adsorbed (n=4) and then 
2.5x10
4
 HUVECs were added to each disc (11,765 cells/cm
2
). The negative control was 
cells seeded on PCL discs without any VEGF exposure. After 72hrs of static culture to 
allow for attachment and growth, the medium was replaced with 500µl fresh EGM 
Medium and 100µl MTS solution (CellTiter96 Aqueous One Solution Promega) was 
added to each sample. PCL discs were incubated with the reagent at 37
o
C for 4 hours 
after which triplicates were read at 490nm. Cells were also seeded at 0, 2x10
4
, 4x10
4
, 
8x10
4
, 16x10
4
 cells/well in triplicate to create a standard curve (cell number vs. 
absorbance reading). After 1 hour, 100µl MTS solution was added to the 500µl EGM 
medium in each well and absorbance was read at 490nm. 
In Vivo Bioactivity: Subcutaneous Implantation 
65µg/ml BMP2 inner scaffold modules were assembled with 5µg/ml VEGF (B+5V) or 
10µg/ml VEGF (B+10V) outer scaffold modules, and the scaffolds were implanted 
subcutaneously in 5-6 week old female C57BL/6N mice.  The negative control was 
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5µg/ml VEGF outer modules combined with inner modules that had no adsorbed BMP2. 
The positive control was 65µg/ml BMP2 inner modules combined with outer modules 
that had no adsorbed VEGF. Scaffolds were randomly assigned a side to be implanted 
such that at least one sample from each group was implanted on each left and ride side. 
The dorsal hair was shaved, an incision was made, and two pockets were created angling 
toward the left and right front paws. One assembled scaffold was implanted into each soft 
tissue pocket. Mice were sacrificed at 4 and 8 weeks post-surgery, and the scaffolds were 
explanted for bone growth analysis. The specimens were placed in Z-Fix (Anatech, Battle 
Creek, MI) overnight, washed in diH20 for 24 hours, and stored in 70% EtOH until 
testing. Table 6.1 describes the total sample numbers and the number of samples used for 
microCT and histology analysis methods. This study was conducted in compliance with 
the regulations set forth by the University Committee on Use and Care of Animals at the 
University of Michigan. N=6 samples from each group were used in mechanical testing; 
however, the results of this test were inconclusive because the machine was not sensitive 
enough to detect changes in scaffold mechanical properties due to low regenerated bone 
volume.  Four samples were used for the negative control because no bone was expected 
to regenerate in an ectopic site and these samples would not be utilized in bone volume 
analyses. 
Group µCT Scan Histology Total Samples 
Time Point 4wk 8wk 4wk 8wk 4wk 8wk 
BMP2+5µg/ml VEGF 9 8 3 2 9 8 
BMP2+10µg/ml VEGF 9 8 3 2 9 8 
BMP2 8 9 2 2 8 9 
VEGF 4 5 1 2 4 5 
Table 6.1: Sample Numbers for In Vivo Analyses 
 Number of samples used in explanted specimen analysis methods 
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Micro-Computed Tomography (MicroCT) 
Fixed scaffolds were scanned in water with a high-resolution (16 µm) microCT scanner 
(Scanco Medical, Wayne, PA), and scans were calibrated to Hounsfield units (HU). Bone 
volume (BV) was defined at a threshold of 1050 HU and calculated using Microview 
software (Parallax Innovations). Tissue mineral content (TMC) and tissue mineral density 
(TMD) data were determined by using exported grayscale data. The total scaffold region 
was represented as a cubical region of interest (ROI) defined as 7mm x 7mm x 4.3mm 
height. Bone formed inside of the inner module ROI (3.5mmx 3.5mm x 4.3mmH) was 
quantified and defined as “inner” module bone volume, and the ROI for bone regenerated 
in the outer module was defined as the inner module BV subtracted from the total BV. 
We chose these ROI’s because the BMP2 was coated on the inner module and bone 
grown outside of this area would be of interest. To determine the quantity of bone 
regenerated in the central region of the inner module pores instead of on the PCL scaffold 
surface, a 0.6750mmD, 4.3mmH cylinder ROI was created in all 4 vertical pores, and the 
total BV in the inner module pores was calculated. Bone ingrowth was defined as the 
ROI BV divided by the available pore volume in that ROI. The available pore volume 
was calculated from the porosity of each module based on a microCT scan of a PCL 
scaffold scanned in air. 
Histology 
Fixed samples from each group were demineralized with RDO Rapid Decalcifier (Apex 
Engineering Products), processed, embedded in paraffin, and stored at -20
o
C. Samples 
were then sectioned at 7µm thickness using a MICRON HM 325 (Thermo Scientific, 
Waltham, WA) and slides were dried overnight at 37
o
C. Sections were stained with 
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hematoxylin and eosin (H&E) to visualize cells, tissue matrix, blood vessels, and general 
tissue morphology. Sections were imaged with a 4x objective. 
Statistical Analysis 
Data are expressed as mean ± standard deviation of the mean. An analysis of variance 
(ANOVA) was used to determine statistical significance between groups. A p-value less 
than 0.05 (α<0.05) was considered statistically significant on a 95% confidence interval. 
6.4  Results 
Protein Binding & Release Kinetics 
8.6±1.4µg BMP2 (0.081±0.013µg/mm
2
, 22%) attached to the inner module. After 
1 hour exposure to 5µg/ml or 10ug/ml VEGF, 3.1±0.9µg (0.0086±0.0025µg/mm
2
, 62%) 
and 8.8±0.9µg (0.0246±0.0026µg/mm
2
, 88%) VEGF bound to the outer module, 
respectively (Figure 6.2A). There was significantly less VEGF bound to the 5µg/ml 
VEGF group when compared to 10µg/ml VEGF group (p=0.00076). There was no 
significant difference in the protein quantity bound between BMP2 and 10µg/ml VEGF. 
BMP2 release kinetics show a trend of a relatively small burst release in the first two 
days (0.0233±0.007µg) followed by a sustained release (Figure 6.2B). After 21 days, 
0.0316±0.005µg BMP2 (<1%) was released (Figure 6.2C). 
 
Figure 6.2: Protein Binding and Release Kinetics 
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A) Protein bound to the inner and outer scaffold modules after 1 hour exposure was 
quantified. 5µg/ml VEGF bound significantly less protein than the 10µg/ml VEGF and 
65µg/ml BMP2 groups. 
B) Adsorbed BMP2 has a small burst release trend in the first two days followed by a 
sustained release. 
C) Cumulative release shows 0.032±0.005µg BMP2 was delivered after 21 days (n=3). 
 
VEGF Bioactivity 
Increased HUVEC proliferation was detected for cells seeded on 5µg/ml VEGF 
adsorbed PCL discs when compared to the negative control. Cells seeded on PCL discs 
with or without any adsorbed VEGF resulted in 1.77±0.17x10
4
 cells and 1.4±0.09x10
4
 
cells after 3 days of static culture, respectively (Figure 6.3).  
 
Figure 6.3: Adsorbed VEGF Bioactivity 
HUVECs seeded on PCL discs with adsorbed 5µg/ml VEGF resulted in significantly 
increased proliferation in comparison to cells on PCL discs with no VEGF exposure. 
(n=4,*p<0.05) 
 
MicroCT Analysis 
Figure 6.4A shows representative microCT images of the explanted specimen. 
Bone regeneration was localized to the inner module for all of the groups except for the 
VEGF alone group that did not form any visible bone. The bone observed in the microCT 
scans was quantified using Microview (Figure 6.4B) at a 1050 HU threshold. The B+10V 
group had a significant increase in BV from 4 to 8 weeks in the total scaffold (2.7±1.2 to 
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4.6±1.8mm
3
; p=0.031) and inner module (1.6±0.7 to 3.0±0.9mm
3
; p=0.011). No 
significant increase was seen for the B+5V and BMP2 groups from 4 to 8 weeks.  
 
Figure 6.4: Modular Scaffold MicroCT Analysis 
A) Scans taken of specimen explanted after 4 and 8 weeks implantation. Bright white 
areas indicate bone (red arrow), grey areas are the scaffold (red star) and darker grey 
areas indicate scaffold pores (red dashed line). 
B) Bone volume was defined at a 1050HU threshold. The inner module ROI was 
3.5mmx3.5mmx4.3mmH. Bone formed outside of that cubical ROI was defined as 
“outer” module bone volume. There was a significant increase in total and inner module 
regenerated bone volume from 4 to 8 weeks for the B+10V group but not for B+5V or 
BMP2 groups. 
B+10V=BMP2+10µg/ml VEGF; B+5V = BMP2+5µg/ml VEGF (*p<0.05) 
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Bone Ingrowth 
There was a significant increase from 4 to 8 weeks for the BV formed in the inner 
module pores for the B+10V group (p=0.011) but not for the other groups (Figure 6.5A). 
As seen in Figure 6.5B, for all groups there was significantly more bone ingrowth in the 
inner module than the outer module. There was a significant increase from 4 to 8 weeks 
for the B+10V group in the inner module (8.2±3.5 to 14.5±4.6%; p=0.011) and the total 
scaffold (1.86±0.8 to 3.2±1.2%; p=0.0021). BMP2 and B+5V groups did not show a 
significant increase in either the inner or outer modules. At each time point there was 
significantly more bone ingrowth in the experimental groups when compared to the 
VEGF group. 
 
Figure 6.5: Bone Volume in Pores and Bone Ingrowth 
A) There was a significant increase in bone formed in the center of the inner module 
vertical pores for B+10V. The ROI for each pore was 0.6750mmD, 4.3mmH. 
B) Bone regenerated in each module was normalized by the available pore space to 
determine the % bone ingrowth. The B+10V group had a significant increase in total and 
inner module bone ingrowth from 4 to 8 weeks and no change was seen in the outer 
module. 
B+10V=BMP2+10µg/ml VEGF; B+5V = BMP2+5µg/ml VEGF (*p<0.05) 
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TMD & TMC 
 As a reflection on the BV results, the TMC increased significantly for the B+10V 
group from 4 to 8 weeks (1.2±0.6 to 2.5±0.9mg HA). There was no increase for the 
B+5V and BMP2 groups. TMD increased significantly over time for all groups. B+10V 
and BMP2 increased from 460.6±35.9 to 554.5±29.9mg HA/cm
3
 and from 478.4±23.9 to 
553.2±33.7mg HA/cm
3
, respectively (Figure 6.6). At 4 and 8 weeks there was no 
difference in TMD between BMP2, B+5V, and B+10V (p=0.54).  
 
Figure 6.6: Tissue Mineral Density 
Tissue mineral density was calculated for the total, inner module, and outer modules. All 
groups had a significant increase in TMD from 4 to 8 weeks except for the BMP2 group’s 
outer module. 
B+10V=BMP2+10µg/ml VEGF; B+5V = BMP2+5µg/ml VEGF (*p<0.05) 
 
Histology 
Histology staining shows healthy regenerated bone in all of the experimental 
groups. Blood vessels, osteoid, osteocytes, and cellular marrow are seen in the BMP2, 
B+5V, and B+10V groups. The VEGF only scaffolds were comprised mainly of fibrous 
tissue and blood vessels (Figure 6.7).  
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Figure 6.7: Histology: H&E Staining 
BMP2, B+5V and B+10V groups showed osteoid, blood vessel, and fatty marrow 
formation at both time points. 
b=bone, m=marrow, s=scaffold, f=fibrous tissue. 
B+10V=BMP2+10µg/ml VEGF; B+5V = BMP2+5µg/ml VEGF 
 
6.5  Discussion 
Co-culture studies using endothelial cells and osteoblast-like cells have shown 
that the two cell types influence each other, suggesting that there is a coupling between 
osteogenesis and angiogenesis [26-28]. When determining the dual BMP2 and VEGF 
delivery dosages, one should consider that a high VEGF dose can inhibit osteogenesis 
and the ratio is important [29,30]. For this reason, we chose to investigate two VEGF 
doses. One VEGF dose was similar to the BMP2 (1:1), and the other was significantly 
less than the BMP2 dose (1:2). Previous dual delivery studies vary in study design, and 
there is a lack of knowledge as to the quality of ectopic bone regenerated if BMP2 and 
VEGF are co-delivered via adsorption from a modular PCL scaffold.  
Previously in this laboratory, when adsorbed BMP2 was delivered from a PCL 
scaffold and VEGF was delivered from an internal collagen sponge, the BV significantly 
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increased from 4 to 8 weeks with the dual delivery group when compared to BMP2 group 
which did not increase [31]. Although those results were promising, the protein 
integration method is not easily translatable to the clinic because the BMP2 was adsorbed 
onto the PCL scaffold two days prior to implanting and complex machinery created the 
sponge. With that process, the construct would be fabricated outside of the OR and need 
to be sterilized which negatively impacts protein bioactivity. To create a simpler method 
of delivering both proteins, the modular PCL scaffold portions were exposed to their 
respective growth factors for 1 hour at room temperature and then assembled prior to 
implanting. Adsorption was chosen because it can be conducted in an OR environment 
with a short exposure time and does not require complex machinery. Furthermore, using 
a modular scaffold design to deliver VEGF and BMP2 has not been investigated to 
deliver two biologics to the best of our knowledge. 
In this study, we used a modular PCL scaffold to deliver VEGF and BMP2 with 
the goal of further optimizing the pre-fabrication process and increasing the in vivo bone 
regeneration. 10µg/ml VEGF bound the same amount of protein on the outer module as 
the 65µg/ml BMP2 did on the inner module. 5µg/ml VEGF bound significantly less than 
the BMP2 and 10µg/ml VEGF groups resulting in two VEGF dosages. The BMP2 
release trend was similar to the one found previously when the BMP2 was released from 
a different geometry PCL scaffold [16]. A limitation in this study is that the VEGF 
release profile could not be reliably and reproducibly determined due to VEGF’s short 
half-life (about 90min) at 37
o
C [32]. If the protein rapidly degraded, the assay would not 
accurately detect complete proteins releasing off of the surface. It is important to note 
that in vitro release kinetics are not an accurate representation of the release that would 
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occur in vivo due to neglecting physiological effects. Increased endothelial cell 
proliferation indicated that the VEGF adsorbed onto the PCL surface was bioactive. 
 In vivo bone analysis found the B+10V group significantly increased the total and 
inner module regenerated bone from 4 to 8 weeks when compared to B+5V, BMP2, and 
VEGF delivery. The increase in average bone regenerated from 4 to 8 weeks was 3.4 
times higher for B+10V when compared to the BMP2 group.  As a trend, at 4 weeks, 
B+10V had less bone than B+5V and BMP2; however, after 8 weeks it had more bone 
than the other two experimental groups. A possible explanation could be that VEGF 
initially hindered BMP2-induced bone regeneration, but then increased the bone 
regeneration rate so that the ultimate regenerated BV was higher than BMP2 alone. The 
migrating fibroblasts and mesenchymal stem cells could have interacted with the 
diffusing VEGF prior to interacting with the BMP2 which influenced them to 
differentiate into endothelial cells. These cells would have otherwise been influenced 
down an osteogenic lineage when exposed to BMP2.  The increased vasculature could 
then have increased the bone regeneration rate because of increased nutrients and 
migrating cells. 
With respect to bone formed in the center of the pores rather than the pore 
surface, B+10V had an increase in BV, whereas, the other groups did not change over 
time. This increased bone regeneration was reflected in the TMC results. For all 
conditions, the tissue mineral density was within the range of healthy native bone [12,33].  
Bone ingrowth reflected the bone volume results because there was a significant increase 
in the inner module ingrowth over time for the B+10V group but not for B+5V or BMP2 
alone groups. The inner module had the highest ingrowth for all of the experimental 
 137 
 
groups when compared to the outer module because the BMP2 was adsorbed onto the 
inner module. All groups except for the VEGF group showed healthy bone formation 
with osteocytes embedded in osteoid and cellular marrow development.  
 This study’s results reflect those found in a previous study conducted in this 
laboratory which delivered 65µg/ml adsorbed BMP2 from a PCL scaffold and 5µg VEGF 
from an internal collagen scaffold [31]. In both studies, the dual delivery group 
regenerated significantly more bone from 4 to 8 weeks, and the BMP2 group did not. 
Future studies should assess both an earlier time point to quantify neovascularization and 
a later time point to determine if bone volume with dual delivery eventually surpasses 
single growth factor delivery. 
6.6  Conclusion 
 In this study we adsorbed VEGF and BMP2 in a clinically applicable setting onto 
a modular PCL scaffold and found that adsorbing similar VEGF and  BMP2 dosages 
increases the total regenerated bone volume from 4 to 8 weeks in an ectopic site. 
Delivering multiple biologics is advancement to the process of pre-fabricating a bone 
flap, and the results of this study suggest that dual delivery could be a potential method to 
increase the regenerated bone volume. 
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CHAPTER 7 
DUAL DELIVERY OF BMP2 AND EPO FROM A NOVEL MODULAR 
POLYCAPROLACTONE SCAFFOLD TO INCREASE EARLY ECTOPIC BONE 
REGENERATION IN PREFABRICATED FLAPS 
Jane Modes, Colleen Flanagan, Paul Krebsbach, Sean Edwards, and Scott Hollister 
assisted with the preparation of this chapter. 
Submitted to Tissue Engineering Part C Nov, 2014 
7.1  Abstract 
A potential method to repair large craniofacial bone defects is to implant a 
scaffold with associated proteins into the latissimus dorsi, and then transplant it to the 
defect as a vascularized flap. Bone morphogenetic protein-2 (BMP2) delivered from 
polycaprolactone (PCL) produces bone when implanted subcutaneously. Erythropoietin 
(EPO) works synergistically with BMP2. In this study, adsorbed EPO and BMP2 are 
locally co-delivered from a modular PCL scaffold to increase ectopic bone growth. EPO 
(200IU/ml) and BMP2 (65µg/ml) were adsorbed onto the outer and inner portions of a 
modular scaffold, respectively. Protein binding and release studies were first quantified. 
Subsequently, EPO+BMP2 and BMP2 scaffolds were implanted subcutaneously in mice 
for 4 and 8 weeks. 8.6±1.4µg BMP2 (22%) and 140±29IU EPO (69.8%) bound to the 
scaffold and <1% and 83% was released in 7 days, respectively. Increased endothelial 
cell proliferation indicated EPO bioactivity. At 4 and 8 weeks, BMP2+EPO produced 
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more bone (5.1±1.1 and 5.5±1.6mm
3
) than BMP2 (3.8±1.1 and 4.3±1.7mm
3
). 
BMP2+EPO had more ingrowth (1.4±0.6%) in the outer module when compared to 
BMP2 (0.8±0.3%) at 4weeks. Dual delivery produced more dense cellular marrow while 
BMP2 had more fatty marrow. Dual delivery is a potential method to regenerate more 
bone for a pre-fabricated flap. 
Keywords: BMP, Polycaprolactone, Protein adsorption, Bone tissue engineering 
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7.2  Introduction 
The gold standard for treating a large craniofacial bone defect is an autograft 
usually taken from the fibula or iliac crest. This defect can be caused by trauma, tumor 
resection, or developmental abnormalities.  Methods to tissue engineer a bone flap are 
under investigation to overcome the drawbacks associated with autografts including high 
donor site morbidity, increased risk of infection, and defect geometry mismatch. Tissue 
engineering a flap can be conducted in vitro or in vivo. In vitro, the scaffold with added 
cells would be place in an external bioreactor. However, regenerating a large bone 
volume in vitro is time consuming, and it is difficult to maintain an optimal nutrient 
perfusion of the scaffold [1].  As an alternative, we propose the process of pre-fabricating 
a bone flap in vivo which involves implanting a scaffold with associated biologics into 
the back muscle and then transplanting it to the defect site after a maturation period as a 
boney vascularized flap. Previous studies have created pre-fabricated flaps by utilizing a 
titanium cage, filling it with Bio-Oss blocks soaked in bone morphogenetic protein-7 
(BMP-7) and cells, and implanting the construct inside of the patient’s latissimus dorsi 
muscle [2-10]. After six weeks, the implant was transferred to the defect site but due to 
loading issues, the implant fractured and failed [2].  
We are looking to advance this pre-fabrication process by integrating patient 
specific design, 3D printing, and multiple biologics delivery [11]. Poly-Ɛ-caprolactone 
(PCL) is a biocompatible and biodegradable polymer which can be 3D printed using a 
selective laser sintering (SLS) manufacturing technique to produce scaffolds of complex 
geometry based on the patient’s CT scan [12]. SLS printing can reproducibly create 
scaffolds with designed porosity, mechanical properties, and permeability. Furthermore, 
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PCL leads to less inflammation and generates less acidic byproducts when compared to 
polylactic acid based co-polymers [13]. PCL is also currently utilized in 510(k) approved 
cranioplasty bone filling applications [14,15]. Previously in our laboratory we found 
BMP2 adsorbed onto a porous PCL scaffold in a clinically applicable setting (1 hour 
protein exposure at room temperature environment) regenerates bone when implanted 
subcutaneously in a murine model [16]. 
A flap needed for a large defect would need a large bone volume as well as a rich 
vascular network to supply nutrients to the growing bone, remove waste, and form a 
vascular pedicle that can be connected to a vessel at the defect site.  Furthermore, for 
oncology patients awaiting adjuvant therapy, the speed at which bone is regenerated in 
the donor muscle site is essential. We hope to increase the regenerated bone volume at an 
earlier time point when compared to BMP2 delivery alone by delivering erythropoietin 
(EPO) along with the BMP2 in a clinically applicable manner.  
EPO is a protein that stimulates erythropoiesis, acts as a cytokine for red blood 
cell precursors in the bone marrow, and has been shown to promote angiogenesis in a 
variety of tissues [17]. EPO indirectly impacts bone healing by influencing hematopoietic 
stem cells to produce BMP2 [18-20]. In vitro, EPO has shown to directly influence 
mesenchymal stem cells to differentiate into osteoblasts indicating that they must have 
EPO receptors [19,20]. EPO receptors are also expressed on endothelial cells, neurons, 
and trophoblast cells [19]. EPO has been used clinically to treat anemia and has some 
angiogenic properties [21-23].  
EPO can be delivered systemically; however, drawbacks include serious side 
effects such as increased blood viscosity, hypertension and thromboembolic events 
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[21,24,25]. To avoid the drawbacks associated with systemic delivery, some studies have 
looked at local EPO delivery. Kobayashi et al delivered EPO using a gelatin hydrogel at 
the surface of a rabbit heart [26] and Chen et al delivered EPO using fibrin gel to increase 
neovascularization [27]. Interactions between EPO and BMP2 have been studied in vitro 
[19,20] and in vivo [28,29], and results have shown synergistic effects on bone formation. 
For example, BMP2 was delivered from a collagen scaffold implanted in a rat calvarial 
defect, and EPO was injected subcutaneously at the defect site every other day for 2 
weeks [28]. At 6 weeks the dual delivery group produced a greater bone volume fraction 
when compared to BMP2 alone [28].  
Although these dual delivery results are promising, there is limited knowledge on 
the effects of locally delivering both BMP2 and EPO on ectopic bone regeneration for 
pre-fabricated flap applications. In addition, the use of 3D printed modular delivery of 
multiple growth factors has not been reported. In this study, we investigated the in vitro 
binding, release, and bioactivity of adsorbed BMP2 and EPO from a modular PCL 
scaffold and, furthermore, analyzed the regenerated ectopic bone volume and spatial 
distribution. 
7.3  Materials & Method 
PCL Scaffold Fabrication 
Solid PCL discs (6mmD, 2mmH), and 44% porous inner (3.5mm sides, 4.3mmH, 
106mm
2
SA) and 79% porous outer (7mm sides, 4.3mmH, 357mm
2
SA) PCL scaffolds 
were fabricated via SLS using a Formiga P100 (EOS, Inc., Novi, MI) (Figure 7.1). PCL 
powder (43-50kDa Polysciences, Warrington, PA) was mixed with 4 wt% hydroxyapatite 
(Plasma Biotal Limited, UK). After manufacturing, the scaffolds were air blasted, 
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sonicated in 70% ethanol (EtOH), sterilized in 0.22µm filtered 70% EtOH, and air-dried 
under sterile conditions. 
 
 
Figure 7.1: Modular Scaffold Assembly 
BMP2 was adsorbed onto the inner scaffold module and EPO was adsorbed onto the 
outer scaffold module. The two scaffolds were then assembled 
 
EPO Binding to PCL Scaffolds 
100µg EPO (Creative Biomart, Shirley, NY) was reconstituted in 1ml sterile Dulbecco’s 
phosphate buffered saline (DPBS) to result in 12,000 IU/ml (0.1mg/ml). The stock 
solution was further diluted to the desired concentrations in DPBS. The outer modular 
scaffolds were placed in an ultra low bind 24 well plate (Costar) and washed in DPBS to 
wet the surface. Scaffolds were then exposed to 1ml EPO solution at room temperature 
for 1 hour (n=3). 100 IU/ml per PCL disc was used for bioactivity studies to conserve 
materials and 200 IU/ml per scaffold was used for binding, release, and in vivo studies. 
Finally, scaffold modules were washed in DPBS to remove loosely bound protein. The 
washes and the remaining EPO solution following the exposure were collected to 
indirectly quantify EPO remaining in the solution utilizing a protein quantification kit 
(Fluoroprofile, Sigma).  A standard curve was created from 2.5µg/ml to 0µg/ml (300 
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IU/ml to 0 IU/ml).  A volume of working solution (Fluoroprofile reagent and buffer) was 
added to an equal volume of unknown EPO sample. Samples were read in triplicates with 
a fluorometric reader (520nm excitation, 620 emission).  
𝐸𝑃𝑂 𝐵𝑜𝑢𝑛𝑑 (𝐼𝑈)
= (𝐸𝑃𝑂 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑡𝑜 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑) − (𝐸𝑃𝑂 𝑖𝑛 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
+ 𝐸𝑃𝑂 𝑖𝑛 𝑤𝑎𝑠ℎ𝑒𝑠) 
BMP2 Binding and Quantification 
BMP2 was adsorbed onto the inner scaffold modules as previously described [16]. 
Briefly, 1mg lyophilized BMP2 (BMP2-01H, Creative Biomart, Shirley, NY) was 
dissolved in 1ml 20mM acetic acid and it was then further diluted in BuPH (#28372, 
Pierce) buffer with 0.5M EDTA (pH 7.0) to 65µg/ml. A BMP2 ELISA (Peprotech), 
specific for e.coli derived BMP2, was used to quantify the protein content in the 65µg/ml 
BMP2 solution (average detected concentration was 28.12±4.6µg/ml), and the binding 
studies were normalized to this value. Briefly, the inner scaffold modules were washed in 
BuPH buffer (pH 7.2) followed by BuPH+0.5M EDTA buffer to wet the surface, exposed 
to 1ml of 65µg/ml BMP2 for 1 hour at 23
o
C (n=3), and washed in water (diH20) prior to 
use.  The washes and the BMP2 solution remaining after exposure were collected, 1% 
Bovine Serum Albumin (BSA) was added to result in 0.1% BSA content and samples 
were stored at -80
o
C until ELISA analysis for BMP2 content.   
𝐵𝑀𝑃2 𝐵𝑜𝑢𝑛𝑑 (µ𝑔)
= (𝐵𝑀𝑃2 𝑖𝑛 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 𝑏𝑦 𝐸𝐿𝐼𝑆𝐴)
− (𝐵𝑀𝑃2 𝑖𝑛 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 + 𝐵𝑀𝑃2 𝑖𝑛 𝑤𝑎𝑠ℎ𝑒𝑠) 
The ELISA was carried out according to the manufacturer’s directions.  
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Release Kinetics 
The outer scaffold modules with adsorbed EPO were manually assembled with the inner 
scaffold modules that had no BMP2 adsorbed (Figure 7.1). Constructs were submerged in 
1ml DPBS and incubated at 37
o
C, 95% humidity, 5% CO2. The supernatant was collected 
and replenished at 1, 2, 3, 5, and 7 days after initial exposure. Samples were stored at -
80
o
C until FluroProfile assay analysis for protein content.  
The inner scaffold modules with adsorbed BMP2 were assembled with an outer module 
that had no adsorbed EPO, submerged in 1ml DPBS, and incubated at 37
o
C, 95% 
humidity, 5% CO2. The supernatant was collected and replenished 1, 2, 3, 5, and 7 days 
after initial exposure. Supernatants with a final 0.1% BSA content were stored at -80
o
C 
until BMP2 quantification with an ELISA.  
Adsorbed EPO Bioactivity 
Previous studies in the laboratory show that BMP2 adsorbed to PCL surface maintains 
bioactivity as seen by C2C12 cell Alkaline Phosphatase production [16]. In this study, 
endothelial cell proliferation was used to indicate EPO bioactivity as done in other 
studies [30-32]. A disc geometry with a flat surface was used for this assay due to a well 
defined surface area and a simple geometry. This assay’s goal was to assess the protein’s 
bioactivity and not the extent of bioactivity.  Second passage human umbilical 
endothelial cells (HUVECs) were cultured in EGM-2 growth medium (Lonza CC-3162) 
for 4 days at 37
o
C, 95% humidity, 5% CO2. Cells were trypsinized using 0.05% Trypsin 
with EDTA (Gibco) and quantified with an automatic cell counter - MoxieZ 
(Orflo,Ketchum, ID). 
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1ml EGM-2 growth media was added to PCL discs exposed to 100 IU EPO (n=4) and 
2.0x10
4
 HUVECs were seeded on each disc (11,765cells/cm
2
). Cells seeded onto discs 
without EPO exposure and PCL discs without cells served as the negative control.  After 
72 hours static culture, the cell medium was replaced with 500µl fresh EGM-2 Medium 
and 100µl MTS solution (CellTiter96 Aqueous One Solution Promega) was added per 
well. Constructs were incubated with the MTS reagent at 37
o
C for 4 hours and triplicates 
for each condition were read at 490nm on a microplate reader. 
Cells were also seeded at 0, 2x10
4
, 4x10
4
, 8x10
4
, 16x10
4
 cells/well in triplicate to create a 
standard curve (cell number vs. absorbance reading). After 1 hour, 100µl MTS solution 
was added to the in 500µl EGM medium in each well, and the absorbance was read at 
490nm on a microplate reader.   
In Vivo Bioactivity: Subcutaneous Implantation 
BMP2 inner scaffold modules (adsorbed with 65µg/ml BMP2) were assembled with 
outer scaffold modules (adsorbed with 200 IU/ml EPO) for the dual delivery BMP2+EPO 
group.  The negative control was outer modules with 200 IU/ml EPO adsorbed and no 
BMP2 adsorbed onto the inner modules (EPO group). The positive control was inner 
modules with 65µg/ml BMP2 adsorbed and no EPO adsorbed onto the outer modules 
(BMP2 group). Scaffolds from each group were implanted subcutaneously in 5-6 week 
old female C57BL/6N mice.    
The mouse dorsal hair was shaved and an incision was made in the back. Two 
subcutaneous pockets were created, one on each side, and a scaffold was placed into each 
pocket. Scaffolds were randomly assigned a side to be implanted such that half of the 
samples from each group were implanted on both the right and left sides. The positive 
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control (the BMP2 group) was implanted in a parallel study such that a BMP2+EPO and 
BMP2 scaffold were not implanted in the same mouse. Mice were sacrificed at 4 and 8 
weeks post-surgery to assess bone regeneration. The explanted specimens were placed in 
Z-Fix (Anatech, Battle Creek, MI) overnight, washed in diH20 for 24 hours and stored in 
70% EtOH until assays were performed. Table 7.1 describes the total sample numbers 
and the number of samples used for each specific analysis method.  This study was 
conducted in compliance with the regulations set forth by the University Committee on 
Use and Care of Animals at the University of Michigan.  
Group µCT Scan Histology Total Samples 
 4wk 8wk 4wk 8wk 4wk 8wk 
BMP2+EPO 9 8 3 2 9 8 
BMP2 8 9 2 2 8 9 
EPO 9 8 3 2 9 8 
Table 7.1: Sample Numbers for In Vivo Analysis.  
Number of samples used in explanted specimen analysis methods 
 
Micro-Computed Tomography (MicroCT) 
Fixed scaffolds were scanned in water with a high-resolution (16µm) microCT scanner 
(Scanco Medical, Wayne, PA), and the scans were calibrated to Hounsfield units (HU). 
Bone volume (BV) was defined at a 1050HU threshold using Microview software 
(Parallax Innovations, Ilderton, ON). Tissue mineral density (TMD) was determined 
using exported grayscale data. The total scaffold region was represented as a cubical 
region of interest (ROI) defined as 7mm x 7mm x 4.3mm height. An ROI defining the 
inner scaffold module (3.5mmx 3mmx 4.3mmH) was used to determine bone formation 
within the module. Bone regenerated in the outside scaffold modules was calculated as 
the inner scaffold module BV subtracted from the total scaffold BV. The total, inner 
module, and outer module scaffold bone ingrowth was calculated as the BV divided by 
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the available pore volume in each region. Available pore volume was calculated from the 
porosity of each ring based on the microCT scan of an assembled modular scaffold (pre-
implantation). To determine the amount of bone formed in the central region of the inner 
module pores instead of on the PCL surface, a 0.6750mmD, 4.3mmH cylinder ROI was 
created in all 4 vertical pores, and the total BV in inner module pores was calculated. 
TMD was calculated for the total, inner module, and outer module scaffolds.  
Histology 
Fixed scaffolds from each group were decalcified with RDO (Sigma), processed, and 
embedded in paraffin. Samples were then sectioned at 7µm thickness using a MICRON 
HM 325 (Thermo Scientific) and slides were incubated at 37
o
C overnight to dry. Sections 
were stained with hematoxylin and eosin (H&E) to visualize cells, tissue matrix, blood 
vessels, and general tissue morphology.  Sections were imaged with a 4x objective. 
Statistical Analysis 
Data are expressed as mean ± standard deviation of the mean. An analysis of variance 
(ANOVA) was used to determine statistical significance between groups. A p-value less 
than 0.05 (α<0.05) was considered statistically significant on a 95% confidence interval. 
7.4  Results 
Protein Binding and Release Kinetics 
After 1 hour protein exposure, 139.6 ± 28.6 IU EPO (69.8%) and 8.56 ± 1.4µg 
BMP2 (22%) bound to the outer and inner scaffold modules, respectively. After 7 days, 
0.0311 ± 0.0053µg BMP2 (<1%) and 119.2 ± 29.4IU EPO was released (85%) from the 
PCL surface (Figures 7.2A & 7.2C). For both proteins, there was a relatively small burst 
release in the first two days of 45.8 ± 24 IU EPO (32.8%) and 0.017 ± 0.007µg BMP2 
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(0.2%) (Figures 7.2B & 7.2D). HUVECs seeded on EPO adsorbed PCL discs 
experienced increased cell proliferation (2.4 ± 0.3x10
4
 cells/disc) when compared to cells 
seeded on PCL discs without any protein exposure (1.6±0.1x10
4
cells/disc) (Figure 7.3).  
 
Figure 7.2: Protein Release Profiles 
A) BMP2 cumulative release profile. After 7 days, 0.0311±0.0053µg BMP2 was released 
into 1xPBS at 37
o
C. 
B) BMP2 release. A small burst release occurred in the first two days followed by 
sustained release. 
C) EPO cumulative release profile. After 7 days, about 119.2±29.4IU of the 
139.6±28.6IU bound was released. 
D) EPO released over 7 days with a small burst release in the first two days. (n=3/group). 
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Figure 7.3: Adsorbed EPO Bioactivity 
HUVEC cells seeded on PCL disc exposed to EPO showed increase levels of 
proliferation. n=4; *p<0.05. 
 
MicroCT: Bone Volume 
Visual analysis of the microCT scans show BMP2 only groups regenerated bone 
localized mainly on the inner module which had been adsorbed with the osteogenic factor 
(Figure 7.4A). The BMP2+EPO group regenerated bone not only in the inner module but 
also in the surrounding outer module.  At both time points the dual delivery BMP2+EPO 
group produced more bone than the BMP2 group. The EPO group regenerated little to no 
visible bone. Microview software was utilized to quantify the bone volume observed in 
the microCT scans.  At 4 weeks, the dual delivery group regenerated significantly more 
total bone (5.1±1.1mm
3
) than the BMP2 group (3.8±1.1mm
3
) (p=0.019) (Figure 7.4B). 
BMP2+EPO had more bone regenerated in the inner module, although it was not 
significantly more (p=0.068), and in the outer module (p=0.276). At 8 weeks, a similar 
trend was observed; however, there was no significant difference between dual and single 
GF delivery (p=0.279). Overall, BMP2+EPO regenerated more total, inner module, and 
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outer module bone volume than the BMP2 group. At both time points, the BMP2 and 
BMP2+EPO groups had significantly more bone volume than the EPO group (less than 
0.2mm
3
). 
 
Figure 7.4: MicroCT Analysis of Regenerated Bone 
A) Representative microCT images. The BMP2 group regenerated bone localized to the 
inner module and EPO+BMP2 regenerated bone in the outer module pores as well as in 
the inner module. 
B) EPO+BMP2 resulted in significantly more total regenerated bone compared to the 
BMP2 group (*p<0.05). 
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Bone Ingrowth and TMD Analysis 
Bone ingrowth analysis was not conducted for the EPO group because little to no 
regenerated bone volume was detected. At 4 and 8 weeks both of the BMP2+EPO and 
BMP2 groups had the same bone volume form in the inner module pores (Figure 7.5A). 
At 4 weeks BMP2+EPO had significantly more bone ingrowth in the outer module 
(1.44±0.6%) when compared to the BMP2 group (0.81±0.3%) (p=0.018) (Figure 7.5B). 
The increased bone ingrowth for dual delivery also occurred at 4 weeks in the inner 
module, however, the increase was not significant (p=0.067). With respect to the total 
scaffold, BMP2+EPO had significantly more ingrowth than BMP2 at 4 weeks (p=0.03). 
There were no significant differences in ingrowth between the two groups throughout the 
scaffold at 8 weeks (Figure 7.5B).  
 
Figure 7.5: Pore Bone Growth and Scaffold Ingrowth 
A) Bone volume formed inside of the inner module vertical pores was quantified at a 
1050HU threshold. Pore ROIs used were 4.3mm height, 0.670mm diameter 
B) Dual delivery had higher bone ingrowth in the total, inner module, and outer module 
at 4 weeks (*p<0.05). 
 
TMD analysis showed that regenerated bone in the BMP2 group was significantly 
more mineralized than that of the BMP2+EPO group at 4 weeks (505.8±31.1 mg HA/cm
3
 
vs. 440.18±29.1 mg HA/cm
3
; p=0.0001) and at 8 weeks (583.0±35.7mg HA/cm
3 
vs. 
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501.7±40.6mg HA/cm
3
; p=0.001). Further analysis of inner and outer scaffold module 
TMD at 4 weeks showed the BMP2 group had significantly more dense bone in the outer 
module when compared to the inner module (p=0.06). The BMP2+EPO group had no 
difference in TMD between the two scaffold modules. At 8 weeks, both BMP2 and 
BMP2+EPO groups had uniform TMD throughout the scaffold (Figure 7.6).  
 
Figure 7.6: Tissue Mineral Density Analysis of Regenerated Bone 
TMD of the total, inner module, and outer module was determined using Microview 
software. At 4 weeks the BMP2 group had more dense bone in the outer module and the 
dual delivery group had the same density bone throughout the scaffold *p<0.05. 
 
Histology 
Histology staining showed bone marrow, osteoid, blood vessels and osteocytes 
embedded in bone matrix for the BMP2+EPO and BMP2 groups. The dual delivery 
group had more dense cellular marrow and the BMP2 group seemed to have more fatty 
marrow. The EPO group was comprised mostly of fibrous tissue (Figure 7.7). For both 
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groups, osteocytes were embedded in the osteoid and osteoblasts were located at the 
periphery of forming bone. 
 
Figure 7.7: Histology: H&E Staining 
BMP2+EPO and BMP2 groups showed osteoid, blood vessel, and marrow formation at 
both time points. The BMP2+EPO group had more dense cellular marrow and the BMP2 
group had more fatty marrow. b=bone, m=marrow, s=scaffold, f=fibrous tissue. 
 
7.5  Discussion 
Medtronic’s InfuseTM product has been FDA approved for BMP2 delivery from a 
collagen type 1 sponge for a variety of applications: spinal fusion, the treatment of open 
tibial fractures, sinus augmentation, and dental procedures [33]. Due to BMP2’s short 
half-life, a 1.5mg/ml BMP2 dose was needed (greatly exceeding native concentrations of 
18.8-22pg/mL) which resulted in a large burst release during the first 2-3 days causing 
adverse reactions in some patients [34]. Amgen’s product EPOGEN® is also FDA 
approved and uses the EPO protein to increase red blood cell levels caused by chronic 
kidney disease in anemic patients. This administration avoids the need for red blood cell 
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transfusions [35,36]. Since these proteins are already FDA approved, the next step of dual 
delivery is feasible, although some regulatory hurdles would increase.  
Although local BMP2 delivery from various scaffolds in a subcutaneous model 
has been widely studied for bone tissue engineering applications, there are very few 
investigations into local EPO delivery. EPO has been delivered via injectable hydrogels 
[37,38], gelatin [26] and fibrin gel [27] for angiogenesis studies; however, only one study 
of which we are aware has delivered EPO from a porogen-leached protein microbubble 
polyglycolic acid (PLGA) scaffold for the purpose of bone regeneration [29]. This 
delivery vehicle was used to investigate the effects of dual EPO and BMP2 delivery on 
bone regeneration in a calvarial defect model. There is limited to no knowledge of the 
binding and release of adsorbed EPO on PCL and, furthermore, the effect of dual EPO 
and BMP2 delivery on bone regenerated in an ectopic location for the application of pre-
fabricated flaps is unknown.  
In this study we used adsorption as the protein binding method to PCL due to the 
potential translational nature of this process. A short protein exposure time (<1hour) at 
room temperature prior to scaffold implantation is ideal for operating room environments. 
More complex processes that bind the protein outside of the OR will face increased 
regulatory hurdles such as sterilization, shelf life, maintained efficacy studies etc. 
Additionally, in this study a modular scaffold design is used which is a novel method to 
deliver multiple growth factors. The two components are simple to assemble while 
maintaining their geometric complexity due to SLS manufacturing.  
One hour adsorption resulted in 139.6 ± 28.6 IU EPO (69.8%) and 8.56 ± 1.4µg 
BMP2 (22%) bound. After 7 days, less than 1% BMP2 was released. Even though this is 
 160 
 
a small amount, it is shown to be therapeutically relevant in the in vivo study. Since an 
ELISA was used to detect the protein, the remaining BMP2 could have released off the 
surface but may have degraded which would go undetected by the assay. Another 
explanation is that it may not have released and required in vivo proteolytic activity to be 
released. As for EPO, 85% of the bound protein was released in the first week in vitro. 
HUVECs proliferated significantly more on PCL discs with adsorbed EPO indicating that 
the bound or released EPO was still bioactive. We have shown in previous studies that 
BMP2 released after adsorption onto PCL was still bioactive as seen with alkaline 
phosphatase activity [16]. 
In vivo, a modular scaffold that delivered EPO combined with BMP2 produced 
significantly more total bone at 4 weeks when compared to the BMP2 group. This 
increased early bone formation is important for pre-fabricated flap applications because 
the flap would mature faster for oncology patients awaiting adjuvant therapy. At 8 weeks, 
the dual delivery group still had more bone than the BMP2 alone group; however, the 
increase was not significantly different. Upon visual inspection, the BMP2 group 
regenerated bone localized to the inner module area where the BMP2 was adsorbed. The 
BMP2+EPO group regenerated bone in both the outer and inner modules indicating 
EPO’s influence was not spatially constricted to the outer module. It may have had a 
synergistic effect on bone production in adjacent areas. Since EPO was released rather 
quickly, it could have diffused to interact with migrating cells. Bone formation was also 
controlled and limited within the scaffold boundary. Dual delivery produced more bone 
than the BMP2 group, but the amount of bone that grew in the inner module pores was 
the same; therefore, dual delivery may have grown more bone on the surface of the pores. 
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 Bone ingrowth analysis found BMP2+EPO regenerated significantly more bone 
in the outer module available pore space at 4 weeks when compared to BMP2 alone. This 
increased bone growth seen with the dual delivery group could be explained by the 
synergistic effects between EPO and BMP2. EPO has shown to play a role in 
osteoclastogenesis and osteoclasts can recruit MSCs to the site of bone remodeling [28]. 
If EPO caused an initial increase in osteoclast numbers, this may have resulted in 
increased bone forming cells recruited to the construct. Interestingly, although dual 
delivery had more bone than the BMP2 group, the BMP2 group had a higher TMD when 
compared to BMP2+EPO at both time points. One potential explanation for this 
difference could be that the dual delivery bone was forming faster than BMP2 alone and 
the osteoblasts may not have been mineralizing the osteoid at the same rate. Despite the 
difference, dual delivery resulted in uniform TMD throughout the scaffold in the range of 
native bone; whereas, BMP2 had more dense bone in the outer module when compared to 
the inner module. With regard to developing a bone flap, having more bone with TMD in 
the normal range may be an advantage over less bone with higher mineral content 
overall.  Gross tissue morphology analysis of explanted samples finds a more dense 
cellular marrow for the BMP2+EPO groups and a more fatty marrow for the BMP2 
groups. This difference should be further investigated in future studies.   
 In this study we successfully detected adsorbed EPO and BMP2 binding and 
release kinetics from a novel modular PCL scaffold. Once adsorbed to the surface, these 
proteins maintain bioactivity.  These two proteins are already FDA approved for several 
clinical indications, and the simple binding process can be conducted in a clinically 
applicable environment (1hour protein to scaffold exposure at ambient temperature). 
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Furthermore, delivering EPO along with the osteogenic protein BMP2 resulted in 
increased bone regeneration in comparison to single BMP2 or EPO delivery. Since the 
implant is acellular when implanted, circulating mesenchymal stem cells and fibroblasts 
could be interacting with the delivered growth factors and inducing bone formation. 
Future studies should investigate the effects of altering the BMP2 and EPO dose ratios, 
and more studies could be completed to elucidate the mechanisms of EPO and BMP2 
synergy to further optimize the dual delivery protocol.   
7.6  Conclusions  
The speed at which bone forms in a pre-fabricated flap is crucial for oncology 
patients awaiting adjuvant therapy. In this study we have found that delivering EPO along 
with BMP2 could be a potential method to regenerate a greater bone volume at an earlier 
time point when compared to BMP2 alone delivery. Local dual delivery of EPO and 
BMP2 has not been investigated in depth, and delivering multiple biologics may advance 
the process of pre-fabricating flaps for skeletal reconstruction.   
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CHAPTER 8 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
8.1 Conclusions 
 Work presented in this dissertation represents significant contributions to the field 
of scaffold bone tissue engineering. There are multiple methods to deliver bone 
morphogenetic protein-2 (BMP2) from a biomaterial. Neither clinical applicability, nor 
the resulting bone regenerated in vivo, has been taken into consideration. The vascular 
endothelial growth factor (VEGF) and BMP2 dual delivery studies further optimized the 
regenerated bone volume by increasing the bone formation from 4 to 8 weeks. Finally, 
when compared to BMP2 delivery alone, the regenerated bone volume at 4 weeks was 
significantly increased when erythropoietin (EPO) was delivered with BMP2. By 
increasing the regenerated bone volume, a pre-fabricated flap can mature faster and be 
explanted to the defect site at an earlier time point. Future work with dual growth factor 
delivery should focus on adsorbing both proteins onto the entire scaffold to result in 
uniform bone distribution throughout the construct. Also, the protein dosages should be 
optimized to regenerate the most ectopic bone growth.  
8.1.1 Adsorbed BMP2 Produces More Bone than Conjugated BMP2 
There are multiple methods of binding BMP2 to biomaterial scaffolds requiring 
protein to scaffold exposure times ranging from 1-24 hours in environments ranging from 
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4
o
C-37
o
C [1-4]. Ideally, protein binding should be completed in less than one hour and at 
room temperature if it is conducted in a clinical setting. If the protein is incorporated onto 
the scaffold outside of the operating room (OR) room, regulatory hurdles increase 
significantly due to factors such as unknown sterilization effects on growth factor 
bioactivity and shelf life limitations. Adsorption and conjugation protocols have been 
superficially compared but have not been directly compared with such rigorously 
controlled scaffold geometry such as those printed using selective laser sintering 
technology [5,6]. Furthermore, studies have not compared in vitro binding and release 
studies and correlated them to in vivo bone regeneration. In our study, we found 
conjugation bound more protein than adsorption at a lower concentration and at room 
temperature. As the BMP2 concentration increased, the same amount of protein bound 
after 1 hour exposure at room temperature for both adsorption and conjugation. BMP2 
was bioactive once adsorbed onto the poly-Ɛ-caprolactone (PCL) surface; however, 
conjugated BMP2 showed little to no signs of in vitro bioactivity. This inactivity may be 
because the chemical binding covered the protein’s active site, the BMP2 was packed too 
tightly on the surface so cells could not access it, or physiological enzymes are needed to 
cleave the protein from the surface. It is important to note that preparing the PCL scaffold 
for conjugation required three days, whereas, adsorption required little advanced 
preparation. BMP2 adsorbed under a clinically relevant loading scenario made BMP2 
available faster than conjugation (which had a sustained release).  
When placed in vivo, the higher dose of adsorbed BMP2 (65µg/ml) regenerated 
the greatest bone volume that was also equally distributed throughout the scaffold pore 
space (bone ingrowth). Conjugation regenerated significantly less bone than the 
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adsorption groups. The elastic modulus was higher for the adsorption groups indicating 
superior mechanical properties when compared to conjugation, and the tissue mineral 
density (TMD) for both adsorption and conjugation groups were within the range of 
native bone. From the results of this study, we can conclude that the simpler adsorption 
method may be more optimal for use in the clinic because adsorbed BMP2 is bioactive in 
vitro, produces bone in vivo, increases the scaffold’s elastic modulus, and produces 
healthy fatty bone marrow. 
8.1.2 Dual Delivery of BMP2 and VEGF from a PCL/Collagen Sponge Construct 
Increases the Bone Regenerated from 4 to 8 Weeks 
An irradiated large bone defect site is difficult to reconstruct and will not easily 
support a bone graft. An ideal bone flap would be composed of bone tissue as well as a 
rich vascular network to provide nutrients to and remove waste from the regenerating 
bone. Vessels also provide transportation for cells that are migrating to the implant site to 
assist with further remodeling. VEGF is a potent angiogenic growth factor that plays a 
role in bone healing [7-9]. A few studies delivered antibiotics and growth factors from 
collagen sponges and found a rapid release trend [10-15]. To imitate natural sequential 
expression of the two proteins, we combined the slower releasing BMP2 adsorbed PCL 
scaffold from AIM I with an internal collagen sponge to rapidly deliver VEGF. We found 
that BMP2 was bioactive after being subjected to the sponge fabrication conditions, and 
the VEGF released from the collagen sponge was also bioactive as indicated by increased 
human umbilical vein endothelial cell (HUVEC) proliferation.  
In vivo, as a trend, initially at 4 weeks dual BMP2 and VEGF delivery regenerated 
less bone than BMP2 alone; however, at 8 weeks the dual delivery group had more bone 
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than BMP2 alone. Although the differences between the groups at each time point were 
not significant, there was a significant increase in bone volume from 4 to 8 weeks for the 
dual delivery group but not for the BMP2 alone group. Perhaps the released VEGF 
initially influenced migrating mesenchymal stem cells and fibroblasts to differentiate into 
endothelial cells rather than into osteoblasts resulting in less bone volume. However, after 
the vascular network was established, the bone formation may have rapidly increased due 
to increased migrating cells and nutrient transfer. To corroborate the bone volume results, 
the elastic modulus, TMD, and bone ingrowth also increased over time for the dual 
delivery group but did not change for the BMP2 alone group. In the future, a longer time 
point and larger sample number should be used to determine if dual delivery eventually 
regenerates significantly more bone than BMP2 alone. A limitation in this study was the 
inability to accurately measure the VEGF release profile. Without the release data, we 
could not be certain how much VEGF was delivered in comparison to the BMP2. This 
ratio is crucial to the bone volume formed [16]. Although the results from this study were 
promising, creating the collagen sponge required two days after the scaffold was coated 
with BMP2 which could negatively affect the protein’s bioactivity.   
8.1.3 Dual Delivery of BMP2 and VEGF from a Modular PCL Scaffold Increases the 
Bone Regenerated from 4 to 8 Weeks 
As mentioned in Section 8.1.2, developing a rich vasculature is crucial to 
sustaining a large bone flap. Delivering potent angiogenic factor VEGF along with BMP2 
is a possible method to increase bone regeneration. However, clinical constraints should 
be taken into account when designing the protein binding protocol to mitigate regulatory 
hurdles [7-9]. Considering AIM II results  (Section 8.1.2), we developed a modular PCL 
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scaffold such that BMP2 and VEGF were adsorbed on the inner and outer modular 
scaffold components, respectively, and then assembled prior to implantation. This 
protocol is more applicable for use in the OR setting because the PCL components were 
exposed to the proteins for 1 hour at room temperature.  The amount of 65µg/ml BMP2 
that bound on the inner module was similar to the 10µg/ml VEGF that bound to the outer 
module. 5µg/ml VEGF bound significantly less than the two aforementioned groups, 
which created two protein dose ratios.  With respect to VEGF, we were unable to 
calculate the release profile due to the protein’s rapid degradation rate and short half-life. 
We found that adsorbed VEGF was bioactive due to increased HUVEC proliferation, and 
the in vivo bone regeneration trend followed the trend found with the PCL/collagen 
sponge construct (Section 8.1.2). The higher VEGF dose (10µg/ml) resulted in less bone 
than BMP2 alone (65µg/ml) group initially but then resulted in more than the BMP2 
group at 8 weeks.  The 10µg/ml VEGF dual delivery group had a significant increase in 
bone volume and ingrowth over time from 4 to 8 weeks, whereas, the 5µg/ml VEGF dual 
delivery and the BMP2 alone groups did not show an increase. Since we were unable to 
reliably determine the VEGF release profiles, we cannot confirm how much VEGF was 
released with the BMP2. As previously mentioned, it is important to note that the in vitro 
release profile may not correlate to the in vivo release due to neglecting physiological 
factors. A limitation in this study was that the mechanical testing machine parameters 
were not sensitive enough for this PCL geometry. Overall, delivering adsorbed VEGF 
(10µg/ml) along with BMP2 (65µg/ml) results in an increased bone regeneration rate 
from 4 to 8 weeks when compared to single BMP2 delivery.  
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8.1.4 Local Dual Delivery of EPO and BMP2 from a Modular PCL Scaffold Increases 
Early Bone Regeneration in an Ectopic Location 
 Clinicians will be hesitant to use as potent of an angiogenic factor as VEGF in an 
oncology patient because it could stimulate aberrant blood vessel production. EPO is a 
hematopoietic growth factor that has angiogenic properties, positively effects bone 
formation, and is Food and Drug Administration (FDA) approved [17-22]. Limited 
studies have investigated dual delivery of BMP2 and EPO [23,24], and local dual 
delivery from a scaffold has not yet been studied in an ectopic site to the best of our 
knowledge. In this study we found an average of 22% BMP2 bound to and <1% released 
from the inner module and 70% EPO bound to and 83% EPO released from the outer 
module (modular scaffold from Section 8.1.3). Once adsorbed, EPO bioactivity was 
indicated by increased HUVEC proliferation.   
In vivo, BMP2 and EPO co-delivery regenerated significantly more bone and 
percent ingrowth than BMP2 alone at 4 weeks. At 8 weeks dual delivery was still greater, 
however, the difference was not significant. The increase in regenerated bone from 4 to 8 
weeks was similar for both groups. Both groups had bone regenerating in the inner 
module where the BMP2 was adsorbed. Surprisingly, the dual delivery group had 
significantly more bone volume regenerating on the outer module when compared to 
BMP2 alone scaffolds. This indicates that the influence of EPO was not spatially 
constricted to the outer module, and it may have had a synergistic effect on bone 
production in adjacent areas. Since EPO was released rather quickly, it could have 
diffused to interact with migrating cells. Histology showed that the EPO and BMP2 dual 
delivery group had a more dense cellular marrow versus the more fatty marrow 
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associated with the BMP2 alone group.  From these results, we can conclude that 
delivering EPO along with BMP2 from a modular scaffold significantly increases the 
regenerated ectopic bone at 4 weeks. The time in which the bone flap matures is crucial 
to oncology patients awaiting adjuvant therapy. In this study, the protein binding process 
is more clinically translatable since both of the proteins are FDA approved [15,21,22], 
although some hurdles may increase.  
8.2 Future Work 
8.2.1 Utilize Other Conjugation BMP2 Binding Methods and BMP2 Detection Assays 
The sulfo-SMCC conjugation method was utilized in AIM I, and we believe an 
unfavorable reaction occurred because the cysteine group is located inside of the BMP2 
protein structure and could be inaccessible to the sulfo-SMCC. We did not confirm where 
the sulfo-SMCC bound to the BMP2 protein chemically. In the future, fluorescence 
correlation spectroscopy should be utilized to assess protein binding to the PCL scaffold. 
Additionally, protein conformational changes should be analyzed with a Fourier 
transform infrared spectroscopy (FTIR) technique.  These tests will give an insight into 
the protein binding site availability. Due to a very small amount of protein released in 
vitro, another protein detection method such as I
125
 radio-labeling should be conducted to 
confirm the release results. Heparin [5,25], 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) [26] and poly(ethylene-glycol) (PEG) [27] are a few of the other 
conjugation methods previously used to bind BMP2 to a surface.  The bone regenerated 
after using one of these mentioned binding methods may be different than that found with 
sulfo-SMCC conjugation and should be investigated. FTIR can also be used in these 
studies to further understand the changes in protein morphology.  
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 Along with altering the conjugation chemistry, future studies should investigate 
the point at which increasing the BMP2 solution concentration does not increase the 
regenerated bone volume in vivo. Once this threshold concentration is found, other 
growth factors (such as VEGF and EPO) can be co-delivered to further increase the 
regenerated bone volume.  
8.3.2 Assess Different Methods of Delivering VEGF from Inside of the BMP2 Scaffold 
It required two days to fabricate the collagen sponge inside of the PCL scaffold to 
deliver VEGF. A simpler method to deliver VEGF can be considered by mixing the 
VEGF solution into a fibrin gel and injecting it into the scaffold prior to implantation. 
The VEGF would diffuse out rather quickly in comparison to the adsorbed BMP2 - much 
like the VEGF released from the internal collagen sponge. Furthermore, for both AIMS II 
and III, we were unable to accurately detect the released protein. In the future, we should 
seek alternative methods to quantify the released VEGF such as radio-labeling or an 
enzyme-linked immunosorbent assay (ELISA). Future studies using the modular scaffold 
geometry should also use a more sensitive mechanical testing frame to calculate the 
specimen’s elastic modulus. Nanoindentation is a sensitive alternative to the compression 
test frame to assess the local mechanical properties.  
8.3.3 Optimize Dual Delivery of BMP2 & VEGF and BMP2 & EPO 
In the modular PCL scaffold studies, the two proteins were individually adsorbed 
onto two scaffolds modules that were then manually assembled. With this design, the 
bone was generally localized to the inner module where the BMP2 was adsorbed. To 
increase the bone regenerated throughout the whole scaffold, a solution containing both 
VEGF and BMP2 or EPO and BMP2 should be created, and the entire PCL scaffold 
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should be submerged in this dual protein solution. This protocol would further simplify 
the dual delivery process while considering a clinical setting. Competitive binding must 
be considered if using this protocol. To understand the protein binding efficiencies, a 
constant BMP2 concentration can be used while gradually increasing the concentration of 
the second protein. Binding efficiencies will give insight as to how much of each protein 
is binding. The assay used to quantify protein binding would need to be specific to the 
protein; therefore, ELISA should be utilized rather than a generic protein assay. Binding 
between the protein and the PCL surface should be assessed using surface plasmon 
resonance or fluorescence correlation spectroscopy, and conformational changes should 
be determined with FTIR.  
The contents of this dissertation advance the field of bone tissue engineering and 
the pre-fabrication process. We successfully regenerated bone on a designed PCL 
scaffold after implantation in an ectopic location and further optimized the regenerated 
bone volume by delivering multiple growth factors. There also exist a few limitations 
when translating this research into the clinic. An irradiated wound bed will be 
challenging to reconstruct considering it is not conducive to bone healing let alone to 
supporting the integration of a large bone graft.  Increasing vascularity and the amount of 
bone in the scaffold will be crucial for applying this to oncology patients.  Furthermore, 
the minimal regenerated bone volume needed to provide load bearing support and 
stimulate further bone remodeling once transplanted to the defect site is unknown. The 
studies in this dissertation have laid a foundation for pre-fabricated bone flaps using 
single and dual growth factor delivery from PCL scaffolds. Future studies should 
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investigate application in a large animal model that requires larger scaffold geometry to 
quantify the requirements for mechanical strength, bone volume, and vasculature. 
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